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Renal cell carcinoma (RCC) is the most common type (>80%) of kidney cancer that arises from the
cells of the renal tubules. Although RCC is relatively rare and only represents approximately 3% of
all adult cancer, an alarming increase in incidence has been observed in the past five decades.
Worldwide, approximately 150,000 new cases are diagnosed with RCC each year, and around
95,000 affected people die from the disease annually. While patients with early, localized RCC have
a good prognosis, those with advanced disease (metastatic RCC) do not respond to most traditional
therapeutic approaches, and survival for such patients is often less than 1 year. Unfortunately, most
patients are diagnosed with advanced RCC, which causes anti-RCC treatment more challenging.
Even so, with the advent and improvement of edge-cutting biomedical techniques, a significant
amount of new information concerning the epidemiology, molecular genetics, immunologic char‐
acteristics, and therapy for patients with these tumors has appeared. Through the integration of
molecular-based technologies, systematic tissue procurement and medical informatics, research
data can rapidly be translated into useful diagnostic and treatment strategies. In fact, the increasing
understanding of the pathogenesis of RCC has led to the development of novel targeted agents.
New anti-RCC drugs have now been approved and commercially available, some potential drugs
are also under clinical trial.
Here, to provide urologist and kidney cancer researchers with updated knowledge of RCC biolo‐
gy, current treatment practices, and novel treatment strategies, experts from all over the world,
combining their our experience, explored and reviewed the latest developments in molecular ge‐
netics, surgery, and novel therapeutic strategies for renal tumors and organized into this book
Renal Tumor. This book contains 11 chapters in three parts, covering the roles of partial nephrec‐
tomy, radical nephrectomy, and laparoscopy, as well as the latest developments in molecular ge‐
netics and immune dysfunction, signal transduction, and anti-RCC drugs associated with the
diseases. Also discussed are imaging and screening for RCC, its diagnosis, paraneoplastic syn‐
dromes, and prognostic factors in metastatic disease.
It is hoped that Renal Tumor will offer all physicians treating kidney cancer as well as researchers
current practical knowledge about the nature, diagnosis, prognosis, management and treatment
of this difficult disease.
Finally, thanks to all the authors who have contributed their valuable time to write all the chap‐
ters. Without their efforts and dedication, the formation of this book would never be possible.
Jindong Chen, Ph.D.
Research Associate Professor, Co-director,
Kidney Cancer Research Laboratory, Department of Urology
University of Rochester Medical Center, Rochester, NY, USA
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Genetics of Renal Tumors
Ryoiti Kiyama, Yun Zhu and Tei-ichiro Aoyagi
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/54588
1. Introduction
Kidney and urinary tract cancers accounted for a total of 16936 cases and 6764 deaths in 2007
in Japan (Matsuda et al., 2012), which is roughly 2% of all cancers. Renal cell carcinoma (RCC)
is the most common type of kidney cancer, and is classified into three major subtypes, clear
cell RCC, papillary RCC and chromophobe RCC, representing 80, 10, and 5% of all RCCs, and
the majority of renal tumors are sporadic although 2-4% are hereditary (Hagenkord et al., 2011).
A number of genes have been studied in association with renal tumors, including those
involved in tumorigenesis, and the progression and outcome of the cancer, by means of
mutational searches, gene expression profiling, proteomics/metabolomics and pathological/
clinical studies. The genes can be classified into several categories, such as familial, sporadic,
epigenetic and quantitative, depending on the timing of their expression, and the factors
affecting their effects, such as microRNA (miRNA) and metabolites have emerged. Since
tumorigenesis is believed to be initiated with genetic/epigenetic modulations of at least several
genes, but not a single gene alone, the balance among these cancer-related genes is considered
to be more important than the contribution of a dramatic change caused by a single gene. Thus,
an extensive and competitive search for oncogenes and tumor suppressor genes based on the
search for their mutations was immediately accompanied by the search for interacting
proteins/factors at the mutation sites. This indicates that lineages of gene functions, or signaling
pathways, are important to understanding tumorigenesis, as well as the progression and
outcome of the cancer. Although such pathways are not fully understood, it is important to
summarize the latest knowledge of genes and their functions in terms of the coordinated
functions of genes to achieve a basic understanding of cancer and to use the information
obtained for diagnostics/therapeutics.
Here, we summarize and discuss the genes associated with renal tumors (Section 2) and then
show one of them, Kank1, from gene-function networks or signaling pathways (Section 3). We
© 2013 Kiyama et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
© 2013 Kiyama et al.; licensee InTech. This is a paper distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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also discuss a methodology for collecting information on multiple gene functions with a simple
pathological system (Section 4).
2. Genes associated with renal tumors
While kidney cancer ranked 9th in 2002 in the European Union and the United States
(Baldewijns et al., 2008), its mortality rate was not high in Japan (12th in 2002 and 2007: Matsuda
et al., 2012). Although this difference could be attributable to risk factors such as smoking,
hypertension and long-term dialysis, there might be a contribution of genes associated with
the cancer. In spite that RCC shows a poor survival rate (less than 19%) for patients with
metastasis, molecular pathological tests, such as those dividing good and poor prognosis
groups, have not been established (Stewart et al., 2011). A lack of such effective tests may be
one of the reasons why the mortality rate in Japan has been gradually increasing from 1.8%
(2002) to 2.0% (2007).
A large majority of RCC cases are sporadic and only 2-4% are hereditary. There are cas‐
es  where  gene expression profiling cannot  distinguish between them (Beroukhim et  al.,
2009),  suggesting common genetic factors between them. Several genes are known to be
associated  with  RCC,  such  as  VHL,  TSC1  and  TSC2,  which  play  different  roles  in  the
mechanism of  cancer  and  so  have  different  advantages  in  diagnostics/therapeutics.  The
information  about  genes  can  be  categorized  by  the  levels  of  genomics,  transcriptomics,
proteomics  and others  including metabolomics,  and used to  understand the mechanism
of cancer, to support diagnostic or therapeutic processes. In this section, we focus on the
roles and merits of these genes.
2.1. Genes associated with tumorigenesis
Since a majority of sporadic cancers originate from a recessive mutation that causes a loss of
function of a particular type of gene, loss of heterozygosity (LOH) is an important step in the
disabling of a functional gene (or a wild-type allele) to give a mutated and cancer phenotype.
Such genes are termed tumor suppressor genes, and so far, more than 100 have been reported
(Fearon, 2002; Polinsky, 2007). Among them, twenty well-characterized genes showed both
familial and sporadic phenotypes (Sherr, 2004). Since a cancer phenotype can be revealed by
morphological changes, growth stimulation, gaining immortality and/or others, there are quite
a few functions associated with tumor suppressor genes. Thus, it is easier to examine tumori‐
genesis in association with genomic status, mutations and/or epigenetic modifications, by
analyzing the loci specific to RCC.
2.1.1. VHL gene
The gene best known to be associated with RCC is the von Hippel-Lindau (VHL) gene, whose
inactivation accounts for nearly 100% of hereditary cases and sporadic clear cell RCC cases
(Baldewijns et al., 2008). This gene was found by positional cloning from the locus associated
with the VHL disease, a familial syndrome accompanying cancer in the eye, brain, spinal cord,
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kidney, pancreas and adrenal glands. The VHL gene encodes the 30-kDa protein VHL, 213
amino acid residues long, and is implicated in the regulation of hypoxia-inducible factors
(HIFs) (Maher et al., 2011). The VHL protein forms a complex with elongin B, elongin C and
cullin-2, and the complex has ubiquitin ligase E3 activity and is involved in the ubiquitination
and degradation of HIFα, the α subunits of transcription factors HIF-1 and HIF-2, which form
a dimer with HIFβ and regulate the transcription of hypoxia-inducible genes such as those for
VEGF (vascular endothelial growth factor), PDGF (platelet derived growth factor) and TGFα
(transforming growth factor α) (Kondo and Kaelin, 2001; Kaelin, 2009; Fig. 1). However, the
cancer found in VHL disease is sporadic and the lifetime risk of RCC in VHL disease patients
is about 70% (Maher et al., 2011). So, it is reasonable to assume that additional genes are
involved in RCC and the mutations in VHL are not the definitive cause of RCC, which is one
of the reasons to explore new genes and genetic loci (see below). Meanwhile, the status of the
VHL gene is important for the treatment of VHL disease and kidney cancer patients. HIF-
responsive gene products, such as VEGF and PDGF, activate the angiogenesis of tumors and
therefore are good therapeutic targets. Inhibitors of VEGF and PDGF, sunitinib and sorafenib,
have been approved by the US Food and Drug Administration (Kaelin, 2009).
Figure 1. Summary of signal transduction pathways associated with RCC.
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The MET protooncogene was found in hereditary papillary RCC without mutations in the VHL
gene (Schmidt et al., 1997). MET encodes a membrane receptor (MET) for hepatocyte growth
factor (HGF). MET has tyrosine kinase activity, and HGF activates this kinase activity and
initiates signaling for mitogenesis and migration (Fig. 1). While aberrantly active MET triggers
tumor growth, angiogenesis and metastasis, such cases are relatively rare (~5%) among
sporadic papillary RCC, suggesting other genes to play a major role in the tumorigenesis
(Baldewijns et al., 2008).
2.1.3. TSC1/TSC2 genes
Two tumor suppressor genes, TSC1 and TSC2, were found in a study of tuberous sclerosis
complex (TSC), which is known to develop into various types of RCCs, including clear cell
RCC, papillary RCC and chromophobe RCC (Borkowska et al., 2011). The TSC1 and TSC2
proteins form a heterodimer and inhibit the mammalian target of rapamycin (mTOR; a key
signaling mediator for cell growth), by inactivating a small GTPase Rheb (an activator of
mTOR) as a GTPase-activating protein (GAP) (Linehan et al., 2010; (Fig. 1). However, muta‐
tions are not frequently found in sporadic RCC (Parry et al., 2001) and therefore its role is not
completely clear yet.
2.1.4. PBRM1 gene
Several genes, UTX (or KDM6A), JARID1C (or KDM5C) and SETD2, were found in close
association with clear cell RCC by a recent technology of the next-generation sequencing
(Dalgliesh et al., 2010). As these genes are related with the methylation status of lysine residues
of hitone H3, further mutation studies were conducted to identify a SWI/SNF chromatin
remodeling complex gene, PBRM1, to be frequently (over 40%) mutated in clear cell RCC
(Varela et al., 2011). PBRM1 is mapped to chromosome 3p21 and encodes the BAF180 protein,
a chromatin targeting subunit of a SWI/SNF chromatin remodeling complex, which regulates
replication, DNA repair and cell proliferation/differentiation. Knock-down of this gene
enhanced colony formation and migration of cancer cells, suggesting this gene to be a tumor
suppressor gene. Further studies are needed to reveal a mechanism of cancer involving PBRM1
and to find its clinical application.
2.1.5. Genes related to hereditary renal cancer syndromes
Approximately 2-4% of RCC cases are hereditary and some genes have been identified as the
genes responsible for hereditary renal cancer (HRC) syndromes (Verine et al., 2010). Apart
from the genes already mentioned above (VHL, MET, TSC1 and TSC2), several more genes
have been described in association with HRC syndromes, including FH and FLCN genes. FH
is the gene responsible for a HRC syndrome, hereditary leiomyomatosis and renal cell cancer
(HLRCC), in which affected individuals often develop cutaneous and uterine leiomyoma and
an aggressive form of papillary RCC (Linehan et al., 2004). The FH gene encodes an enzyme
(FH) catalyzing the conversion of fumarate to malate in the tricarboxylic acid (Krebs) cycle.
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From the analysis of their mutations, this gene is considered as a tumor suppressor gene
(Sudarshan et al., 2007). Although the mechanism that leads FH alterations to cancer is not
clearly understood, there is a link between fumarate dysregulation and impaired HIF hydrox‐
ylation (Isaacs et al., 2005).
FLCN, on the other hand, is the gene responsible for Birt-Hogg-Dubé (BHD) syndrome, which
is a rare autosomal dominant disease including kidney tumors, predominantly chromophobe
RCC. Mutations in this gene were found in approximately 80% of BHD kindreds and loss of
expression of this gene were frequently found in kidney tumors from BHD patients, suggesting
this gene to be a tumor suppressor gene (Baldewijns et al., 2008).
2.1.6. Other genes
Several genes were recently implicated in association with RCC, including BAP1, SETD2 and
NF2, by means of advanced technologies such as the next-generation sequencing, a microarray-
based analysis and a mouse transgene analysis. BAP1 plays a role of a tumor suppressor and
encodes a nuclear deubiquitinase, which is inactivated in 15% of clear cell RCC cases (Peña-
Llopis et al., 2012). Mutations in BAP1 anticorrelates with those in another tumor suppressor
gene, PBRM1, and these mutations comprise a subtype of clear cell RCC (70% of all clear cell
RCC cases). The BAP1 protein may work with host cell factor-1 (HCF-1), a scaffold protein, to
regulate transcription factors and suppress cell proliferation.
SETD2 was found by the analysis of accumulated transcripts containing premature termina‐
tion codons and encodes a histone methyltransferase, which is responsible for trimethylation
of the lysine residue at position 36 of histone H3 and may play a role in suppressing tumor
development (Duns et al., 2012).
NF2  was identified as a tumor suppressor gene by the analysis of knock-out mice (Mor‐
ris and McClatchey, 2009). The mice developed kidney tumors in 6-10 months with char‐
acteristics of hyperactive epidermal growth factor receptor (EGFR) signaling. Merlin,  the
NF2  gene product,  was implicated in suppressing tumorigenesis by inhibiting hyperacti‐
vated EGFR signaling.
2.2. Genes implicated in diagnostic markers and therapeutic targets
The recurrence of RCC is 20 to 40%, depending on the stage and grade of tumor (Chin et al.,
2006). So, it is important to understand the genes (and their products) associated with pro‐
gression/metastasis to predict the outcome of cancer. The classification of RCC subtypes is
apparently not possible by a single marker, but could be done using combinations of markers
such as vimentin, epithelial cell adhesion molecule (EpCAM), glutathione S-transferase α
(GSTα), carbonic anhydrase II (CA II), cytokeratin 7 (CK7) and cluster of differentiation 10
(CD10) (Stewart et al., 2011).
Important  prognostic  markers  for  RCC  represent  specific  cellular  signaling  pathways,
such  as  the  VHL  and  mTOR  pathways.  The  VHL  pathway  gives  several  well-studied
markers, such as VHL, HIFs, VEGF and carbonic anhydrase 9 (CAIX), although their ap‐
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plicability is sometimes questionable (Stewart et al.,  2011). HIF-responsive gene products
are  potential  markers  representing angiogenesis  (VEGF,  PDGF,  SDF,  CXCR4,  TGFβ and
CTGF), glucose uptake and metabolism (HK2 and PDK4), pH control (CAIX and CAXII),
invasion/metastasis  (MMP1,  SDF,  CXCR4  and  c-Met),  and  proliferation  and  survival
(TGFα) (Smaldone and Maranchie, 2009).
Another pathway for potential makers is the mTOR pathway (Fig. 1). The main cascade of this
pathway is PI3K/AKT/mTOR, which mediates signals by activating phosphoinositide 3-kinase
(PI3K) through kinases such as receptor tyrosine kinases to generate phosphatidylinositol
(3,4,5)-trisphosphate (PIP3), which further activates AKT via phosphorylation and phospho-
AKT activates mTOR complex 1 (mTORC1) through inhibition of the TSC1/TSC2 complex
(Allory et al., 2011). Then, mTORC1 phosphorylates proteins such as P70-S6 kinase and
activates protein synthesis and cell proliferation. Importantly, HIF-1α expression is dependent
on mTORC1 signaling (Toschi et al., 2008). Potential markers in this pathway include P70-S6
kinase, PTEN (a phosphatase that decreases PIP3) and phospho-AKT.
2.3. Mutation sites and LOH loci
A comprehensive analysis of RCC genomes has been done through genomic (Hatano et al.,
2001; Cifola et al., 2008), transcriptomic (Takahashi et al., 2001; Takahashi et al., 2003; Cifola et
al., 2008) and proteomic/metabolic (Perroud et al., 2006; Raimondo et al., 2012) approaches.
We used a genome-subtraction technique, or the in-gel competitive reassociation method
(Kiyama et al., 1995; Rodley et al., 2003), for cloning the sites of LOH that occurred in a RCC
genome by subtracting normal DNA from cancer DNA of the same patient (Hatano et al.,
2001). The minimum size of LOH (caused by hemizygous deletions) detected by this method
was roughly 50 kb. This resolution was made possible by MseI, which recognizes TTAA, a
sequence appearing frequently in human genomic DNA, and completely digests genomic
DNA to sizes mostly below 1 kb. Such a high resolution has not been used even in recent
genome-wide association studies (see Jacobs et al., 2012, for example). A total of 187 clones
were mapped on the chromosomes and a total of 44 candidate regions, where at least two
clones were mapped within 5 Mb, were selected and analyzed for mapping the sites of LOH
in 61 cancer cases (Table 1). Among them, we found interesting LOH sites at 5q32-q34, 6q21-
q22, 8p12 and 9p24, whose frequencies are relatively high among RCC and whose lengths are
less than ~10 Mb (Hatano et al., 2001; Sarkar et al., 2002; Fig. 2). A tumor suppressor gene,
Kank1, was found at 9p24 after extensive analysis of the LOH site by examining the loss of
function upon its mutation; the loss of expression of the gene at mRNA and protein levels in
RCC, and the loss of suppression of tumor growth in renal tumor cells (Sarkar et al., 2002).
2.4. Chromosomal abberations in RCC
Chromosomal abberations are often observed in RCC (Ross et al., 2012). Deletions of chromo‐
some 3p, where the VHL gene resides, are found in most sporadic and familial clear cell RCCs.
Distinctive abnormalities were reported for papillary RCC, where, in contrast to clear cell RCC,
most of the tumors are characterized by trisomy of chromosomes 7 and 17 along with loss of
Y, while the 3p arm is intact. In Xp11.2 RCC, the gene fusion was observed between the TFE3
Renal Tumor8
gene on the X chromosome and either of ASPL (17q25), PRCC (1q21), PSF (1q34), NonO (Xq12)
and CLTC (17q23) (Kuroda et al., 2012). All of the gene fusions result in overexpression of the
TFE3 protein, a transcription factor. Among them, the translocation of t(X;17)(p11.2q25), which
fuses the ASPL and TFE3 genes, is most frequently observed. Meanwhile, there are some
unclassified cases, such as those where trisomy 7/17 in areas typical of papillary RCC and both
trisomy 7/17 and 3p loss in areas with clear cell RCC were observed (Ross et al., 2012).
2.5. Exploration of new genetic markers
Even though a number of genetic markers have been reported, they are not currently used for
the diagnosis of RCC. As discussed in Section 1, this is because understanding a single gene
or a few genes is not enough for a diagnosis of sufficient reliability. For diagnosing more
complex and more specific states of diseases or disease phenotypes, groups of markers that
are able to more accurately distinguish the phenotypes are needed. Such markers should be
derived from the direct process of the disease and therefore would represent the signal
transduction that occurs within the cell. There are several new technologies which might open
the door to a more comprehensive understanding of RCC especially at the level of cellular
signaling: array-based genome-wide association studies, microRNA (miRNA) studies and
next-generation sequencing-based expression profiling.
Figure 2. Significant LOH regions in RCC. LOH regions of less than ~10 Mb were identified as the minimum overlap‐
ping regions of LOH by subtraction cloning of mutated regions followed by the quantitative allelic analysis of over 60
RCC cases using microsatellite markers (see Hatano et al., 2001; Sarkar et al., 2002).
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Table 1. Summary of LOH at significant locations among 44 sites. For details, see Hatano et al. (2001) and Sarkar et al.
(2002). Only the loci in which more than 10 % of RCC patients had LOH are shown. The LOH analysis is applicable to
only female patients for the cluster at Xq26-q28. There were a total of 44 clusters containing more than two of 187
clones analyzed within 5 Mb. The locations of the clusters other than those shown above are as follows: 1p31.1,
1p13.3-p22.3, 1p13.3-q12, 1q12-p21.1, 2p21-p22, 2p12-q11.2, 4p14, 4p13.3-p21.1, 4q22, 4q32, 10p14-p15.1,
10p12.1-p12.2, 12q13.3-q15, 13q13-q14.1, 13q14.2-q14.3, 16q12.1-q12.2, and 20p11.2-p12.
Recent advances in high-resolution genomic arrays have enabled us to analyze 1,000 or more
disease cases efficiently, and thus to give statistically significant loci associated with the
diseases. Such an approach was applied to the study of RCC. A genome-wide association study
Renal Tumor10
based on more than 5,000 RCC cases revealed two loci, 2p21 and 11q13.3, to be associated with
RCC susceptibility (Purdue et al., 2011). Although the authors claimed these sites to be
previously unidentified, both of the loci were actually identified in 2001 (Hatano et al., 2001;
Table 1). While the association is statistically significant, the frequencies among RCC cases are
not very high (less than 20%), and therefore, it is doubtful that these sites alone can be used
for diagnosis. The candidate genes in these loci which contribute to the association are EPAS1
encoding hypoxia-inducible factor-2α (HIF2α) and SCARB1 encoding a scavenger receptor.
While HIF2α was known to be associated with RCC though it has not yet been used clinically,
SCARB1 is new and its association with RCC may indicate a new signaling pathway. The array-
based genome-wide association technique was also applied to the study of copy-number
variations (Krill-Burger et al., 2012).
The study of miRNA is rapidly providing as new information about disease phenotypes.
MiRNA, a group of short non-coding RNA with lengths of 19-22 nucleotides, differs from
mRNA in that it has a role in gene function, and, while information about mutations is
important for mRNA, quantity is mostly emphasized for miRNA. So, while there are cases
where mRNA bearing a mutation without a change in its quantity contributes to a disease
phenotype, there would be few such cases for miRNA. Naturally, the linkage of a disease to a
genomic location reveals in most cases a mutation in a gene. This may indicate that miRNA
contributes to quantitative change as a group as a result of changes in transcriptional efficiency
caused by alterations to the transcriptional machinery or genomic location/status, or by
epigenetic modifications. In contrast to mRNA, however, the quantity of miRNA can be
controlled rapidly and specifically, and thus, miRNA could be more advantageous for the
rapid control of the amount of specific proteins, which is important in signal transduction.
Such cases were reported for TGFβ, WNT, Notch and EGF signaling in association with
homeostasis, cancer, metastasis, fibrosis and stem cell biology (Inui et al., 2010), and VHL-
signaling and VEGF-signaling in association with RCC (Fendler et al., 2011). Several miRNAs
were reported to be induced or repressed by VHL-induced hypoxia in RCC and regulate the
PI3K/AKT/mTOR pathway and Wnt signaling/β-catenin pathway to control cell proliferation,
tumorigenesis and other cellular functions (Redova et al., 2011).
Next-generation sequencing technology was applied to genome-wide expression profiling of
miRNA related to clear cell RCC (Osanto et al., 2012). By analyzing 22 RCCs, 100 miRNA
differentially expressed between clear cell RCC and matched normal tissues were found. While
the biological relevance of these novel miRNAs is unknown, they may be potential diagnostic
markers or targets for therapeutics.
3. Kank family genes and renal tumors
3.1. Structure of Kank-family genes
The human Kank1 gene was found as a candidate tumor suppressor gene for renal tumors at
9p24, and encodes a protein containing ankyrin-repeats at the C-terminus and coiled-coil
motifs near the N-terminus (Sakar et al., 2002). Based on domain and phylogenetic analyses,
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3.1. Structure of Kank-family genes
The human Kank1 gene was found as a candidate tumor suppressor gene for renal tumors at
9p24, and encodes a protein containing ankyrin-repeats at the C-terminus and coiled-coil
motifs near the N-terminus (Sakar et al., 2002). Based on domain and phylogenetic analyses,
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Kank2, Kank3 and Kank4 were found to form a family with Kank1 (Zhu et al., 2008). Five repeats
of the ankyrin-repeat motif comprise the basic structure of all Kank proteins (Fig. 3A). In
addition, each Kank protein contains different combinations of four types of coiled-coil motifs.
They also have a conserved region close to the N-terminus, named the KN-motif (Zhu et al.,
2008; Fig. 3A), which contains a leucine-rich region and an arginine-rich region.
Figure 3. (A) Schematic structure of human Kank family proteins. Black boxes indicate the Kank N-terminal (KN) motif.
Gray boxes indicate coiled-coil motifs. White boxes indicate the ankyrin-repeat (ANK) motifs. (B) A hypothetical model
of Kank1 functions. Kank1 is transported to areas of membrane ruffling, such as lamellipodia, through association
with Kif21a. Kank1 regulates RhoA and Rac1 activities through interaction with 14-3-3 in PI3K/Akt signaling and
IRSp53 in Rac1 signaling, respectively. These interactions negatively regulate the formation of actin stress fibers and
lamellipodia, and finally decrease cell migration. Kank1 and BIG1 may exist in a multimolecular complex that affects
Golgi/MTOC orientation and regulates cell polarity during directed migration. Kank1 may inhibit Rho activation by
binding to Rho-regulating proteins, like Daam1, which may result in negative regulation of cytokinesis.
Yeast-two hybrid or mass-spectrometrical studies have shown that Kank1 can directly bind to
several proteins, such as 14-3-3 proteins, insulin receptor substrate (IRS) p53, Kif21a and
Disheveled-associated activator of morphogenesis 1 (Daam1). Kank1 binds to IRSp53 and
Daam1 at its coiled-coil domain (Kakinuma et al., 2011). In addition, there is a 14-3-3-binding
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motif, serine at position 167, located between the first and second coiled-coil motifs. Kif21a is
a unique protein found to interact with the ankyrin-repeat domain of Kank1 (Kakinuma et al.,
2008 & 2009; Roy et al., 2009; Suzuki et al., unpublished data). Although the function of the
KN-motif is not clear, it contains several potential motifs for a nuclear localization signal (NLS)
and nuclear export signal (NES). These signals may contribute to nucleo-cytoplasmic shuttling
of Kank1, and further affect the subcellular distribution of β-catenin (Wang et al., 2006; Previdi
et al., 2010).
3.2. Functions of Kank-family genes
Some studies have demonstrated that Kank-family genes are related to various cell func‐
tions. VAB-19, an ortholog of the Kank1 protein in C. elegans, was reported to occur with
components  of  an  epidermal  attachment  structure.  It  plays  an  antagonistic  role  in  the
regulation  of  actin  cytoskeleton and halts  basement  membrane opening associated with
cell invasion and tissue remodeling (Ding et al.,  2003; Ihara et al.,  2011). The deletion of
Kank1  is associated with parent-of-origin-dependent inheritance of familial cerebral palsy
(Lerer et al.,  2005). There have also been reports that Kank1  was fused with the gene for
platelet-derived growth factor receptor β (PDGFRβ) and that the fusion protein was a vi‐
tal regulator of hematopoietic cell proliferation (Medves et al.,  2010 & 2011). Meanwhile,
Kank1  expression  was  down-regulated  in  patients  with  polycythemia  vera,  suggesting
this gene to be related to myeloproliferative disorders (Kralovics et al., 2005). Some stud‐
ies have described about the functions of other Kank-family members. Kank2, found as a
novel podocyte-associated protein, may contribute to the regulation of actin dynamics in
podocyte  foot  processes  in  the  renal  filter  physiology and diseases  (Xu et  al.,  2011).  In
addition, NBP, an ortholog of Kank3 in zebrafish, interacts with Numb, an adaptor pro‐
tein  implicated  in  various  basic  cellular  processes,  through  the  PTB  domain,  which  is
well conserved among vertebrate Kank  genes. In embryogenesis, NBP accumulates at the
cell  periphery  during gastrulation  and,  later  in  the  development,  is  concentrated at  the
basal  poles  of  differentiated  cells.  These  findings  suggest  a  role  for  NBP  in  regulating
cell adhesion and tissue integrity (Boggetti et al., 2012).
Kank1 may contribute to several regulatory activities, such as regulation of the actin cytoske‐
leton, cell migration and the cell cycle through interactions with the proteins described above
(Sakar et al., 2002; Kakinuma et al., 2008 & 2009; Roy et al., 2009; Suzuki et al., unpublished
data; summarized in Fig. 3B). Kank1 regulates the Rac1-dependent formation of lamellipodia
and the activity of RhoA, resulting in the inhibition of cell migration. This function is mediated
through two binding partners of Kank1, 14-3-3 and IRSp53. Kank1 binds to the Akt-phos‐
phrylation motif of 14-3-3θ, 14-3-3γ, 14-3-3η and 14-3-3ε. Interaction between these two
proteins is enhanced by growth factors such as insulin and epidermal growth factor (EGF)
(Kakinuma et al., 2008). This interaction regulates the activation of RhoA through the
PI3K/Akt signaling pathway. When a 14-3-3 binding motif is phosphorylated by Akt, 14-3-3
is separated from an activation complex for RhoA, and binds to Kank1 resulting in the
inhibition of RhoA activities, and thereby decreases the formation of actin stress fibers and
inhibition of cell migration (Kakinuma et al., 2008). The coiled-coil domain of IRSp53, which
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Kank2, Kank3 and Kank4 were found to form a family with Kank1 (Zhu et al., 2008). Five repeats
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addition, each Kank protein contains different combinations of four types of coiled-coil motifs.
They also have a conserved region close to the N-terminus, named the KN-motif (Zhu et al.,
2008; Fig. 3A), which contains a leucine-rich region and an arginine-rich region.
Figure 3. (A) Schematic structure of human Kank family proteins. Black boxes indicate the Kank N-terminal (KN) motif.
Gray boxes indicate coiled-coil motifs. White boxes indicate the ankyrin-repeat (ANK) motifs. (B) A hypothetical model
of Kank1 functions. Kank1 is transported to areas of membrane ruffling, such as lamellipodia, through association
with Kif21a. Kank1 regulates RhoA and Rac1 activities through interaction with 14-3-3 in PI3K/Akt signaling and
IRSp53 in Rac1 signaling, respectively. These interactions negatively regulate the formation of actin stress fibers and
lamellipodia, and finally decrease cell migration. Kank1 and BIG1 may exist in a multimolecular complex that affects
Golgi/MTOC orientation and regulates cell polarity during directed migration. Kank1 may inhibit Rho activation by
binding to Rho-regulating proteins, like Daam1, which may result in negative regulation of cytokinesis.
Yeast-two hybrid or mass-spectrometrical studies have shown that Kank1 can directly bind to
several proteins, such as 14-3-3 proteins, insulin receptor substrate (IRS) p53, Kif21a and
Disheveled-associated activator of morphogenesis 1 (Daam1). Kank1 binds to IRSp53 and
Daam1 at its coiled-coil domain (Kakinuma et al., 2011). In addition, there is a 14-3-3-binding
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motif, serine at position 167, located between the first and second coiled-coil motifs. Kif21a is
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et al., 2010).
3.2. Functions of Kank-family genes
Some studies have demonstrated that Kank-family genes are related to various cell func‐
tions. VAB-19, an ortholog of the Kank1 protein in C. elegans, was reported to occur with
components  of  an  epidermal  attachment  structure.  It  plays  an  antagonistic  role  in  the
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data; summarized in Fig. 3B). Kank1 regulates the Rac1-dependent formation of lamellipodia
and the activity of RhoA, resulting in the inhibition of cell migration. This function is mediated
through two binding partners of Kank1, 14-3-3 and IRSp53. Kank1 binds to the Akt-phos‐
phrylation motif of 14-3-3θ, 14-3-3γ, 14-3-3η and 14-3-3ε. Interaction between these two
proteins is enhanced by growth factors such as insulin and epidermal growth factor (EGF)
(Kakinuma et al., 2008). This interaction regulates the activation of RhoA through the
PI3K/Akt signaling pathway. When a 14-3-3 binding motif is phosphorylated by Akt, 14-3-3
is separated from an activation complex for RhoA, and binds to Kank1 resulting in the
inhibition of RhoA activities, and thereby decreases the formation of actin stress fibers and
inhibition of cell migration (Kakinuma et al., 2008). The coiled-coil domain of IRSp53, which
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is the site for the interaction with active Rac1, binds to Kank1. Endogenous Kank1 and IRSp53
are co-localized at the site of membrane protrusions such as lamellipodia, which are needed
for cell migration. Overexpression of Kank1 inhibits the formation of lamellipodia induced by
active Rac1 in NIH3T3 cells, and knockdown of Kank1 enhances the formation. Therefore,
Kank1 negatively regulates membrane protrusions at the leading edge of cells, by inhibiting
the association between active Rac1 and IRSp53 (Roy et al., 2009). Taken together, Kank1
regulates cell migration through inhibition of IRSp53 in Rac1 signaling and inactivation of
RhoA activity through PI3K/Akt signaling (Fig. 3B). As the Kank1 locus shows loss of heter‐
ozygosity in RCC and the expression of the Kank1 gene is suppressed in RCC, Kank1 may
contribute to the malignant transformation of cells such as metastasis.
Kank1 regulates cell migration by inhibiting Rac1 signaling and RhoA activity as descri‐
bed above. To fulfill this function, Kank1 needs to be located at the leading edge of cells
and affect  the neighboring membrane.  Because Kank1 has no membrane-targeting motif
or membrane protein to associate with,  some proteins may help transport  Kank1 to the
site of membrane ruffling. Kank1 interacts with the third and fourth coiled-coil domains
of KIF21a, a member of the Kif4-class superfamily of kinesin motors that acts as a plus-
end kinesin  motor  (Marszalek  et  al.,  1999;  Kakinuma et  al.,  2009),  at  its  ankyrin-repeat
domain.  Overexpression  of  Kif21a  or  one  of  the  Kif21a  mutants  (R954W)  enhances  the
translocation of Kank1 to the membrane. In contrast, knockdown of Kif21a decreases the
amount  of  Kank1  at  the  membrane  (Yamada  et  al.,  2005;  Kakinuma  et  al.,  2009).  Al‐
though the mechanisms involved need further study, translocation of Kank1 mediated by
Kif21a  may  affect  cell  migration  (Fig.  3B).  Kank1  is  also  functionally  associated  with  a
protein, brefeldin A-inhibited guanine nucleotide-exchange 1 (BIG1), a binding partner of
Kif21a. Although there is no direct interaction between these two proteins, they may ex‐
ist  in a multimolecular complex that maintains the orientation of the Golgi/microtubule-
organizing  center  (MTOC)  and  regulates  cell  polarity  during  directed  migration.
Furthermore, a protein complex containing BIG1, Kif21a and Kank1 may contribute to di‐
rected transport along microtubules (Li et al., 2011).
Overexpression  of  Kank1  suppresses  the  cell  cycle  and cell  growth  (Sakar  et  al.,  2002).
We  observed  that  the  overexpression  of  Kank1  blocked  cytokinesis  and  generated  bi‐
nucleated  cells.  We  also  found  co-localization  of  endogenous  Kank1  with  Rho,  a  key
molecule required in cytokinesis for regulating the constriction of the contractile ring, at
the contractile ring during cytokinesis of NIH3T3 cells (Kamijo et al., 2006; Li et al., 2010;
Kakinuma et al., 2011; Suzuki et al., unpublished data). The coiled-coil domain of Kank1
binds to  another  protein,  Daam1 (Suzuki  et  al.,  unpublished data).  Daam1 belongs to a
novel  protein  family  containing  formin  homology  domains  and  has  been  implicated  in
the  regulation  of  cell  polarity  associated  with  the  Wnt/Frizzled/Rho  signaling  pathway
(Jantsch-Plunger  V et  al.,  2000;  Kosako H et  al.,  2000).  Although the  mechanism is  still
not  clear,  Kank1  may  block  cytokinesis  by  regulating  Rho  activity  through the  interac‐
tion  with  Daam1 (Fig.  3B).  Therefore,  it  may reveal  a  new mechanism of  regulation  of
cytokinesis and tumor suppression.
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3.3. Kank-family genes and renal tumors
The Kank1 gene was found at 9p24 by a comprehensive analysis of human chromosomes for
loss of heterozygosity (LOH) in RCC (Sakar et al., 2002). Kank1 family proteins localize at the
area of cytoplasma in renal tubular cells and glandular cells of some digestive and endocrine
organs (Roy et al., 2005). Kank family genes show different expression patterns at the mRNA
and protein levels in normal and tumor kidney tissues and some kidney tumor cell lines (Zhu
et al., 2008; Wang et al., 2005). Loss of expression of Kank1 in RCC was confirmed by Western
blotting, RT-PCR and immunohistochemical analyses (Sakar et al., 2002, Roy et al., 2005). In
addition, immunostaining in RCC showed decreased expression of Kank1 in high grade
tumors (Zhu et al., 2011). Therefore, the Kank family genes may be related to renal carcinoma,
and function as tumor suppressors.
A  growth  inhibitory  effect  of  Kank1  has  been  reported.  Overexpression  of  Kank1  in
HEK293 cells  resulted in cell  cycle  arrest  at  G0/G1.  On the other  hand,  growth suppres‐
sion of tumor cells  was caused by Kank1  gene expression using nude mice abdominally
injected  with  HEK293  cells  stably  expressing  Kank1  (Sakar  et  al.,  2002).  These  findings
demonstrated that Kank1 can regulate the growth of  cells  and can also regulate the ab‐
normal growth of cancer cells. Kank1 may exert its growth inhibitory effect by regulating
Rho activity mediated via its association with Daam1, resulting in abnormal nuclear divi‐
sion,  and thus blocking the cytokinesis  of  cancer cells  (Suzuki et  al.,  unpublished data).
According to recent studies,  Kank1 can negatively regulate the formation of  actin stress
fibers and cell migration (Kakinuma et al., 2008; Roy et al., 2009). When cells need to con‐
trol migration, Kank1 could be transferred to the leading edge of the moving cells’ mem‐
branes,  mediated  by  Kif21a,  and  co-localized  with  IRSp53.  Kank1  may  bind  to  IRSp53
competing  with  active  Rac1,  and  thus  inhibits  integrin-induced  cell  spreading  and  the
formation of lamellipodia. Simultaneously, Kank1 may inactivate RhoA, which is control‐
led by binding with 14-3-3, inhibit the formation of actin stress fibers and ultimately in‐
hibit  cell  migration.  Loss  of  expression  of  Kank-family  proteins  may  enhance  cell
migration in renal cell carcinoma. Since enhancement of cell migration is related to meta‐
stasis, Kank-family proteins might be related to the malignancy of renal cell carcinoma.
According to studies to date, the Kank1 protein may act as a tumor suppressor through
inhibition of cell migration and cell cycle. These functions are facilitated by several proteins
interacting with Kank1, including 14-3-3, IRSp53, Kif21a and Daam1. Further studies of the
interactions of these proteins will help us to understand clearly the role of Kank family proteins
in tumorigenesis.
3.4. Clinical study of Kank1 gene in renal cancer patients
3.4.1. Genetic and clinical characteristics of renal tumors
Kidney cancer accounts for about 4% of adult cancers, with an estimated 64,770 new cases
annually in the US (Siegel et al., 2012). Of kidney cancers, 92% are pathologically diagnosed
as RCC. This “RCC” has interesting and unique characteristics when investigated from a
clinical view point. Although 95% of patients with T1-T2 RCC survived 5 to 10 years, among
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clinical view point. Although 95% of patients with T1-T2 RCC survived 5 to 10 years, among
Genetics of Renal Tumors
http://dx.doi.org/10.5772/54588
15
those with metastatic disease the 5 year survival rate was 26% (DeCastro and McKiernan,
2008). Renal cancer is resistant to conventional chemotherapeutic agents and also to radiation
therapy. Many cancer-related genes have been found in renal cancer, including a multi-drug
resistance gene (Walsh et al., 2009), anti-apoptotic genes (Bilim et al., 2009), and radiation
resistant components (Kransny et al., 2010). The most characteristic genomic structure in renal
cancer is the VHL-related hypoxia-inducible factor gene and its cascades shown in hereditary
RCC and sporadic RCC cases (Linehan et al., 2011). The down-regulation in expression of
Kank1, our main theme, was also found from the study of renal cancer and normal renal tubular
cells (Sarkar et al., 2002), as we mentioned in other sections. The current WHO classification
of RCC in 2004 (Deng and Melamed, 2012) follows the earlier Heidelberg and Rochester
classifications, recognizing the heterogeneity of RCC, and describes distinct types of RCC with
unique morphologic and genetic characteristics. The most popular histological type, clear cell
RCC, accounts for 80 % of all RCC cases. Compared with clear cell RCC, papillary RCC (10%)
and chromophobe RCC (5%) are more benign. Collecting duct (bellini) (1%) type or other rare
sarcomatous types of RCCs are more aggressive (Deng and Melamed, 2012). However, once
metastasis occurs, papillary and choromophobe RCCs are more resistant to immunological
and new molecular targeting agents than clear cell RCC (Chowdhury et al., 2011). These clinical
features characterize the complexity of the clinical categorization of RCC.
Kank1  was found by a genome subtraction method among the genes at 9p24 susceptible
to  RCC  (Sarkar  et  al.,  2002).  A  devoted  study  revealed  that  Kank1  belongs  to  a  four-
member family, has splice variants, and plays a role in cell migration, intracellular trans‐
port  and  cell  division,  suggesting  that  Kank1  has  a  kind  of  tumor  suppressor  function
(Kakinuma et al., 2009). In this section, the expression of the Kank1 protein in renal can‐
cer specimens resected from RCC patients is indicated using immunohistochemical meth‐
ods,  and  the  relationship  between  the  expression  and  tumor  pathology,  patient  status,
and clinical outcomes is examined.
3.4.2. Expression of Kank1 protein in renal cancer and autologous normal kidney
1. Expression of Kank1 in RCC
We tried to find a RCC-related gene at 9p24, which lead to the discovery of Kank1. Of nine
ESTs analyzed in the 9p24 region, only three (WI-17492, WI-12779 and WI-19184) were
expressed in the kidney. The Kank1 gene was associated with WI-12779. This Kank1-associated
EST lost its expression in six out of eight cancer cases. Kank1 expression was examined in 5
matched normal kidney and cancer pairs by Western blotting using an anti-Kank1 antibody,
which was obtained as mentioned below. Reduced or loss of Kank1 expression in cancer was
observed in all 5 cases.
2. Immunohistochemical study of Kank1 expression in RCC and the relationship between its
expression and clinical-pathological outcomes
One hundred and five formalin-fixed paraffin-embedded slides including normal renal
tubular cells and RCC were subjected to immunohistological staining for Kank1 with a
monoclonal antibody. An anti-Kank1 (total Kank1) antibody was generated by a previously
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reported method (Roy et al., 2005). In brief, amino acids 406 to 580 of the Kank1 protein were
fused in-frame with the glutathione S-transferase gene in the vector pGEX. After induction of
the fusion protein in E. coli, it was purified and used to immunize mice. A mouse hybridoma
cell producing an anti-Kank1 antibody was selected and amplified for further use.
The histological subtypes of RCC analyzed here were as follows; 92 clear cell RCCs, 11 papillary
RCCs, 5 chromophobe RCCs and 7 other histological types. We compared all histological
subtypes with clear cell RCC. The evaluation of positivity of staining was done by two
independent examiners, who decided that the sample was positive when more than 30 % of
cells were stained with the antibody, weakly positive (±) when 5 to 30 % cells were stained,
and negative when less than 5 % cells were stained. The 2004 WHO histological classification
(Eble et al., 2004), 2002 TNM classification (Edge et al., 2010) and Fuhrman nuclear grade
(Fuhrman et al., 1982) were used in this study. Kaplan-Meyer cause-specific survival was
determined and statistical difference in positivity was evaluated by the Kluskal-Wallis test
using Stat View™ software following the instructions.
Representative examples of positive and negative staining for the Kank1 protein in clear cell
RCC and positive staining in normal renal tubular cells are indicated in Fig. 4. Normal renal
tubules usually expressed Kank1. Of 92 clear cell RCCs, Kank1 was positive in 47 cases (52%).
Kank1 was weakly positive (less than 30% of cells) in 14 cases (15%). Kank1 was negative in
29 cases (33%). The results grouped by clinical outcome (clear cell RCC) and histology are
summarized in Table 2. There was no relation or special tendency between the staining results




Clear cell Alive without cancer 29 11 18
Alive with cancer 7 1 4
Dead 11 2 7
Others 16 alive, 7 dead 21 2 1
Table 2. Immunohistological staining of Kank1 antibody classified by clinical outcome (clear cell RCC) and histological
subtypes. Sums of the numbers of patients do not match all the evaluated numbers due to inavailabilty of follow-up
to judge the clinical outcome.
There were no differences in the survival curves for clear cell RCC among the groups (Fig. 5).
However, when the positivity rate was evaluated among the groups divided by the Furman
nuclear grade, a highly malignant grade of clear cell RCC showed high Kank1 positivity (p <
0.05), while the others did not (Table 3). In clear cell RCC, 42% of grade 1 tumors were Kank1
negative, while 80% of grade 3 tumors were Kank1 positive. In other histological types, there
was no apparent difference among nuclear grades (most of them showed Kank1). When sub-
divided by pathological T stages, higher T stages of clear cell RCC showed a tendency to
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ods,  and  the  relationship  between  the  expression  and  tumor  pathology,  patient  status,
and clinical outcomes is examined.
3.4.2. Expression of Kank1 protein in renal cancer and autologous normal kidney
1. Expression of Kank1 in RCC
We tried to find a RCC-related gene at 9p24, which lead to the discovery of Kank1. Of nine
ESTs analyzed in the 9p24 region, only three (WI-17492, WI-12779 and WI-19184) were
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monoclonal antibody. An anti-Kank1 (total Kank1) antibody was generated by a previously
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reported method (Roy et al., 2005). In brief, amino acids 406 to 580 of the Kank1 protein were
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the fusion protein in E. coli, it was purified and used to immunize mice. A mouse hybridoma
cell producing an anti-Kank1 antibody was selected and amplified for further use.
The histological subtypes of RCC analyzed here were as follows; 92 clear cell RCCs, 11 papillary
RCCs, 5 chromophobe RCCs and 7 other histological types. We compared all histological
subtypes with clear cell RCC. The evaluation of positivity of staining was done by two
independent examiners, who decided that the sample was positive when more than 30 % of
cells were stained with the antibody, weakly positive (±) when 5 to 30 % cells were stained,
and negative when less than 5 % cells were stained. The 2004 WHO histological classification
(Eble et al., 2004), 2002 TNM classification (Edge et al., 2010) and Fuhrman nuclear grade
(Fuhrman et al., 1982) were used in this study. Kaplan-Meyer cause-specific survival was
determined and statistical difference in positivity was evaluated by the Kluskal-Wallis test
using Stat View™ software following the instructions.
Representative examples of positive and negative staining for the Kank1 protein in clear cell
RCC and positive staining in normal renal tubular cells are indicated in Fig. 4. Normal renal
tubules usually expressed Kank1. Of 92 clear cell RCCs, Kank1 was positive in 47 cases (52%).
Kank1 was weakly positive (less than 30% of cells) in 14 cases (15%). Kank1 was negative in
29 cases (33%). The results grouped by clinical outcome (clear cell RCC) and histology are
summarized in Table 2. There was no relation or special tendency between the staining results




Clear cell Alive without cancer 29 11 18
Alive with cancer 7 1 4
Dead 11 2 7
Others 16 alive, 7 dead 21 2 1
Table 2. Immunohistological staining of Kank1 antibody classified by clinical outcome (clear cell RCC) and histological
subtypes. Sums of the numbers of patients do not match all the evaluated numbers due to inavailabilty of follow-up
to judge the clinical outcome.
There were no differences in the survival curves for clear cell RCC among the groups (Fig. 5).
However, when the positivity rate was evaluated among the groups divided by the Furman
nuclear grade, a highly malignant grade of clear cell RCC showed high Kank1 positivity (p <
0.05), while the others did not (Table 3). In clear cell RCC, 42% of grade 1 tumors were Kank1
negative, while 80% of grade 3 tumors were Kank1 positive. In other histological types, there
was no apparent difference among nuclear grades (most of them showed Kank1). When sub-
divided by pathological T stages, higher T stages of clear cell RCC showed a tendency to
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express Kank1 (p = 0.07) (Table 4). Other factors such as patient’s age, gender and the size of
the tumor (largest diameter) had no relation to the expression of Kank1 in clear cell and other
RCCs (data not shown).
Figure 4. Immunohistochemical analysis of Kank1 protein in clear cell RCC. There was a case of positive staining of
Kank1 protein in both normal renal tubular cells (upper left) and clear cell RCC (lower left), while another case indi‐
cates negative staining of Kank1 in clear cell RCC (lower right) while it was positive in the normal renal cells (upper
right) (reduced from 40× images).
Figure 5. Kaplan-meyer’s overall survival curve of RCC patients classified by Kank1 positivity (○ psitive; △ weakly posi‐
tive; □ negative). None of these survival curves showed statistical differences.
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Kank1
(+) (±) ( - )
Clear cell RCC grade 1 9 6 11
grade 2 31 6 19
grade 3 8 2 0
Others grade 1 5 0 0
grade 2 12 1 1
grade 3 5 1 0
Table 3. Results of Kank1 staining classified by histological grade.
Kank1
(+) (±) ( - )
Clear cell RCC pT1 27 10 17
pT2 5 2 8
pT3 14 2 4
pT4 2 0 0
Others pT1 11 1 1
pT2 5 0 0
pT3 5 0 0
pT4 1 1 0
Table 4. Results of Kank1 staining classified by pathological stage.
3.4.3. Meaning of Kank1 expression and clinical outcome
Many RCC cells showed inactivation of the Kank1 gene as shown here. This inactivation
presumably occurs at the early stage of carcinogenesis in normal renal tubular cells. Because
hemizygous methylation of Kank1 was observed in many cancer cells (Sarkar et al., 2002),
inactivation of Kank1 could be caused in both alleles by an epigenetic modification such as
methylation, rather than by mutations.
Concerning the genetic abnormality of RCC, mutations in the VHL gene are most prevalent
especially in clear cell RCC (Arai and Kanai, 2011). While VHL mutations can be found quite
often in sporadic clear cell RCC, they are not significant in other RCC histological subtypes or
benign oncocytoma. VHL mutations affect the activation of hypoxia-inducible factors, and
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investigation of this pathway will contribute to a new molecular targeting therapy for RCC
(Suwaki et al., 2011). The difference in VHL mutations among the RCC histological subtypes
suggests a difference in carcinogenesis for each histological subtype, though the origin of the
cancer is always a renal tubular cell.
Given that the alteration of Kank1 expression occurred at the early stage of carcinogenesis, our
findings that Kank1 expression differed among the histological subtypes of RCC might reflect
a difference in cancer development (Kim et al., 2005). In clear cell RCC, the loss of Kank1
expression occurred at a high rate in the lower grade tumors, and the expression was reoc‐
curred as the malignant grade increased. Although the reason for this is not clear, it is
presumed that epigenetic modifications such as methylation might have been removed when
the malignant grade increased, and consequently, the expression reoccurred (Kisseljova and
Kisseljov, 2005). There was no difference in Kank1 expression between the samples obtained
from the groups of patients who survived or not (Table 2). This may reflect the fact that
histological grade does not necessarily contribute to clinical outcome, but clinical stage (i.e.
the presence of metastasis) is more crucial to obtaining a good prognosis (RCC patients
diagnosed at the early stage have more than a 90% five year survival rate) (Lane and Kattan,
2008). The discordance of T stage (tumor size) and the malignant grade on Kank1 expression
could also be supposed for the same reason. A similar result was found for the expression of
CDKN2A encoding a growth suppressor protein, which is located at 9p21 and close to Kank1
(9p24) (unpublished data). Although the loss of Kank1 expression resulted in increased
proliferation and poor differentiation in in vitro study (Sarkar et al., 2002), our results about
the in vivo expression of Kank1 in clinical cases proved that reduced expression does not
necessarily reflect a high grade malignancy or poor clinical outcome. These contradictory
experimental and clinical results are very interesting, because they suggest that malignant
transformation of a normal renal tubular cell has many genetic alterations and clinical outcome
is contributed to by many factors in RCC.
4. Prospect of using Kank family genes in genetic diagnosis and gene
therapy for renal tumors
4.1. Future diagnostics for RCC
The lack of clinical impact of the current diagnostic markers for RCC apparently requires
progress in methodology, biology and pathology (Stewart et al., 2011). The progress in
methodology needs the quality of the methods to satisfy the specificity, stability and biological
relevance of the markers for diagnosis. For this, sufficient numbers, tens to thousands, of
markers would be needed and such markers could be obtained only through cellular signaling
analyses. There are quite a number of potential protein and genetic markers for diagnosis and
therapeutic targets of RCC based on the information of signal transduction (see Section 2), and
more information would be added in the future. While sampling is easier for DNA and RNA-
based assays, protein assays such as immunohistochemistry and more advanced mass-
spectrometry techniques have problems of contamination and degradation/modification at
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sampling and processing. In immunohistochemisty, protein cross-linking at the preparation
steps disturbs antibody binding. Sampling of homogenously expressed proteins is crucial for
the stability of assays, but would not be possible for most sampling cases as the tissue itself is
not homogenous. However, diagnosis even for such cases could be possible with markers
sufficiently distinguishing heterogenously expressed proteins in different parts of the diseased
tissue. In all cases, a statistical significance analysis should be included as a standard evaluation
step for quality control of multi-marker systems such as DNA microarrays (Shi et al., 2010).
Biologically relevant markers will be made available in the future based on the analysis of
signal transduction, because, as shown in Fig. 1 (Section 2), there are a number of markers
available even within a single signaling pathway and there are sufficient numbers of different
pathways affected by the disease, which will contribute to the stability of assays. As discussed,
the VHL and mTOR pathways have drawn much attentions to prognosis/diagnosis and
therapeutic targets for RCC, but there are more pathways such as the Myc and FLCN pathways
and pathways related to VEGF, PDGF and TGFα, and some are specific to subtypes of RCC
(Linehan et al., 2010; Allory et al., 2011).
Meanwhile, pathologically relevant markers will also be made available in the future, although
the situation is different from other technologies due to the technical limit in the number of
markers to examine simultaneously.
4.2. A new fluorescence-based immunohistochemical technique
One obstacle  to  improving immunohistochemistry  is  the  availability  of  markers.  Immu‐
nostaining is a relatively simple technique and thus can be used in unequipped laborato‐
ries  and  hospitals,  because  the  preparation,  storage  and  handling  of  samples  are
relatively  simple.  However,  ordinary immunostaining is  based on single-dye (or  single-
marker)  colorimetric  techniques  such as  the  alkaline  phosphatase-based method.  This  is
because  of  a  lack  of  multi-dye  (or  multi-marker)  colorimetric  techniques  due  to  expen‐
sive  devices  and,  especially,  inavailability  of  stable  fluorescent  dyes.  Fluorescent  dyes
have been used in many technologies although this has not happened yet in immunohis‐
tochemistry  because  of  the  lack  of  their  sufficient  stability.  Stable  fluorescent  dyes  are
thus needed for progress in immunohistochemistry.
We reported applications of a new fluorescent dye, Fluolid, for DNA microarray assays and
immunohistochemistry (Zhu et al., 2011). Fluolid dyes, including Fluolid-Orange, show
stability against heat and excess light compared with other dyes (Fig. 6) and thus can be stored
for more than a year without losing fluorescence (data not shown). So, multi-color immuno‐
histochemistry with stable fluorescent dyes will change the pathological diagnostics in several
ways: long-term storage of stained sections, simultaneous multi-marker detection and
handling of fluorescently stained sections. Heat and light stable fluorescent dyes will enable
us to store fluorescently stained sections at room temperature for a long time, which will be
important for follow-up studies by microdissection of specific regions.
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Figure 6. Stability of fluorescently labeled IgG. (A) Photostability of Fluolid-Orange- or Cy3-labeled IgG under irradia‐
tion for up to 150 sec with a laser beam at 488 nm. (B) Heat stability. Fluolid-Orange- or Cy3-labeled IgG was left in an
environment of 100ºC and fluorescence was measured every 30 min. For details, see Zhu et al. (2011).
4.3. Future therapeutics
As discussed in Section 4.1, future diagnosis will be based on sufficient numbers of protein
markers possibly obtained from signal transduction pathways, which will give a statistically
significant decision even for cases where no decisive markers, such as disease-causing
mutations or constitutive active proteins, are available. In the case of future therapeutics,
multiple targets will also be considered to be an effective strategy. Signal transduction-based
targeted therapeutics have already been developed for some diseases and drugs such as
imatinib or Gleevec/Glivec, a small molecule inhibitor against activated tyrosine kinase activity
by the Bcr-Abl fusion gene used for the treatment of chronic myelogenous leukemia, are
available (Radford, 2002). Other monoclonal antibody-based drugs such as trastuzumab or
Herceptin, which blocks a growth factor receptor HER2/neu (c-erbB-2) to treat breast cancer,
and panitumumab or Vectibix, which blocks HER1 to treat colorectal cancer, have been
developed based on signal-transduction. Although these drugs are effective, continuous use
will sometimes generate drug-resistant cancer (Schenone et al., 2011). So, treatment with
multiple targeting drugs will be important in future therapeutics and the same is true for the
matched diagnostics about multiple targets.
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1. Introduction
Sunitinib malate (Sutent, Pfizer inc., New York, NY) is an orally administered, multitargeted
inhibitor of tyrosine kinases, including vascular endothelial growth factor (VEGF) receptor,
platelet-derived growth factor (PDGF) receptor, stem cell factor receptor (KIT), fms-like ty‐
rosine kinase (FLT) -3, CSF-1R, and RET. Since the introduction of sunitinib for patients with
advanced renal tumor [1], significant objective responses of sunitnib have been revealed
[2-6]. In a randomized, multicenter, phase III trial enrolled 750 patients with previously-un‐
treated metastatic renal tumor to receive either sunitinib or interferon (IFN) -α, sunitinib
was superior to IFN-α in the objective response rate (47% vs 12%), progression-free survival
time (11.0 vs 5.0 months), and overall survival time (26.4 vs 21.8 months) [3, 4]. Also in a Jap‐
anese, multicenter, phase II trial enrolled 51 patients with first-line and pretreated metastatic
clear-cell renal tumor to recieve sinitinib, significant responses of sunitinib have been report‐
ed that objective response rate was 52.9%, the median progression-free survival time was
12.2 and 10.6 months, and the median overall survival time was 33.1 and 32.5 months in
first-line and pretreated patients, respectively [5, 6]. Sunitinib is approved worldwide for
first-line treatment of advanced clear-cell renal tumor. However, approximately half of pa‐
tients with advanced renal tumor do not see clinical benefits from sunitinib treatment. A
prognostic marker is needed for selecting patients who will benefit most from sunitinib.
It has been advocated that the necessity of determining molecular and clinical biomarkers
that may predict efficacy of sunitinib. The identification of biomarkers to predict response is
urgently needed. This chapter provides a brief overview of the signaling pathways of renal
tumors and introduces biomarkers to predict response to sunitinib of clinical variables.
© 2013 Fujita et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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2. Signaling pathways in renal tumors
Renal tumors originates from the tubular structures of the kidney and is calssified into four
major histological cell types. Clear-cell renal tumor is the most common type, accounting for
approximately 75% of all renal tumors. Other types are followed by papillary renal tumor
(approximately 15%), chromophobe renal tumor (approximately 5%), and renal oncocytoma
(approximately 5%) [7].
The most important molecular disorder in renal tumors involves the von Hippel-Lindau
(VHL) tumor suppressor gene, which is responsible for clear-cell renal tumors. The protein
production of the VHL gene, which is located on chromosome 3p25, prevents angiogenesis
and suppresses tumors [7]. Inactivating the phosphorylated VHL protein activates hypoxia-
inducible factor (HIF) and the induction of VEGF in clear-cell renal tumors. Mesenchymal-
epithelial transition factor (MET) and fumarate hydratase (FH) are responsible for papillary
renal tumors. While chromophobe renal tumors, Birt-Hogg-Dube (BHD) tumor suppresor
gene is mutated [8]. The inherited renal tumor genes VHL, MET, FH, folliculin, succinate dehy‐
drogenase, tuberous sclerosis complex (TSC) 1, and TSC2 are all involved in metabolic path‐
ways related to oxygen, iron, energy, and nutrient sensing [9].
Alterations in proto-oncogenes and tumor suppressor genes leads to dysregulated signal
transduction that underlies the abnormal growth and proliferation of cancer cells. Signaling
proteins that are centrally located in important cancer-associated signaling networks can
serve as therapeutic targets [10].
2.1. Angiogenetic signaling pathways
Renal tumors are frequnently characterized by hypoxic conditions. Hypoxia and compensa‐
tory hyperactivation of angiogenesis are thought to be particularly important in renal tu‐
mors, given the highly vascularized nature and the specific association of mutation in VHL,
a critical regulator of the hypoxic response. Hypoxic signaling is mediated by HIF. Increased
expression of HIF target genes is implicated in promoting cancer, inducing both changes
within the tumor and changes in the growth of adjacent endothelial cells to promote blood
vessel growth. The expression level of VEGF in renal tumors is known to strongly correlate
with microvessel density [10].
2.2. PI3K/AKT/mTOR pathway
Mammalian target of rapamycin (mTOR) and protein kinase B (AKT) are key oncogenic
process including cell proliferation, survival, and angiogenesis. PI3K promotes the genera‐
tion of phosphatidylinositol-3, 4, 5-triphosphate. Signaling from VEGF and PDGF through
AKT activates mTOR. Components of this PI3K/AKT/mTOR pathway are constitutively acti‐
vated in renal tumors compared to normal renal tissues [11].
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2.3. HGF/MET pathway
Changes in expression and activity of hepatocyte growth factor (HGF) and its receptor c-
MET have been associated with renal tumors. HGF binding to MET leads to phosphory‐
lation of two tyrosine residues at the C-terminus of MET, which leads to the recruitment
of adapter proteins and activation of PI3K/AKT pathway to promote renal tumor growth
and metastasis [12].
3. Biomarkers of response to sunitinib in renal tumors
3.1. Prognostic model
In the cytokine era, Motzer et al. [13] reported Memorial Sloan-Kettering Cancer Center
(MSKCC) risk classification, which is based on data from 463 patients with advanced renal
tumor who were treated with IFN-α cytokine therapy as first-line systemic therapy. The
MSKCC risk classification extracted five variable risk factors for short survival: low Karnof‐
sky performance status (PS) (< 80%), high lactate dehydrogenase (> 1.5 times the upper limit
of normal), low serum hemoglobin, high corrected serum calcium (> 10 mg/dL), and time
from initial renal tumor diagnosis to IFN-α therapy of less than one year. Each patient was
assigned to one of three risk groups: those with zero risk factors (favorable risk), those with
one or two risk factors (intermediate risk), and those with three or more risk factors (poor
risk). The median time to death was 30, 14, and 5 months in the favorable, intermediate, and
poor-risk groups, respectively [13]. These five risk criteria are now most frequently used
prognostic model for patients with advanced renal tumor.
In the era of targeted therapy, Heng et al. [14] reported a new prognostic model that added
platelet and neutrophil counts to the MSKCC model from a large multicenter study of 645
patients with metastatic renal tumor who were treated with targeted therapy. This study in‐
cluded three groups of patients: 396 patients treated with sunitinib, 200 patients treated with
sorafenib, and 49 patients treated with bevacizumab. Four of the five adverse prognostic fac‐
tors according to the MSKCC risk classification−low hemoglobin, high corrected serum cal‐
cium, low Karnofsky PS, and time from the initial renal tumor diagnosis to the start of
treatment of less than one year−emerged as independent predictors of poor survival. Addi‐
tionally, platelets greater than the upper limit of normal range, and neutrophils greater than
the upper limit of normal range, emerged as independent adverse prognostic factors.
MSKCC model with the addition of platelet and neutrophil counts can be incorporated into
patient care of targeted therapies [14].
3.2. C-reactive protein
C-reactive protein (CRP), a non-specific inflammatory acute-phase protein, is a representa‐
tive marker of systemic inflammatory response. CRP levels correlate with the production of
proinflammatory cytokines, such as interleukin (IL) -6 [15], and with tumor progression [16,
17]. It has been recognized as an important prognostic marker in the cytokine era. Atzpo‐
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transduction that underlies the abnormal growth and proliferation of cancer cells. Signaling
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a critical regulator of the hypoxic response. Hypoxic signaling is mediated by HIF. Increased
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within the tumor and changes in the growth of adjacent endothelial cells to promote blood
vessel growth. The expression level of VEGF in renal tumors is known to strongly correlate
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Mammalian target of rapamycin (mTOR) and protein kinase B (AKT) are key oncogenic
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2.3. HGF/MET pathway
Changes in expression and activity of hepatocyte growth factor (HGF) and its receptor c-
MET have been associated with renal tumors. HGF binding to MET leads to phosphory‐
lation of two tyrosine residues at the C-terminus of MET, which leads to the recruitment
of adapter proteins and activation of PI3K/AKT pathway to promote renal tumor growth
and metastasis [12].
3. Biomarkers of response to sunitinib in renal tumors
3.1. Prognostic model
In the cytokine era, Motzer et al. [13] reported Memorial Sloan-Kettering Cancer Center
(MSKCC) risk classification, which is based on data from 463 patients with advanced renal
tumor who were treated with IFN-α cytokine therapy as first-line systemic therapy. The
MSKCC risk classification extracted five variable risk factors for short survival: low Karnof‐
sky performance status (PS) (< 80%), high lactate dehydrogenase (> 1.5 times the upper limit
of normal), low serum hemoglobin, high corrected serum calcium (> 10 mg/dL), and time
from initial renal tumor diagnosis to IFN-α therapy of less than one year. Each patient was
assigned to one of three risk groups: those with zero risk factors (favorable risk), those with
one or two risk factors (intermediate risk), and those with three or more risk factors (poor
risk). The median time to death was 30, 14, and 5 months in the favorable, intermediate, and
poor-risk groups, respectively [13]. These five risk criteria are now most frequently used
prognostic model for patients with advanced renal tumor.
In the era of targeted therapy, Heng et al. [14] reported a new prognostic model that added
platelet and neutrophil counts to the MSKCC model from a large multicenter study of 645
patients with metastatic renal tumor who were treated with targeted therapy. This study in‐
cluded three groups of patients: 396 patients treated with sunitinib, 200 patients treated with
sorafenib, and 49 patients treated with bevacizumab. Four of the five adverse prognostic fac‐
tors according to the MSKCC risk classification−low hemoglobin, high corrected serum cal‐
cium, low Karnofsky PS, and time from the initial renal tumor diagnosis to the start of
treatment of less than one year−emerged as independent predictors of poor survival. Addi‐
tionally, platelets greater than the upper limit of normal range, and neutrophils greater than
the upper limit of normal range, emerged as independent adverse prognostic factors.
MSKCC model with the addition of platelet and neutrophil counts can be incorporated into
patient care of targeted therapies [14].
3.2. C-reactive protein
C-reactive protein (CRP), a non-specific inflammatory acute-phase protein, is a representa‐
tive marker of systemic inflammatory response. CRP levels correlate with the production of
proinflammatory cytokines, such as interleukin (IL) -6 [15], and with tumor progression [16,
17]. It has been recognized as an important prognostic marker in the cytokine era. Atzpo‐
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dien et al. [16] reported data from 425 patients who received cytokine-based home therapy.
On multivariate analysis, elevated CRP (≥ 1.1 mg/dL) was a poor prognostic factor, and Kaplan-
Meier analysis demonstrated that patients with elevated CRP had significantly worse over‐
all survival [16]. Casamassima et al. [17] reported that normal CRP (≤ 0.8 mg/dL) was the most
independent prognostic factor for 110 patients treated with IL-2-based immunotherapy. Ram‐
sey et al. [18] investigated the Glasgow Prognostic Score, which is based on a combination of
hypoalbuminemia and elevated CRP (> 1.0 mg/dL). They found that CRP was independent‐
ly associated with cancer-specific survival in 119 patients receiving immunotherapy [18]. Saito
et al. [19] described that CRP kinetics have an impact on survival in patients with metastatic
renal tumor treated with immunotherapy and/or metastasectomy. A decrease of CRP level
during treatment predicts better prognosis in patients with metastatic renal tumor, and pro‐









Age 0.988 (0.920−1.061) 0.7410
Gender 0.573 (0.139−2.355) 0.4384
ECOG PS0 4.200 (0.884−19.947) 0.0598
MSKCC non-poor 0.150 (0.026−0.864) 0.0206 0.632 (0.058−6.850) 0.7042
First-line 0.879 (0.238−3.249) 0.8468
Normal CRP 17.600 (1.961−157.970) 0.0011 13.525 (1.111−164.602) 0.0163
Adverse events
Hypertension 3.667 (0.954−14.094) 0.0523
HFS 6.500 (1.537−27.490) 0.0069 2.272 (0.324−15.930) 0.4104
Stomatitis 3.200 (0.826−12.404) 0.0844
Diarrhea 1.375 (0.368−5.136) 0.6347
Altered taste 8.250 (1.498−45.436) 0.0064 4.422 (0.533−36.655) 0.1517
Fatigue 5.133 (1.131−23.303) 0.0238 1.572 (0.192−12.841) 0.6740
Leukopenia 8.333 (0.867−80.130) 0.0337 5.436 (0.190−155.246) 0.2717
Anemia 1.771 (0.392−8.003) 0.4559
Thrombocytopenia 758.701 (0.000) 0.0670
Increased creatinine 2.182 (0.566−8.415) 0.2505
TSH abnormalities 2.812 (0.734−10.774) 0.1255
Table 1. Univariate and multivariate logistic regression analyses for selected variables
In the targeted therapy era, Fujita et al. [20] recently reported that CRP is an independent
prognostic indicator for patients with advanced renal tumor treated with sunitinib. A total of
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41 consecutive patients between December 2008 and August 2011 were enrolled in this study.
All patients had histologically proven clear-cell renal tumor. Non-tumor variables which were
selected from pretreatment characteristics and treatment-related adverse events were ana‐
lyzed on univariate and multivariate logistic regression analysis. Pretreatment characteris‐
tics were age, gender, Eastern Cooperative Oncology Group (ECOG) PS 0, MSKCC non-
poor (favorable and intermediate)  risk,  first-line treatment,  and normal CRP. Treatment-
related adverse events were hypertension, hand-foot skin reaction (HFS), stomatitis, diarrhea,
altered taste, fatigue, leukopenia, anemia, thrombocytopenia, increased creatinine, and thyroid-
stimulating hormone (TSH) abnormalities. On univariate analyses among pretreatment char‐
acteristics,  MSKCC non-poor risk classification and normal  CRP level  were significantly
correlated with response to treatment (P = 0.0206 and 0.0011, respectively). Among adverse
events,  HFS,  altered taste,  fatigue,  and leukopenia were significantly corralated with re‐
sponse to treatment (P = 0.0069, 0.0064, 0.0238, and 0.0337, respectively). Variable values in the
multivariate analysis included MSKCC non-poor risk classification, normal CRP, HFS, al‐
tered taste, fatigue, and leukopenia. After adjusting for differences in these variables, nor‐
mal CRP was independently associated with response to treatment (P = 0.0163).
Patients were grouped into two cohorts: those with normal CRP levels (≤ 0.30 mg/dL) and
those with elevated CRP levels (> 0.30 mg/dL), according to the normal values provided by
the manufacturer. The cohort with normal CRP comprised 10 males and 3 females (total 13
patients; 31.7%) with a median age of 63 years (range 46−77 years). The elevated CRP cohort
comprised 20 males and 8 females (total 28 patients; 68.3%) with a median age of 64 years
(range 36−80 years). MSKCC risk classification was favorable for 15.4% of the normal CRP
cohort and intermediate for 86.4%. In contrast, in the elevated CRP cohort, MSKCC risk clas‐
sification was favorable for 21.4%, intermediate for 46.4%, and poor for 32.2%. The differ‐
ence in risk classification between the two groups was statistically significant (P = 0.0377).
There were no statistically significant differences in any other pretreatment variables and tu‐
mor characteristics. The rate of partial response plus stable disease to treatment was 84.6%
for the normal CRP cohort and 35.7% for the elevated CRP cohort. The higher response rate






13 (31.7%) 28 (68.3%)
Gender (n (%)) 0.7118
Male 10 (76.9) 20 (71.4)




Mean ± standard deviation 64.8 ± 9.0 63.2 ± 9.1
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dien et al. [16] reported data from 425 patients who received cytokine-based home therapy.
On multivariate analysis, elevated CRP (≥ 1.1 mg/dL) was a poor prognostic factor, and Kaplan-
Meier analysis demonstrated that patients with elevated CRP had significantly worse over‐
all survival [16]. Casamassima et al. [17] reported that normal CRP (≤ 0.8 mg/dL) was the most
independent prognostic factor for 110 patients treated with IL-2-based immunotherapy. Ram‐
sey et al. [18] investigated the Glasgow Prognostic Score, which is based on a combination of
hypoalbuminemia and elevated CRP (> 1.0 mg/dL). They found that CRP was independent‐
ly associated with cancer-specific survival in 119 patients receiving immunotherapy [18]. Saito
et al. [19] described that CRP kinetics have an impact on survival in patients with metastatic
renal tumor treated with immunotherapy and/or metastasectomy. A decrease of CRP level
during treatment predicts better prognosis in patients with metastatic renal tumor, and pro‐









Age 0.988 (0.920−1.061) 0.7410
Gender 0.573 (0.139−2.355) 0.4384
ECOG PS0 4.200 (0.884−19.947) 0.0598
MSKCC non-poor 0.150 (0.026−0.864) 0.0206 0.632 (0.058−6.850) 0.7042
First-line 0.879 (0.238−3.249) 0.8468
Normal CRP 17.600 (1.961−157.970) 0.0011 13.525 (1.111−164.602) 0.0163
Adverse events
Hypertension 3.667 (0.954−14.094) 0.0523
HFS 6.500 (1.537−27.490) 0.0069 2.272 (0.324−15.930) 0.4104
Stomatitis 3.200 (0.826−12.404) 0.0844
Diarrhea 1.375 (0.368−5.136) 0.6347
Altered taste 8.250 (1.498−45.436) 0.0064 4.422 (0.533−36.655) 0.1517
Fatigue 5.133 (1.131−23.303) 0.0238 1.572 (0.192−12.841) 0.6740
Leukopenia 8.333 (0.867−80.130) 0.0337 5.436 (0.190−155.246) 0.2717
Anemia 1.771 (0.392−8.003) 0.4559
Thrombocytopenia 758.701 (0.000) 0.0670
Increased creatinine 2.182 (0.566−8.415) 0.2505
TSH abnormalities 2.812 (0.734−10.774) 0.1255
Table 1. Univariate and multivariate logistic regression analyses for selected variables
In the targeted therapy era, Fujita et al. [20] recently reported that CRP is an independent
prognostic indicator for patients with advanced renal tumor treated with sunitinib. A total of
Renal Tumor34
41 consecutive patients between December 2008 and August 2011 were enrolled in this study.
All patients had histologically proven clear-cell renal tumor. Non-tumor variables which were
selected from pretreatment characteristics and treatment-related adverse events were ana‐
lyzed on univariate and multivariate logistic regression analysis. Pretreatment characteris‐
tics were age, gender, Eastern Cooperative Oncology Group (ECOG) PS 0, MSKCC non-
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mal CRP was independently associated with response to treatment (P = 0.0163).
Patients were grouped into two cohorts: those with normal CRP levels (≤ 0.30 mg/dL) and
those with elevated CRP levels (> 0.30 mg/dL), according to the normal values provided by
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patients; 31.7%) with a median age of 63 years (range 46−77 years). The elevated CRP cohort
comprised 20 males and 8 females (total 28 patients; 68.3%) with a median age of 64 years
(range 36−80 years). MSKCC risk classification was favorable for 15.4% of the normal CRP
cohort and intermediate for 86.4%. In contrast, in the elevated CRP cohort, MSKCC risk clas‐
sification was favorable for 21.4%, intermediate for 46.4%, and poor for 32.2%. The differ‐
ence in risk classification between the two groups was statistically significant (P = 0.0377).
There were no statistically significant differences in any other pretreatment variables and tu‐
mor characteristics. The rate of partial response plus stable disease to treatment was 84.6%
for the normal CRP cohort and 35.7% for the elevated CRP cohort. The higher response rate
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ECOG PS (n (%)) 0.0595
0 12 (92.3) 18 (64.3)
≥ 1 1 (7.7) 10 (35.7)
MSKCC risk classification (n (%)) 0.0377
Favorable 2 (15.4) 6 (21.4)
Intermediate 11 (84.6) 13 (46.4)
Poor 0 (0) 9 (32.2)
Prior nephrectomy (n (%)) 0.2767
Yes 12 (92.3) 22 (78.6)
No 1 (7.7) 6 (21.4)
T stage (n (%)) 0.8187
T1 or T2 6 (46.2) 14 (50.0)
≥ T3 7 (53.8) 14 (50.0)
Grade (n (%)) 0.6628
1 or 2 9 (69.2) 17 (60.7)
3 3 (23.1) 8 (28.6)
Prior immunotherapy (n) 0.2482
IFN-α 9 14
IL-2 and IFN-α 3 6




















No. metastatic sites (n (%)) 0.1929
1 6 (46.1) 8 (28.6)
≥ 2 6 (46.1) 20 (71.4)
Treatment (n (%)) 0.2122
First-line 3 (23.1) 13 (46.4)
Second-line 6 (46.1) 6 (21.4)
Third-line 4 (30.8) 9 (32.2)
Responses (n (%)) 0.0022
Partial response plus stable disease 11 (84.6) 10 (35.7)
Table 2. Patient characteristics grouped by CRP level
The median progression-free survival time for the elevated CRP cohort was 6.0 months. In
contrast, the median progression-free survival time for the normal CRP cohort was signifi‐
cantly longer, at 19.0 months (log-rank P = 0.0361).
Figure 1. Kaplan-Meier progression-free survival for patients grouped by CRP level
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CRP is a significant independent prognostic indicator for patients with advanced renal tu‐
mor treated with sunitinib. Pretreatment CRP level could be a useful biomarker for response
to sunitinib treatment [20].
3.3. Selected adverse events
Sunitinib has been related a variety of adverse events, key notable clinical adverse events
included diarrhea (61%), fatigue (54%), hypertension (30%), stomatitis (30%), HFS (29%),
and asthenia (20%) [4]. Laboratory abnormalities also found that included leukopenia (78%),
anemia (79%), increased creatinine (70%), and thrombocytopenia (68%) [4]. If adverse events
depends on the degree of systemic exposure to sunitinib, on which clinical efficacy also de‐
pends, adverse events might be potential predictors of sunitinib efficacy [21]. Several au‐
thors have described the correlation between sunitinib responses and selected treatment-
related adverse events.
3.3.1. Hypertension
Hypertension is commonly associated with targeted therapy. It develops when VEGF stimu‐
lates production of nitric oxide and prostacyclins in vascular endothelial cells [22, 23], vaso‐
dilatory mechanisms become inhibited, and peripheral vascular resistance increases, leading
to increased blood pressure.
Rini et al. [24] demonstrated that sunitinib-associated hypertension is associated with im‐
proved clinical outcomes without clinically significant increases in hypertension-associated
adverse events. This analysis included large pooled data from four clinical trilas of 4915 pa‐
tients with metastatic renal tumor who were treated with sunitinib. Sunitinib-induced hy‐
pertension had significantly better outcomes than those without treatment-induced
hypertension in the objective response rate (54.8% vs 8.7%), the median progression-free sur‐
vival time (12.5 vs 2.5 months), and the median overall survival time (30.9 vs 7.2 months, P<
0.001 for all) [24].
Bono et al. [25] reported that sunitinib-induced hypertension was associated with frequent
tumor response (P = 0.001), significantly longer disease progression time (P = 0.0003), and
overall survival time (P = 0.001). On multivariate analysis including the variables of pretreat‐
ment hemoglobin, pretreatment calcium level, PS, time from diagnosis to onset of metasta‐
sis, and treatment-related hypertension, hypertension was an independent predictor of
progression-free survival (P = 0.0030) [25].
Szmit et al. [26] reported that patients who developed hypertension related to sunitinib
treatment experienced significantly longer progression-free survival time and overall sur‐
vival time compared to those who did not hypertension (P< 0.00001). Patients treated with at
least 3 antihypertensive agents experienced significantly longer progression-free survival
time (P = 0.00002) and overall survival time (P = 0.00001) compared either with patients who
received one or two medications or with patients who received no medications [26].
Rixe et al. [27] reported that appearance or worsening hypertension was found to be the sin‐
gle independent predictor of a better clinical response to sunitinib on multivariate analysis
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using logistic regression model (P = 0.009). Furthermore, grade 3 hypertension was correlat‐
ed with a better outcome (P = 0.03). The appearance of hypertension, particularly grade 3,
was associated with higher treatment response to sunitinib in metastatic renal tumors. Early
and intensive antihypertensive therapy with the goal of maintaining the sunitinib use may
improve response rate in those patients [27].
Overall, hypertension related to sunitinib was a positive predictive factor associated with
significantly better objective response rate, longer progression-free survival and overall sur‐
vival in patients with metastatic renal tumor treated with sunitinib.
3.3.2. Hypothyroidism
Treatment-related hypothyroidism has been reported a useful predictor of progression-free
survival for metastatic renal tumors undergoing treatment with sunitinib [28]. In the 52 patients
with metastatic renal tumor treated with sunitinib, 13 patients (25.0%) developed hypothyr‐
oidism during treatment. Subclinical hypothyroidism was defined as serum TSH above the
upper limit of normal, with total triiodothyronine (T3) and thyroxine (T4) within normal limits.
Clinical hypothyroidism was defined as low serum T3 and T4 together with elevated TSH.
Hypothyroidism was associated with a longer progression-free survival time (P  = 0.032).
Hormone replacement with 1-thyroxine did not have an influence on survival [28].
3.4. Others
Han et al. [29] reported the initial tumor enhancement on contrast-enhanced computed to‐
mography (CT) could be useful as a clinical predictor during targeted therapy in 198 meta‐
static lesions of 46 patients. On multivariate analyses, tumor enhancement and enhancement
pattern were associated with objective responses (P = 0.003 and 0.028, respectively). Addi‐
tionally, tumor enhancement was associated with tumor size reduction (P = 0.004). On Cox
proportional hazards models, only tumor enhancement was associated significantly with
the time to size reduction and progression-free survival time (P = 0.03 and 0.015, respective‐
ly). Tumor enhancement on contrast-enhanced CT was associated with tumor size reduc‐
tion, time to response, and time to progression of individual metastases in patients with
metastatic renal tumor who received targeted therapy [29].
Kayani et al [30] revealed prognostic significance of 18F-fluorodeoxyglucose-positron emis‐
sion tomography (FDG-PET)/CT as a biomarker of response to sunitinib. A total of 44 pa‐
tients with newly diagnosed untreated metastatic renal tumor were enrolled in this study.
18F-FDG-PET/CT scans were conducted before, after 4 weeks, and after 16 weeks of sunitinib
given. On multivariate analysis, a high SUVmax and an increased number of PET-positive le‐
sions correlated with shorter overall survival. The early metabolic responses are associated
with a pharmacodynamic effect of drug and it is not until later identification with acquired
resistance occurs [30].
Yuasa et al. [31] reported that initial tumor size is inversely associated with the tumor reduc‐
tion rate of individual metastatic sites and primary tumors in patients with metastatic renal
tumor who underwent targeted therapy. A data from 139 metastatic and 16 primary lesions
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CRP is a significant independent prognostic indicator for patients with advanced renal tu‐
mor treated with sunitinib. Pretreatment CRP level could be a useful biomarker for response
to sunitinib treatment [20].
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Sunitinib has been related a variety of adverse events, key notable clinical adverse events
included diarrhea (61%), fatigue (54%), hypertension (30%), stomatitis (30%), HFS (29%),
and asthenia (20%) [4]. Laboratory abnormalities also found that included leukopenia (78%),
anemia (79%), increased creatinine (70%), and thrombocytopenia (68%) [4]. If adverse events
depends on the degree of systemic exposure to sunitinib, on which clinical efficacy also de‐
pends, adverse events might be potential predictors of sunitinib efficacy [21]. Several au‐
thors have described the correlation between sunitinib responses and selected treatment-
related adverse events.
3.3.1. Hypertension
Hypertension is commonly associated with targeted therapy. It develops when VEGF stimu‐
lates production of nitric oxide and prostacyclins in vascular endothelial cells [22, 23], vaso‐
dilatory mechanisms become inhibited, and peripheral vascular resistance increases, leading
to increased blood pressure.
Rini et al. [24] demonstrated that sunitinib-associated hypertension is associated with im‐
proved clinical outcomes without clinically significant increases in hypertension-associated
adverse events. This analysis included large pooled data from four clinical trilas of 4915 pa‐
tients with metastatic renal tumor who were treated with sunitinib. Sunitinib-induced hy‐
pertension had significantly better outcomes than those without treatment-induced
hypertension in the objective response rate (54.8% vs 8.7%), the median progression-free sur‐
vival time (12.5 vs 2.5 months), and the median overall survival time (30.9 vs 7.2 months, P<
0.001 for all) [24].
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sis, and treatment-related hypertension, hypertension was an independent predictor of
progression-free survival (P = 0.0030) [25].
Szmit et al. [26] reported that patients who developed hypertension related to sunitinib
treatment experienced significantly longer progression-free survival time and overall sur‐
vival time compared to those who did not hypertension (P< 0.00001). Patients treated with at
least 3 antihypertensive agents experienced significantly longer progression-free survival
time (P = 0.00002) and overall survival time (P = 0.00001) compared either with patients who
received one or two medications or with patients who received no medications [26].
Rixe et al. [27] reported that appearance or worsening hypertension was found to be the sin‐
gle independent predictor of a better clinical response to sunitinib on multivariate analysis
Renal Tumor38
using logistic regression model (P = 0.009). Furthermore, grade 3 hypertension was correlat‐
ed with a better outcome (P = 0.03). The appearance of hypertension, particularly grade 3,
was associated with higher treatment response to sunitinib in metastatic renal tumors. Early
and intensive antihypertensive therapy with the goal of maintaining the sunitinib use may
improve response rate in those patients [27].
Overall, hypertension related to sunitinib was a positive predictive factor associated with
significantly better objective response rate, longer progression-free survival and overall sur‐
vival in patients with metastatic renal tumor treated with sunitinib.
3.3.2. Hypothyroidism
Treatment-related hypothyroidism has been reported a useful predictor of progression-free
survival for metastatic renal tumors undergoing treatment with sunitinib [28]. In the 52 patients
with metastatic renal tumor treated with sunitinib, 13 patients (25.0%) developed hypothyr‐
oidism during treatment. Subclinical hypothyroidism was defined as serum TSH above the
upper limit of normal, with total triiodothyronine (T3) and thyroxine (T4) within normal limits.
Clinical hypothyroidism was defined as low serum T3 and T4 together with elevated TSH.
Hypothyroidism was associated with a longer progression-free survival time (P  = 0.032).
Hormone replacement with 1-thyroxine did not have an influence on survival [28].
3.4. Others
Han et al. [29] reported the initial tumor enhancement on contrast-enhanced computed to‐
mography (CT) could be useful as a clinical predictor during targeted therapy in 198 meta‐
static lesions of 46 patients. On multivariate analyses, tumor enhancement and enhancement
pattern were associated with objective responses (P = 0.003 and 0.028, respectively). Addi‐
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18F-FDG-PET/CT scans were conducted before, after 4 weeks, and after 16 weeks of sunitinib
given. On multivariate analysis, a high SUVmax and an increased number of PET-positive le‐
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treated with targeted agents were analyzed. Both univariate and multivariate linear regres‐
sion analyses revealed that only the initial tumor size was associated with the rate of reduc‐
tion in individual tumors (P< 0.001) [31].
Abel et al. [32] reported that early 10% decrease in tumor diameter of the primary tumor
was predictive of improved overall survival in patients with metastatic renal tumor treated
with sunitinib. In 75 consecutive treatment-naive patients, median overall survival time for
patients without minor primary tumor response, with minor primary tumor response after
60 days, and with early minor primary tumor response was 10.3, 16.5, and 30.2 months, re‐
spectively. On multivariate analysis, early minor response was an independent predictor of
improved overall survival (P = 0.031) [32].
High visceral fat area could be a predictive biomarker from shorter survival in patients giv‐
en first-line antiangiogenic agents including sunitinib for metastatic renal tumors [33]. In 113
study population, 46 patients received sunitinib as first-line therapy. Visceral fat area was
measured retrospectively on the available CT scans performed before sunitinib initiation at
the level of the umbilicus with the patient in the supine position. ImageJ software was used
to measure pixels with densities in the -190 Hounsfield units to -30 Hounsfield units range
to delineate the visceral compartment and to compute the cross-sectional area of each in cm2.
On multivariate analysis, high visceral fat area was independently associated with shorter
time to progression and overall survival. Visceral fat area measured before starting first-line
targeted therapy is likely to be a simple predictive biomarker in patients with metastatic re‐
nal tumor [33].
Finally, hyponatremia seem to represent significant predictive factor for cancer-specific sur‐
vival in metastatic renal tumors treated with targeted therapy as first-line therapy [34]. A
total of 87 patients treated with targeted therapy including sunitinib, severe (≤ 134 mEq/L)
and mild (135-137 mEq/L) hyponatremia was shown to be significantly associated with can‐
cer-specific survival time (P = 0.001 and 0.013, respectively). In 38 patients treated wth suni‐
tinib, 4 patients (10.5%) developed severe hyponatremia and 8 patients (21.1%) developed
mild hyponatremia. Hyponatremia could be easily and readily determined and might be an
important prognostic factor [34].
4. Conclusions
Candidate biomarkers to predict response to sunitinib have been shown. Among clinical factors,
CRP is a significant independent prognostic indicator for sunitinib. Severe adverse events,
hypertension and hypothyroidism also recognized as biomarkers of favorable efficacy. Addi‐
tionally, tumor enhancement, SUVmax on FDG/PET-CT, tumor size, visceral fat area and hypo‐
natremia have been revealed clinical significance of sunitinib responses. Although further
investigation will be required, these biomarkers can be utilized to measure therapeutic re‐
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Abel et al. [32] reported that early 10% decrease in tumor diameter of the primary tumor
was predictive of improved overall survival in patients with metastatic renal tumor treated
with sunitinib. In 75 consecutive treatment-naive patients, median overall survival time for
patients without minor primary tumor response, with minor primary tumor response after
60 days, and with early minor primary tumor response was 10.3, 16.5, and 30.2 months, re‐
spectively. On multivariate analysis, early minor response was an independent predictor of
improved overall survival (P = 0.031) [32].
High visceral fat area could be a predictive biomarker from shorter survival in patients giv‐
en first-line antiangiogenic agents including sunitinib for metastatic renal tumors [33]. In 113
study population, 46 patients received sunitinib as first-line therapy. Visceral fat area was
measured retrospectively on the available CT scans performed before sunitinib initiation at
the level of the umbilicus with the patient in the supine position. ImageJ software was used
to measure pixels with densities in the -190 Hounsfield units to -30 Hounsfield units range
to delineate the visceral compartment and to compute the cross-sectional area of each in cm2.
On multivariate analysis, high visceral fat area was independently associated with shorter
time to progression and overall survival. Visceral fat area measured before starting first-line
targeted therapy is likely to be a simple predictive biomarker in patients with metastatic re‐
nal tumor [33].
Finally, hyponatremia seem to represent significant predictive factor for cancer-specific sur‐
vival in metastatic renal tumors treated with targeted therapy as first-line therapy [34]. A
total of 87 patients treated with targeted therapy including sunitinib, severe (≤ 134 mEq/L)
and mild (135-137 mEq/L) hyponatremia was shown to be significantly associated with can‐
cer-specific survival time (P = 0.001 and 0.013, respectively). In 38 patients treated wth suni‐
tinib, 4 patients (10.5%) developed severe hyponatremia and 8 patients (21.1%) developed
mild hyponatremia. Hyponatremia could be easily and readily determined and might be an
important prognostic factor [34].
4. Conclusions
Candidate biomarkers to predict response to sunitinib have been shown. Among clinical factors,
CRP is a significant independent prognostic indicator for sunitinib. Severe adverse events,
hypertension and hypothyroidism also recognized as biomarkers of favorable efficacy. Addi‐
tionally, tumor enhancement, SUVmax on FDG/PET-CT, tumor size, visceral fat area and hypo‐
natremia have been revealed clinical significance of sunitinib responses. Although further
investigation will be required, these biomarkers can be utilized to measure therapeutic re‐
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1. Introduction
Over 64000 new renal-cell carcinomas (RCC) are annually detected in the United States, and
13000 people will die from the disease. Most RCC are discovered incidentally on medical
imaging and a great percentage of them may be treated by surgery, but one third of patients
will present either with locally advanced tumor or with metastases[1]. In addition, another
third of patients may develop metastatic disease after initial treatment.
In cancer patients imaging techniques are essential in three aspects. First, at the time of diag‐
nosis and the extension study. Ultrasonography, computed tomography (CT) and magnetic
resonance imaging (MRI) are currently available to evaluate renal masses.
Second,  since  most  RCC are  now early-stage  disease  suitable  for  surgery  with  curative
intent, the patient is candidate to follow-up during years. Early detection of recurrence is
vital, because single-organ disease may be trated by metastasectomy. Again, CT and MRI
are essential  in this  setting.  Also,  these imaging modalities  are useful  to follow-up peo‐
ple with increased susceptibility for RCC, since we have tools to identify at least a sub‐
set of these patients.
And third, imaging techniques are fundamental to evaluate the response to treatment. RE‐
CIST criteria, published in 2000 and revised in 2009, has become the most widely accepted
guideline for evaluate response [2]. Although RECIST criteria have been proved as a useful
tool to asses response in solid tumors, some limitations have been noted. One of these limi‐
tations are observed in patients treated with specific targeted therapies [3].
Traditionally, RCC have been remarkably resistant to chemo- and radiotherapy. Over the last
decade, there has been an increasing knowledge about pathophysiological processes in RCC
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including oncology pathways due to a specific driver mutations: silencing von-Hippel Lindau
gene, angiogenesis alterations, evasion of apoptosis or sustained angiogenesis.These features
have enabled the emergence of a wide spectrum of novel oncology drugs that are designed to
target and interfere with specific aberrant biological pathways. Therefore, morphological crite‐
ria may not provide meaningful data in this setting and the incorporation of new imaging tech‐
niques (MRI diffusion,  perfusion CT, PET scan, etc....)  in the diagnosis of extension and
assessment of efficacy of this drugs may provide unique physiological data that can be correlat‐
ed with histopathological changes and may provide functional information.
In this chapter we will review the main techniques of radiological diagnosis and staging, the
role of new imaging techniques and we will also discuss the validity of the classical criteria
of interpretation of response.
2. Common techniques of characterization of renal lesions
2.1. Ultrasound
Ultrasound (US) is one of the most common techniques used in the initial evaluation of re‐
nal lesions. It is a low cost and easy access technique and it also allows avoiding the expo‐
sure to ionizing radiation and the use of contrast (Figure 1).
Figure 1. Solid mass in right upper kidney (5 x 3.7 cm).
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Although it is an observer-dependent technique, it allows monitoring renal lesions growth
and distinguish between cystic and solid lesions. Ultrasonographic features of cystic lesions
that allow distinction with malignant lesions or abscesses are:
1. Round morphology, smooth and well-defined walls, separating it from the surrounding
parenchyma.
2. There is a strong posterior wall indicating good transmission through the cyst and en‐
hanced transmission beyond the cyst.
3. Absence of internal echoes. The presence of thickened internal septa, calcifications, or
mural vascularity indicate malignancy.
One of its limitations is the evaluation and characterization of small lesions. Jamis found
that CT detected more renal lesions, especially if they were noncontour deforming. 5% of 2
cm lesions were not detected with CT, an 30% were missed in US. Of lesions under 1 cm,
24% were not detected in TC versus 80% with US [4]. Moreover, given the variability in the
echogenicity of malignant kidney, it can be difficult, in the case of isoechoic images, the
identification and distinction of these lesions.
In recent years it has become increasingly important the use of contrast-enhanced ultra‐
sound (CEUS). Current CEUS consist of intravenously injected microbubbles that increase
the number of reflectors in the vascular space. It has different utilities. It is useful in the dif‐
ferential diagnosis of solid and cystic lesions so as to characterize cystic lesions in benign or
malignant [5]. Solid lesions show early arterial enhancement, normally lower than sur‐
rounding parenchyma. The delayed enhancement varies and after an arterial phase lesions
are isoechoic relative to parenchyma. Often because of intralesional necrosis, there are intra‐
lesional areas without contrast enhancement.
It is of particular interest the characterization of complex cystic lesions. Some studies have
reported a sensitivity and specificity similar to CT [6] [7]. It can be considered a valid alter‐
native to CT and MRI in monitoring these lesions that need prolonged follow [8]. It may also
be useful in detecting small renal masses, improving the accuracy of simple ultrasound,
since it allows to observe changes in the thickness of the cortical pyramidal space, not visible
in simple US.
2.2. CT scan
Computed tomography (CT) is the modality of choice for the diagnosis and study of exten‐
sion of renal carcinoma, with a sensitivity greater than 95% (Figure 2) [9]. In addition, the
development of multidetector CT has allowed an increase in the rate of detection and diag‐
nosis in early stages [10].
For the evaluation of suspicious lesions, it is advisable to have a specific protocol. This
should include a scan without contrast to determine the presence of calcification or fatty tis‐
sue within the tumor, and will serve as baseline study to study if these lesions enhance after
contrast administration.
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Figure 2. CT scan, right renal cell carcinoma.
The three perfusion renal phases defined in CT diagnosis are: corticomedullary phase, neph‐
rographic phase, and renal elimination phase (or excretory phase) [11].
The images in the corticomedullary phase help to identify the lesion and its vascular supply,
being optimal for detecting or excluding tumor invasion of the renal veins [12]. The nephro‐
graphic and elimination phase help detecting renal masses, especially those of small size.
The appearance of renal carcinoma in CT varies depending on the size of the tumor vascula‐
ture, the extent of necrosis or intratumoral cystic changes. Enhancement of a renal lesion
shows that it is hypervascular; this is the most important finding in the evaluation of renal
masses, being a useful parameter in differentiating histological subtypes.
Different groups have shown as clear cell  carcinoma has a higher contrast enhancement
than other  histological  subtypes,  especially  papillary  carcinomas [13].  Zhang et  al  show
that 90% of the clear cell renal carcinoma are hypervascular and heterogeneous (with sol‐
id  hypervascular  foci  and  low  attenuation  foci  by  necrotic  or  cystic  changes).  Seventy
five  % of  papillary  carcinomas  were  hypovascular  and 90% had an uniform pattern  or
peripheral uptake while chromophobe tumors often show a moderate and homogeneous
enhancement [10].
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Tumors less than 3 cm sometimes have a smooth contour, they are homogeneous and diffi‐
cult to distinguish from some benign lesions. Renal cystic carcinomas usually have thick‐
ened walls and septa, sometimes with calcification. Three-dimensional CT is important in
staging renal cell carcinoma, with the objective of identifying patients having a resectable tu‐
mor and to define the best therapeutic option. The value of CT is limited to the study of the
perirenal fat. Various criteria have been used to describe the appearance of perirenal fat in‐
filtration. Trabeculation of perirenal fat is not a reliable sign of tumor involvement, and is
found in approximately 50% of patients with localized tumors T1 and T2. It can be caused
by edema, vascular congestion, or prior inflammation [14]. The presence of a nodule uptake
in perirenal fat, is considered the most specific finding of perirenal invasion, with high spe‐
cificity (98%) but low sensitivity (46%) [15].
Helical CT has also been shown to have high accuracy in the diagnosis of renal vein in‐
vasion with  a  negative  predictive  value  of  97% and a  positive  predictive  value  of  92%
(Figure 3) [16].
Figure 3. Renal cell carcinoma with thrombosis of the inferior cava vein.
The adrenal evaluation is important because if no abnormalities are detected on CT, adrena‐
lectomy can be avoided. CT has a high negative predictive value in the detection of adrenal
involvement by RCC. When the adrenal gland is enlarged, displaced or not displayed an
adrenalectomy should be considered [17].
The study of lymph node is based primarily on its size. It is considered that a lymph node
could be metastatic when its diameter is greater than 1 cm. However this approach has a
limited specificity and sensitivity (between 3 and 43% in different studies) because the size
increase may be due to inflammatory changes.
The nodal enhancement pattern helps differentiate between reactive and malignant lympha‐
denopathy. Metastatic lymph nodes can be enhanced after administration of contrast, espe‐
cially if the primary tumor is highly vascularized.
Finally, given that CT plays an important role in detecting distant disease, it is necessary to
conduct a study of the chest and abdomen in the staging of metastatic disease.
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2.3. Magnetic resonance imaging
Magnetic resonance imaging (MRI) is useful when computed tomography cannot be per‐
formed, but it has not proved to be superior to CT in the detection or characterization of
renal masses. The study should include T1 and T2 sequences and opposed-phase images
to  detect  intratumoral  fat.  Dynamic  study after  paramagnetic  contrast  administration  is
essential.
Both CT and MRI have high reliability in delineating the extent of intratumoral thrombus,
since it could change the surgical approach. However, MRI is more sensitive than CT to dif‐
ferentiate between tumoral and non-tumoral thrombus. The tumoral thrombus is heteroge‐
neous or hyperintense on T2-weighted images, with marked enhancement on the
postcontrast images, and, sometimes, it is seen the continuity with the renal tumor. The tu‐
mor thrombus is hypointense, not homogeneous and and does not enhance after contrast
administration [18].
Also, as discussed below, MRI can help us to distinguish between different histological sub‐
types of renal cell carcinoma (RCC), and between these ones and benign tumors such as on‐
cocytomas and angiomyolipomas.
Clear cell RCC usually shows a signal intensity similar to that of the renal parenchyma on
T1-weighted images and it´s high intensity on T2-weighted images (Figure 4). Central ne‐
crosis is common, and it is typically seen as a homogeneus hypointense area in the center of
the mass on T1-weighted images, and hyperintense, rarely hypointense, on T2-weighted im‐
ages [19]. If intratumoral hemorrhage occurs, the appearance of this will depend on the de‐
gree of degradation of its components. A hypointense ring, or pseudocapsule, is sometimes
seen on both T1 and T2-weighted images, and is due to compression of the adjacent renal
parenchyma by the tumor growth. Breakage of this pseudocapsule correlates with advanced
stage and higher nuclear grade [20]. This histological subtype tends to be hypervascular,
with heterogeneous enhancement during the arterial phase. You can also appreciate renal
vein thrombus in more aggressive and advanced tumors. They can also be predominantly
cystic, with only a few areas of solid component [21].
The type I papillary RCC is characterized by a homogeneous hyposignal on T2-weighted
images, with homogeneous low-level enhancement after contrast administration [22]. Some‐
times they show necrosis and hemorrhage. Type II papillary RCC have a more complex ap‐
pearance, with hemorrhage and necrosis. It is common to see a hemorrhagic cystic mass
with enhancing papillary projections at the periphery. In both types is frequent the presence
of a fibrous capsule [23].
Chromophobe RCC may show cystic changes within a solid mass. It is not common the
presence of necrotic foci, even in large tumors. Its appearance on MR can be identical to
those of clear cell RCC [23].
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Figure 4. Clear cell RCC. Heterogeneous tumor with focal posterior bleeding. T2 (left side) and T1 sequence (right
side) with fast gradient contrast, showing renal vein invasion. Courtesy Dr. Armesto-Pérez.
The MR Imaging appearance of oncocytomas is variable and nonspecific. They are typically
spherical and well-defined masses with hyposignal on T1-weighted images and hypersignal
on T2-weighted images, in most cases. The central scar, when present, has a stellate appear‐
ance with low signal intensity on T1-weighted images and high signal intensity on T2-
weighted images, and it may show delayed enhancement after contrast administration.
Sometimes are surrounded by a well-defined hypointense capsule [24].
Angiomyolipoma with a predominant fatty component is isointense relative to fat on all MR
Imaging sequences and its signal intensity is higher than that of the renal parenchyma on
T1-weighted images. Fat-suppression sequences are also useful. Lipid-poor angiomyolipo‐
mas are difficult to distinguish from clear cell RCC with current imaging methods, so may
occasionally be required histopathological evaluation to establish the correct diagnosis [21].
Diffusion-weighted imaging may be useful in differentiating between RCC and oncocytoma
and in the characterization of the different histological subtypes of RCC. Angiomyolipoma,
due to the presence of fat, can give false positives, but it is characterized through conven‐
tional sequences [25] [26].
The whole-body MRI, at present, is positioning itself as one of the techniques of choice for
evaluation of bone marrow in patients with suspected bone metastases with a sensitivity /
specificity (> 90%) higher than the radiology conventional CT and bone scans, and similar to
PET-CT (Figure 5) [27].
Complement the study with diffusion-weighted imaging, besides allowing a faster interpre‐
tation and greater detection of subtle findings could add specificity to the study [28]. This is
particularly relevant with the progressive increased use of new anti tumor drugs in which
this technique may allow better assessment of tumor response [29].
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Figure 5. Whole body MRI. Bone, lung and liver metastases. Courtesy Dr. Armesto-Pérez.
2.4. Bone scan
Bone metastases in RCC is reported in 17-37% of patients and its early identification may have
prognosis importance because its early intervention leads to significant reduction in patient
morbidity. Bone scintigraphy is a very useful tool in diagnosis of bone metastases when those
lesions have sufficient osteoblastic reaction (Figure 6). However, bone metastases in RCC usu‐
ally appear as large expansive lytic lesions, most commonly in the axial skeleton and are poorly
visualized in bone scintigraphy [30], showing variable uptake, with a sensitivity between
10-60% in the diagnosis of this metastases in preselected patients with RCC and high probabili‐
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ty of skeletal involvement with underestimation of the extension of the extension of the meta‐
static involvement, being clearly inferior to other techniques such magnetic resonance imaging
or PET scan [31]. Because most bone metastases are symptomatic, most of authors recommend
the use of bone scintigraphy only in symptomatic patients with or without raised level of alka‐
line phosphatase [32,33], although others believe that because its poor sensitivity, the routine
use of bone scintigraphy in RCC needs to be questioned [34,35].
Figure 6. Bone scan of a patient with renal cancer showing metastases in the right tibia, left femur, pelvis and rib
cage.
2.5. PET
We can study the PET role of in RCC from three points of view: localized disease, extensive
disease and monitoring treatment response.
Localized disease: Most of publications in this patient subset have been made in a retrospec‐
tive way and many of them studied patients from the PET archive and not from the popula‐
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tion of patients with a suspicious kidney mass. More recently we have knows the result of a
prospective study that examined 18 patients with renal lesions suspicious for malignancy di‐
agnosed on CT, MRI or ultrasound [36]. In all patients, a FDG-PET/CT was made and diag‐
nosis of malignancy was suspected when intensity on PET was greater than intensity in the
renal parenchyma and it was different from the physiological excretion in the collecting sys‐
tem. Patients underwent nephrectomy or surgical resection of the renal mass with the re‐
spective histological analysis. PET showed a sensitivity of 46,6% and a specificity of 66,6%.
The median diameter and Furhman grade of FDG positive malignant lesions were signifi‐
cantly higher than in FDG-negative malignant lesions (p< 0,05). It is difficult to draw conclu‐
sions with a study involving a sample of patients so small, but we can see that about half of
the patients could not be diagnosed by PET, so probably we will have to expect better re‐
sults with this diagnostic technique before introducing it as part of a routine preoperative
diagnosis of RCC. A modification of the technique is the immunological PET, using 124I-
cG250 (chimeric girentuximab labeled with 124I) because cG250 functions as an epitope of
CAIX, a transmembrane enzyme that is almost universally expressed in clear cells RCC cells.
With this modality has been observed a 94% sensitivity and 100% specificity, with positive
and negative predictive values of 100% and 90% respectively, in a population of 26 patients
with renal masses suspicious for malignancy [37].
Extensive disease: Although in the metastatic RCC PET has better sensitivity (63-100%) than
in localized disease, some authors believe that FDG-PET currently appears to be too unrelia‐
ble to recommend is routine use in the staging of RCC, because it is less sensitive than radio‐
logical imaging for retroperitoneal lymphadenopathy and bone or lung metastases [38].
However, this technique may have a place detecting recurrence and probably an associated
prognostic value (Figure 7). In a recent study, the authors found a sensitivity and specificity
of 81% and 71% respectively, for FDG-PET in the diagnosis of recurrence, with correct diag‐
nosis in all cases of intra-abdominal (lymph nodes, local recurrence and adrenal glands) and
bone recurrence, with a clear trend for better 5-year survival in PET-negative patients com‐
pared with PET-positive patients: 83% versus 46% respectively [39].
Monitoring treatment response: Systemic treatment in metastatic RCC is represented for
multikinase inhibitors like sorafenib and sunitinib. This drugs are actives because its capaci‐
ty of inhibition on the tyrosine kinase receptor VEGF and the platelet-derived growth factor
receptor, in the endothelial cells and pericytes. Because expression of Glut (a downstream
product of HIF transcriptional activity), it is conceivable that intensity of FDG uptake may
be reflective of the magnitude of the entire pathway [40]. In other words, the variable inten‐
sity of FDG-PET in RCC may reflect variable strength of the HIF signaling pathway. Kayani
et al. studied prospectively 44 treatment naive metastatic RCC. A basal (pretreatment) FDG-
PET was made and them repeated it at 4 and 16 weeks of treatment. The most intense lesion
of each patient (SUV > 2.5) was used as the index lesion and they defined metabolic re‐
sponse as a decrease of > 20% in SUV and metabolic disease progression as an increase of
>20 % or development of new metastatic lesions. In the first comparison (after 4 treatment
weeks) they found a metabolic response in 24 (57%) patients but without correlation with
the PFS or overall survival. In the second comparison (16 treatment weeks), 12 (28%) pa‐
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tients had metabolic disease progression, which correlated with decreased OS and PFS 8HR:
5.96 [95% CI: 2.43-19-02] and 12,13 [95% CI:3,72-46,51]), respectively [41]. With these results,
we can conclude that the FDG-PET probably may be more useful in diagnosing tumor pro‐
gression than treatment response. Another point that deserves to be examined is whether
the cutoff of 20% is appropriate to differentiate responders from those who do not.
Figure 7. PET scan showing loco-regional recurrence (red arrows), in a patient with a previous left nephrectomy.
3. New techniques in imaging of renal tumors
The introduction of functional imaging techniques have allowed us to study in vivo physio‐
logical processes of tissues and tumors. Techniques such as computed tomography (CT) or
magnetic resonance (MR) allow us to study tumor perfusion (angiogenesis). Positron emis‐
sion tomography (PET) scan or spectroscopy RM is useful in the evaluation of tumor metab‐
olism while difusion RM allows the study of the diffusion of water molecules through the
diffusion sequences (cellularity) to assess hypoxia phenomena or changes in the lymph no‐
des function. All these techniques can obtain information on the tumor microenvironment,
including levels of oxygenation, tumor cell proliferation or vascularization and open a dif‐
ferent dimension in the study of patients: diagnosis, staging, treatment planning, evaluation
of response or follow-up [42] [43].
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For example, dynamic techniques (MRI or CT) seem most appropriate for assessing antivas‐
cular drug response or acting in the VEGF/ PDGFR pathway, such as bevacizumab, whose
mechanism of action appears to focus on normalization of tumor vascularization [Jain 2005],
while the PET appears to do better in the case of drugs such as cetuximab, acting in the
EGFR pathway [44] [45] [46].
3.1. Perfusion-CT
Perfusion CT is based on the temporal change of the attenuation of tissues after intravenous
administration of iodinated contrast. This study consists of two phases. The first phase lasts
between 40 and 60 seconds in which the enhancement is mainly due to the contrast distribu‐
tion in the intravascular space and its rapid passage to the extracellular space. This phase
requires high temporal resolution (one acquisition per second). In the second phase the con‐
trast enhancement depends on its distribution between intra-and extravascular compart‐
ments. In this period the acquisition in more spaced and lasts between 2 and 5 minutes [47]
[48] [49,50].
This functional technique can be used to measure a number of parameters including vascu‐
lar blood flow, blood volume, mean transit time, peak enhancement, time to peak enhance‐
ment and capillary permeability. Several studies have validated functional CT data as a
biomarker of angiogenesis [47] [51]. There is growing interest on the use of CT perfusion in
oncology with multiple applications that may be helpful: differential diagnosis between be‐
nign and malignant neoplasms, identifying tumors of unknown origin (with impaired liver
perfusion with occult metastatic disease), definition of prognosis (with best response in tu‐
mors with more perfusion), monitoring response to treatment and development of new
drugs (Figures 8 and 9) [50]. The technique is being applied in multiple tumor types: head
and neck, lung, liver, pancreas, colorectal cancer, lymphoma and prostate.
Figure 8. Renal Cancer. Liver metastasis treated with temsirolimus. Axial CT image (A) and blood volume (B) and
blood flow (C) parametric maps show low perfusion parameters in metastasis. Courtesy Dr. García Figueiras.
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Figure 9. Renal Cancer with diffuse metastatic disease (black arrows) in a 58 year-old female patient. Pre-therapy (left
column) and 10 days post-sunitinib (right column). Axial CT images, blood flow (BF) parametric maps, and curves time-
density show a partial response with disappearance of some metastatic foci, necrotic changes in many of them, a
change in enhancement curve (white arrows) and a BF decrease by 95% in tumor. Courtesy Dr. García Figueiras.
3.2. DCE-MRI
Other functional imaging techniques not specifically focused on the study of angiogenesis,
such as diffusion MRI, enabling the study of tumor cellularity and having quantitative pa‐
rameters such as the apparent diffusion coefficient (ADC). Thus, tumors with high cellulari‐
ty show low ADC [52] [53]. Moreover, since tumor response is associated with destruction
of tumor cells, it is generally associated with increased ADC tumor lesions. The diffusion
thus evaluate the apoptotic and necrotic effect but not angiogenesis, main target of new
drugs.
Preliminary studies have shown significant changes very early in the flow, blood volume
and perfusion with tumor therapy. There is a relationship between changes in Ktrans, Kep
and the area under the curve and the response in different tumors, showing a very marked
functional changes in the vascular supply to the tumor [54] [55]. Therefore these techniques
could be worth to select those patients who will respond to drugs with an early evaluation
of the response using functional imaging.
In a subgroup of patients enrolled in the phase II study discontinuation of sorafenib, DCE-
MRI was performed before and after initiation of treatment. Radiological response by RE‐
CIST criteria was observed in 4/17 patients (ORR 24%), and time to progression was 12.9
months. Ktrans decreased significantly during treatment with sorafenib (60.3% decrease,
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95% CI 46.1 to 74.6%). The percentage decrease in Ktrans and change in tumor size was sig‐
nificantly associated with progression-free survival (p = 0.01 and 0.05, respectively).
3.3. PET
Finally, molecular techniques such as PET show a limited role in the study of metastatic re‐
nal cancer, since this tumor usually has a low activity of glucose metabolism (pathway as‐
sessed by 18F-fluorodeoxyglucose, the most widely used radiotracer). Only in cases where
the tumor shows an increased metabolism of glucose, PET may be useful in the assessment
of the disease and its response to therapy. Other radiotracers that allow the study of impor‐
tant characteristics such as tumor hypoxia, cell proliferation or angiogenesis itself, are still
under evaluation and implementation in clinical practice [56]. In an experimentally way it is
evaluating the introduction of functional imaging techniques in clinical studies, to develop
translational research in oncology imaging applications. In a NCI trial, Dr. Hoffman (Uni‐
versity of Utah) is using DCE-MRI and various types of PET (H2150-PET, FDG-PET, FDL-
PET) in monitoring response to multi-targeted treatment in renal cancer patients.
4. Response evaluation
4.1. Evaluation of response: Antiangiogenics and mTOR inhibitors
We must consider several issues when assessing the therapeutic response of tumors. The
morphological assessment with quantification of changes in size used in the RECIST criteria
("Criteria in Solid Tumors Response") has been our main concern when assessing tumor re‐
sponse [2]. This approach seems true for the use of cytotoxic drugs. However, this assess‐
ment is limited, since the macroscopic changes take time to become evident, often are not
specific and do not provide information on the physiological and molecular component of
tumors [42].
Advances in the field of oncology have led to the development of new drugs in renal cancer
as sunitinib, sorafenib, pazopanib, tivoaznib, axitinib, temsirolimus, everolimus and bevaci‐
zumab [46]. These drugs (mainly cytostatic) cause little change in lesion size. Therefore, RE‐
CIST criteria are not entirely suitable for assessing tumor response, and proper techniques
will vary according to the mechanism of action of the drug.
The recent emergence of techniques for the functional study of angiogenesis, such as perfu‐
sion CT or dynamic MRI allow obtaining quantitative parameters (blood volume, blood
flow mean transit time, ktrans Ve, etc.) and would open a interesting field for assessing tu‐
mor response in a more objective [57] [58] [59]. This could open the door to the development
of a strategy based on the image for the selection of patients to be treated with antiangiogen‐
ic therapies. However, each of these techniques has advantages and disadvantages. Thus,
CT perfusion shows the drawback of radiation necessary for conducting the studies, where‐
as in the case of dynamic MRI the analysis of the results is much more complex.
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The functional  and molecular  imaging techniques  could offer  clear  opportunities  in  the
study of  renal  tumors,  but  nevertheless,  we must  not  forget  that,  for  validation as  bio‐
markers,  would  require  completing  a  qualification  and  validation  process,  which
would  pass  through  standardization  in  the  collection  and  analysis  of  the  images  and
the  correlation  of  the  parameters  obtained  with  patient  outcomes.  Once  this  is  ach‐
ieved,  functional-molecular  techniques,  especially  perfusion  CT,  could  become  promis‐
ing  tools  in  the  selection  of  patients  for  targeted  drug  therapy  and  the  assessment  of
the response [57]  [58].
5. Criterios RECIST/MASS/CHOI
Classically, oncology response evaluation is based on comparison of pre and post-treatment
tumor volume by studying changes in the diameter of the tumors. RECIST criteria in its
original version and its 2009 Update 1.1 are applied routinely in oncology practice [2]. How‐
ever, it is recognized that the response evaluation focused exclusively on size changes have
important limitations, including the importance of excluding changes in tumor metabolism
or not considering the appearance of necrosis or fibrosis as a factor which may be related to
response to treatment. Furthermore, the introduction of new drugs creates the need for a
different evaluation of the tumor and treatment response [46].
The limitations  of  traditional  approaches,  as  the  criteria  of  the  World Health  Organiza‐
tion (WHO) or Response Evaluation Criteria in Solid Tumors (RECIST) in the evaluation
of targeted therapies have been widely documented [64] [65] [57].  Therapies that act  on
tumor vascularity  may have underestimated clinical  benefit  by tumor size  change since
their  mechanism  of  action  (more  cytostatic  that  cytotoxic),  produces  more  stabilization
than tumoral responses.
Without abandoning the use of size criteria as a key element in the assessment of patients
with metastatic renal cancer, some authors have attempted to obtain early information (EP‐
TIC, Early English Post-herapy Imaging Changes) [66] on the prognosis of patients treated
with therapy acting at the VEGF pathway. In this regard, it was demonstrated that a 10%
decrease in the sum of the largest diameters of the lesions in the first control, provides infor‐
mation on the subsequent course of patients. Using only tumor size as endpoint criterion
would leave aside the use of IV contrast.
Subsequently it was observed a relationship between the degree of tumor enhancement be‐
fore therapy and the likelihood of response (being higher in those tumors with greater pre‐
treatment enhancement). Many of these new drugs induce tumor necrosis, causing a
dramatic drop in the enhancement of metastatic lesions in the post-therapy evaluation [67].
Based on these observations and on previous experience with gastrointestinal stromal tu‐
mors treated with imatinib, a set of tumor response criteria based on changes in size and / or
density tumor was established: Choi criteria, modified Choi criteria, MASS criteria and
SACT criteria (Table 1) [56].
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depending on the type of drug tested, being most useful in the case of sorafenib (which
tends to cause more degree of necrosis in lesions) than for sunitinib.
Modified Choi criteria evaluate existing changes in both size and tumor density after treat‐
ment. These criteria could differentiate those patients at risk of disease progression, but
shows a tendency to classify patients as responders.
SACT criteria (Size and Attenuation CT) differ from the modified Choi criteria that estab‐
lish an absolute value of change in tumor density (> 20 UH) rather than a % of change. These
criteria are more reliable in the case of low attenuation pre-therapy lesions, in which it is
easier to obtain a percentage decrease in density.
Finally, the MASS criteria (Morphology, Attenuation, Size, and Structure) include morpho‐
logical and structural elements regardless of the size and density of lesions. These criteria
are intended to take into account the extensive necrotic changes frequently associated with
tumor response to these drugs [63].
However, both SACT as MASS criteria are complicated and basically useful in differentiat‐
ing patients with a long progression-free survival (> 250 days) of those showing a rapid pro‐
gression (<250 days). Overall, we consider that in all these criteria contrast enhancement of
lesions plays a major role, so that both imaging protocols (volume of contrast acquisition
phase, etc.) or factors such as cardiac function patient can significantly influence the results.
6. Summary
The era of molecular biology have created great expectations on our ability to translate these
discoveries into effective treatments for patients. Over the last decade, there has been an in‐
creasing knowledge about pathophysiological processes that are common to most tumors
including: independence from growth signals, insensitivity to growth-inhibitory signals,
evasion of apoptosis, limitless potential for replication, sustained angiogenesis, and tissue
invasion and metastasis. These major pathways deregulated in cancer have a key role in tu‐
mor development and microenvironment. These features have enabled the emergence of a
wide spectrum of novel oncologic drugs that are designed to target and interfere with spe‐
cific aberrant biological pathways. In general, these agents use different strategies to inter‐
fere with specific biological targets, such as blocking growth factors, receptors, or tyrosine
kinase (TK) action.
The use of new drugs in the treatment of advanced or metastatic kidney cancer, with differ‐
ent mechanisms of action compared to conventional chemotherapy raises new questions.
One of the biggest problems with new drugs are produced in the evaluation of the response,
and the incorporation of new imaging techniques (MRI diffusion, perfusion CT, nuclear
medicine, etc....) in the diagnosis of extension and assessment of efficacy.
In this chapter we have reviewed the main techniques of radiological diagnosis and staging,
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1. Introduction
Renal cell cancer is the third most common genitourinary tumour and the seventh most common
cancer. It accounts for about 3% of all malignancies. After prostate cancer and bladder can‐
cer it is the third most common urological tumour. Among urological cancers it shows the
highest mortality [1]. Its incidence has geographic, ethnic and age differences, however over
the last two decades there has been a rising incidence of renal cell carcinoma particularly of
early-stage tumours leading to a paradigm shift in the therapeutic management.
An increased risk of disease is described with a positive family history and the following
diseases: Von Hippel-Lindau (VHL) syndrome, tuberous sclerosis, polycystic renal degener‐
ation, chronic renal insufficiency, dialysis and condition after renal transplantation, arterial
hypertension, adiposity and diabetes mellitus. Other risk factors are drugs (phenacetinabu‐
sus, diuretics) and a number of environmental factors such as asbestos, lead, arsenic, cadmi‐
um and aromatic hydrocarbon compounds. Previous described as typical triad of flank pain,
hematuria and palpable flank tumour (Virchow`s triad) is nowadays rarely seen in far ad‐
vanced tumour stages [2]. The same is true for B symptoms, which is usually a sign of meta‐
stasis already existing.
The increased availability and advances in diagnostic imaging (ultrasound, computed tomog‐
rahy and magnetic resonance imaging) (Fig.1) with an increase in the incidental diagnosis of
renal tumours [3] and an improved understanding of the basic biology of renal cell carcino‐
ma, led in recent years to an improvement in survival rates, however, in approximately one
third of all patients when diagnosed there are metastasis [4] (mainly locoregional lymph nodes,
lung, skeletal system, brain and liver) with a 5-year survival rate of less than 5%.
© 2013 Hach et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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Figure 1. Abdominal magnetic resonance imaging (MRI): Renal tumour of the left upper pole: suspected renal cell
carcinoma
Furthermore a third of patients that have been treated for a locally limited renal cell carcino‐
ma (Fig. 2a,b,c) in the course show recurrence or metastasis. A tool to assess the risk of meta‐
stasis after a nephrectomy is the Mayo Scoring System (Tab.1).
Figure 2. (a) Locally limited renal cell carcinoma of the upper pole; (b) Locally limited renal cell carcinoma in the lateral
convexity; (c) Locally limited renal cell carcinoma with suppression of pelvicocaliceal system
Of crucial prognostic importance is therefore the question of the presence of a locally de‐
fined or metastatic renal cell carcinoma with a median survival of about 50% one year after
the diagnosis of metastasis. This underlines the importance of early detection. Because of
lack of radiosensitivity and chemosensitivity of renal cell carcinoma surgical treatment
(nephrectomy or partial nephrectomy) remains the only curative treatment option for locally
confined tumours. Partial nephrectomy/nephron-sparing nephrectomy, minimally invasive
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techniques, energy ablative techniques and active surveillance have been progressively used
as an alternative option towards open radical nephrectomy which was the historical gold
standard approach. Partial nephrectomy has demonstrated an equivalent oncologic outcome
with an improved renal function and reduction of cardiovascular events. Over the past
years laparoscopic and robot-assisted procedures gained in importance showing similar re‐




















ª According to the 2002 American Joint Committee in Cancer staging system
Risk group Score Estimated metastasis-free
survival after 3 years
Estimated metastasis-free survival after 10
years
Low risk 0-2 98% 92.5%
Intermediate risk 3-5 80% 64%
High risk >6 37% 24%
Table 1. Mayo-Scoring-System (Leibovich BC, Blute ML, Cheville JC et al. Prediction of progression after radical
nephrectomy for patients with clear cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;
97:1663-1671)
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In metastastic renal cell carcinoma the surgical removal of the primary tumour in the sense
of reducing the tumour burden and metastasis respectively for palliative reasons or as part
of a combined tumour therapy may be required. Through such combined therapy concepts
in some cases significant extensions of survival times can be achieved. Integration of surgery
and systemic therapy is essential in the treatment of metastatic renal cell carcinoma. The ear‐
liest possible diagnosis and careful selection of surgical procedure for each patient is the ba‐
sis with the goal of curation and the best possible quality of life.
2. Therapy for localized renal cell carcinoma
For a long time radical nephrectomy was the standard treatment for normal contralateral re‐
nal function and absence of metastasis. The first successful nephrectomy took place on 2 Au‐
gust 1869 by the Heidelberg surgeon Gustav Simon. In the late 1960s the classic radical
nephrectomy with the removal of kidney and adrenal gland within Gerota`s fascia, includ‐
ing removal of the perirenal adipose capsule, of the proximal ureter and the ipsilateral
lymph nodes with a 5-year overall survival rate of 66% for organ-confined tumours was de‐
scribed by Robson [5], (Tab. 2 and 3).





ª According to the 1997 TNM system (AJCC)
Table 2. 5-year cancer-specific survival after nephrectomy/partial nephrectomy as a function of the 1997 TNM stage
(AJCC) (Tsui KH, Shvarts O, Smith RB et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643
patients using the revised 1997 TNM staging criteria. J Urol 2000; 163:1090-1095)





Table 3. 5-year survival rate after nephrectomy, depending on the Robson stage (Guinan PD, Vogelzang NJ, Fremgen
AM et al. Renal cell carcinoma: tumour size, stage and survival. Members of the Cancer Incidence and End Results
Committee. J Urol 1995; 153:901-903)
In the open surgical nephrectomy, the choice of the surgical approach should be taken de‐
pending on the location and size of the tumour as well as the experience of the surgeon. Ba‐
sically the following methods are available: primary retroperitoneal approach to the lumbar
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by use of sub- or intercostal incision, transabdominal or thoracoabdominal. There seems to
be no difference in terms of oncological results.
The laparoscopic nephrectomy (transperitoneal, retroperitoneal or “hand-assisted“) is an‐
other method. This frequently surgical technique is especially used in T1 (up to 7cm tumour
size) and T2 tumours (tumour larger 7cm, limited to the kidney). The surgical steps are basi‐
cally those of the conventional open surgical approach. Comparable oncological results with
open nephrectomy are seen in large tumours as well. [6].
The advantages of laparoscopic nephrectomy are reduction in postoperative pain symptoms
with less pain medication and earlier mobilization. Furthermore faster recovery and better
cosmetic results are mentioned. The frequently discussed risk of implantation metastasis in
the abdominal puncture trocar has only been reported casuistic. A tumour cell spread by the
applied pneumoperitoneum is not known.
The third and most recent method to be mentioned is the robotic-assisted laparoscopic
nephrectomy. Major advantages of this method are the three-dimensional view for the sur‐
geon, up to a 10-fold magnification of the surgical field, a suppression of tremor of the sur‐
geon`s hands through a so-called tremor filter and the free movement of the instruments
which are equivalent to those of the human wrist (so-called “endo wrist instruments”). Ro‐
bot-assisted two approaches are possible: transperitoneal and retroperitoneal approach.
Specific complications of the nephrectomy, regardless of the surgical approach are mainly
injuries to neighbouring organs in particular pleural lesions, spleen, pancreas and duodenal
injuries and bleeding complications. Frequently occurring transient postoperative creatinine
level elevation usually shows a rapid compensation with a healthy contralateral kidney.
As mentioned earlier, in recent years by increasing the availability and development of radi‐
ological examination techniques, there has been an increase of incidentally detected T1 renal
tumours. After the first partial nephrectomy was done in 1887 by Vincenz Czerny at the
University of Heidelberg, it is established today for tumours ≤ 4cm as the gold standard as
well as for tumours up to 7cm in selected patients [7]. Becker et al. showed with the neph‐
rectomy comparable oncologic results and low complication rates in tumours > 4cm [8] or ≥
7cm [9] in selected patients. The 5- year tumour-free survival in this process is over 95%, the
rate of local recurrence is < 1% [10], even though interestingly in section statistics up to 20%
multifocal tumours are detected. A reason for this may lie in a different biological behaviour
of tumours with a different aggressiveness. Whether the multifocal renal cell carcinoma is a
primary multifocal tumour initiation or a secondary intrarenal metastasis is currently un‐
known. Careful preoperative imaging therefore is essential. Aim of the organ-preserving
technique is a complete resection of the tumour with an optimal preserved renal function.
Tumour size 5-year cancer specific survival rate 10-year cancer specific survival rate
< 4cm (T1a) 96% 90%
> 4cm (T1b) 86% 66%
Table 4. 5-year and 10-year cancer-specific survival after partial nephrectomy depending on tumour size (Hafez KS,
Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: impact of tumour size on patient
survival, tumour recurrence and TNM staging. J Urol 1999; 162:1930-1933)
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< 4cm (T1a) 96% 90%
> 4cm (T1b) 86% 66%
Table 4. 5-year and 10-year cancer-specific survival after partial nephrectomy depending on tumour size (Hafez KS,
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Regarding the surgical procedure there is a distinction to be made, especially depending on
tumour size and –localization between a number of techniques such as local tumour resec‐
tion (Fig. 3 and 4) in which a safe distance of a few millimeters should be respected, the
poleresection or segmentresection, the heminephrectomy up to nephrectomy with extracor‐
poreal workbench tumour resection and subsequent autotransplantation of the kidney into
the iliac fossa at very large central tumours and imperative implications.
Figure 3. Local resection of a renal tumour
Figure 4. Local resection of a renal tumour (tumour has already been removed)
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When doing a partial nephrectomy a differentiation is made between the most common ex‐
isting elective indications for peripheral small unilateral tumours (≤ 4cm, equivalent to a tu‐
mour stage pT1a or in specialized centres tumours up to 7 cm diameter, equivalent to a
tumour stage pT1b) in a healthy contralateral kidney, the relative indication in impaired re‐
nal function or pre-existing renal insufficiency, synchronous bilateral organ involvement
and genetic predisposition for multiple tumours as well as the absolute/imperative indica‐
tion of an existing solitary kidney (anatomic or functional). Furthermore with this surgical
procedure a distinction is made between a partial nephrectomy without ischemia, in a warm
ischemia in an anticipated ischemic time of < 20 minutes by disconnection of the renal artery
and the renal vein at the renal hilum and partial nephrectomy in cold ischemia (cooling kid‐
ney down to 15-20°C) in an anticipated ischemic time of > 20 minutes by the application of
4°C cold perfusion solution through the renal artery or by surrounding the organ with ice.
Additionally the implementation of so-called renoprotective measures can follow. These in‐
clude intraoperative administration of an ACE inhibitor for the reduction of post-ischemic
vascular resistance and of mannitol 5% 5-10 minutes before clamping and reopening of the
renal artery, with the aim of reducing the intracellular edema and increasing the diuresis
and as needed heparin for the prevention of renal artery thrombosis.
Retrospective studies have shown a benefit for partial nephrectomy compared to a nephrec‐
tomy with T1a tumours, which can be explained mainly by improved renal function with
reduction of cardiovascular events [11]. Also Go et al. have demonstrated in a large prospec‐
tive study that the loss of renal function is associated with an increase in cardiovascular
mortality and shorter life expectancy [12].
Similar to the nephrectomy the partial nephrectomy is an established laparoscopic proce‐
dure performed for the fist time in 1993 by Winfield and Clayman. When performing a lapa‐
roscopic partial nephrectomy the preparation of the renal hilum takes place after colon
mobilization, identification of the ureter as well as the vena cava. Subsequently the excision
of the tumour with scissors usually in warm, rarely performed in cold ischemia takes place.
After attending to the tumour bed with sutures and/or hemostyptics follows an adaptation
of the remaining parenchyma by using a continuous suture. Last is the recovery of the surgi‐
cal specimen in the extraction bag. Similar to the laparoscopic nephrectomy this method
shows the advantages of a lower mean blood loss, lower analgetic requirements postopera‐
tively as well as shorter convalescence and hospitalisation times however at a heightened
risk of postoperative hemorrhage and usually prolonged ischemic times. Regarding the on‐
cological and functional outcomes there are comparable results between open and laparo‐
scopic partial nephrectomy [13].
Similar to the robot-assisted nephrectomy, the laparoscopic robot-assisted procedure also
used with the nephron-sparing surgery represents another possibility of minimally invasive
surgery. After the introduction of the method in 2004 at first primarily small peripherally
located tumours were considered to be particularly suitable for this technique [14]. With in‐
creasing experience the indication was extended to more complex tumours. Excellent results
of robot-assisted surgical technique in relation to more complex lesions, such as centrally lo‐
cated renal tumours or directly at the renal hilum neighbouring tumours are described [15].
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The three-dimensional view and the magnification of the surgical field has the advantage of
a more precise excision of the tumour. In addition, the robotic-assisted partial nephrectomy
has a much shorter learning curve and shorter ischemic times than the conventional laparo‐
scopic procedure. A special technique for the reduction of the ischemic time is the so-called
“sliding clip renorrhaphy“ during renal reconstruction. In this technique a continous ab‐
sorbable suture with clips for securing both ends is used. These clips can then be moved
along the sutures and this way the renal defect can be closed. With this the warm ischemic
time could be reduced significantly [16]. Another method through which the warm ischemic
time can be reduced is the early removal of the vascular clamps, so-called “early unclamp‐
ing”. Few sutures are used in order to avoid more bleeding before removal of the vascular
clamps, to then care for the remaining still bleeding vessels without ischemia [17]. Also the
selective disconnection of the tumour supplying segmental arteries can reduce the ischemic
time, but at an increased risk of injury during preparation of the hilar vessels. While early
experience with robotic partial nephrectomy have demonstrated no advantages of this sur‐
gical method compared to the conventional laparoscopic approach [14], recent work showed
equivalent results in terms of oncologic outcomes for benefits such as a lower intraoperative
blood loss and shorter warm ischemic times compared to those of conventional laparoscopy.
A multicenter study showed comparable results in terms of the following parameters: dura‐
tion of surgery (laparascopic partial nephrectomy 174 min vs. robotic-assisted partial neph‐
rectomy 189 min), cavity opening (54 vs. 47%), R1-status (3.9 vs. 1%) and postoperative
complications (10.2 vs. 8.6%) [18].
The criticism of the robot-assisted partial nephrectomy are essentially two:
1. Dependency of the surgeon on the assistant during surgery
2. High purchase and maintenance costs for the surgical robot
The surgeon sits at the console and does not stand at the operating table, therefore commu‐
nication between him and his assistant surgeon is extremely important, especially during
critical surgical steps such as the setting of vascular clamps and clips.
Comparative  data  on  the  ratio  of  the  costs  for  an  open,  conventional  laparoscopic  and
robotic partial nephrectomy are limited. Mir et al. compared the costs of open, laparoscop‐
ic and robotic partial nephrectomy in 33 patients. They showed laparoscopic partial neph‐
rectomy to be more cost effective than open partial nephrectomy due to a shorter hospital
stay. Moreover they demonstrated that the laparoscopic procedure is more cost effective
compared the  robotic  approach  because  of  lower  instrumentation  costs  [19].  Studies  on
robotic-assisted cystectomy and prostatectomy however showed significantly higher costs
of robotic surgeries [20, 21].
In summary it can be stated that the preservation of functioning renal parenchyma and
therefore a reduction in renal dysfunction is a clear advantage of partial nephrectomy com‐
pared to nephrectomy. The laparoscopic as well as the robotic-assisted partial nephrectomy
in studies with small numbers of patients (Fig. 5 and 6) represent a safe alternative with low
morbidity for selected patients at appropriate centres with special expertise. Specific compli‐
cations with a partial nephrectomy, regardless which type of surgical approach, most likely
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are postoperative hemorrhage and extravasation of urine (urinoma) which can be treated by
a transient ureter splint or nephrostomy. These complications occur more frequently in pa‐
tients with imperative indications than in elective indications.
Figure 5. Robot-assisted laparoscopic partial nephrectomy
Figure 6. Robot-assisted laparoscopic partial nephrectomy (during enucleation of the tumour)
3. Surgical features
Adrenalectomy: After the ipsilateral adrenalectomy over a long period of time on the
grounds of radicalism was seen regradless of size and extent of the renal tumour as essen‐
tial, the indication for performing a routine adrenalectomy during a nephrectomy is not a
standard these days. As an important aspect the fact is that an adrenal tumour rarely grows
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per continuitatem, but most likely it is a sign of haematogenous metastasis with poor prog‐
nosis. On the other side the safety of imaging by using CT is at 97%. The likelihood of adre‐
nal metastasis in small T1 tumours is less than 1% [22]. After Robson in the 1960s described
a survival benefit for patients that had a standard adrenalectomy [5], were not detected in
subsequent studies [23]. The indication for removal of the adrenal gland is given in case of a
very large renal tumour, an upper pole tumour and a suspected metastasis in the adrenal
gland (preoperative imaging studies or intraoperative finding).
Lymphadenectomy: For a long time conducting a regional lymphadenectomy (paraaortic/
paracaval) was an important part of the nephrectomy. The improved survival times when
performing a lymphadenectomy were proven in part by the work of Robson. Especially in
view of conversion of patients to small asymptomatic renal tumours, the removal of the ipsi‐
lateral lymph nodes is critical discussed similarly to the adrenalectomy. Though diagnosti‐
cally useful, the value of the hilar ipsilateral lymphadenectomy due to few studies regarding
their prognostic significance remains unclear. The therapeutic benefit has not been proven.
Interestingly in autopsy studies it was proven that the result of lymph node metastasis usu‐
ally shows an occult distant metastasis.
Renal vein thrombus and vena cava thrombus: A special feature of the renal cell carcinoma
is the tendency of ingrowth into the venous system. A tumour thrombus in the vena cava is
found in about 4-10% of all cases, a tumour thrombus with growth up into the right atrium
in 0.4% of all cases. Surgical removal of the thrombus should be sought in principle. The sur‐
gical procedure must be scheduled in this case depending on the extent of the thrombus.
Level I:Infiltration of the renal vein
Level II:Infiltration of the infrahepatic vena cava
Level III:Infiltration of the intrahepatic vena cava
Level IV:Infiltration of the suprahepatic vena cava
Renal vein thrombi are removed by clamping the junction into the vena cava, thrombi of
the vena cava below the diaphragm by a cavotomy. If there is an expansion beyond the
hepatic hilum the use of a heart-lung machine is necessary. If there is an expansion to the
right atrium the use of extracorporal  circulation is  required.  An important aspect in the
planning and implementation of these procedures is the interdisciplinary collaboration be‐
tween urologists and cardiac surgeons.  The prognosis of  patients with a tumour throm‐
bus after a successfully carried out surgery is not dependent on the size and extent of the
thrombus, but the metastasis stage. After thrombectomy in a non-metastastic stage 5-year
tumour specific survival rates up to nearly 70% can be achieved [24]. However almost half
of all patients with an extensive vena cava thrombus at diagnosis show lymphatic or hae‐
matogenous metastasis.
Bilateral renal tumours: The incidence of synchronous bilateral renal tumours is at 1.6-6%. In
principle a two-stage procedure is desirable, where initially the smaller and unifocal tumour
can be treated in terms of a partial nephrectomy, with the aim to avoid dialysis in case a
subsequent contralateral nephrectomy is required.
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Local recurrence: The discovery of local recurrence in condition after partial nephrectomy
without evidence of systemic metastasis is seen in <3% of all cases. In this case higher local
recurrence rates are seen with imperative indications, which may be explained by a greater
number of advanced tumours. In principal surgical removal should be made after exclusion
of other metastasis.
4. Other techniques
Energy ablative therapy: The energy ablative method is based on tissue destruction by using
cold or heat. Especially cryoablation (CA) and radiofrequency ablation (RFA) are to be men‐
tioned. There are percutaneous and laparoscopic techniques available. Essentially the indi‐
cation for performing the energy ablative method is limited to palliative situations or as an
alternative for high-risk patients with small, conveniently located renal tumours. Potential
benefits represent mainly the reduced morbidity and the possibility of treating multimorbid
patients in an outpatient setting. The problem is, among other things, the increased risk of
local recurrence [25].
LESS/NOTES: After establishing laparoscopic and robot-supported methods now further
developments of the methodology in terms of a reduction of the required trocars (LESS =
Laparoscopic Single Site Surgery) and the use of so-called “natural orifices“ (NOTES = Natu‐
ral Orifice Translumenal Endoscopic Surgery) take place. Concerning this matter so far how‐
ever there are only casuistics and small case series available.
5. Surgical treatment of metastastic renal cell carcinoma
Given the fact that a third of patients who are suffering from a renal cell carcinoma have a
synchronous and another third after curative intent therapy have a metachronous metasta‐
sis, the following shows the possibilities and the importance of surgical therapy for meta‐
stastic renal cell carcinoma.
Basically in metastatic renal cell carcinoma a distinction must be made between the sole pal‐
liative and the cytoreductive nephrectomy. Indication criterias for palliative nephrectomy
for example are conservative uncontrolled pain or recurrent bleeding. In symptomatic mul‐
timorbid patients with a high surgical risk the possibility of a tumour embolization should
be evaluated. Important here is a sufficient analgesic therapy after completion of the proce‐
dure, because severe pain is a common local complication. An impact on the survival rates
cannot be seen with surgical procedure nor with tumour embolization. In the era of immu‐
nochemotherapy it was shown that cytoreductive nephrectomy followed by immunochemo‐
therapy opposed to receiving only medical therapy shows significantly better survival rates
(7.8 months for interferon vs. 13.6 months for nephrectomy plus interferon) [26]. Whether a
nephrectomy in metastatic stage in the post-immunotherapy era is up-to date needs to be
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evaluated. Results of prospective randomized trials for example CARMENA study (“Clini‐
cal Trial to Assess the Importance of Nephrectomy“) are still pending.
With regard to the surgical treatment of metastasis themselves this indication must be made
primarily in response to the location, size and extent of metastasis findings, the symptoms
and the overall situation of the affected patients.
Solitary pulmonary filiae should be checked for resectability. Are there only a few (up to
three) localized metastasis, then a nephrectomy plus complete resection of metastasis can
lead to a significant survival benefit. Basically patients with synchronous pulmonary meta‐
stasis have a significant worse prognosis than those with a metachronous metastasis. If it is
a disseminated metastasis the initiation of a targeted therapy for (long-term) stabilization of
the disease should be discussed with the patient. The basis for this inhibition of tumour
growth is a modification of growth signaling inside the tumour cell and the (neo)angiogene‐
sis. Currently seven substances (in different indications) are available: tyrosine kinase inhib‐
itors such as sunitinib, sorafenib, pazopanib and axitinib, antibody-based therapies such as
bevacizumab plus interferon-alpha and mTOR (“mamillian target of Rapamycin“) inhibitors
as temsirolimus and everolimus. The use of drugs in the adjuvant setting with advanced re‐
nal cell carcinoma with a high risk of disease progression is currently being evaluated in
clinical trials.
In case of hepatic filiae with a median survival rate of 6-18 months the indication for resec‐
tion in case of a solitary metastasis with a diameter <5 cm should be evaluated if liver func‐
tion is intact. It is essential to inform the patient about this procedure`s high morbidity. For
non-resectable liver metastasis it is possible to perform a CT-guided percutaneous radiofre‐
quency induced thermal ablation (RITA).
In the detection of brain metastasis a surgical approach is to be discussed especially with the
onset of neurological symptoms. The indication for resection of metastasis through stereo‐
tactic radiosurgery (GammaKnife, CyberKnife) or radiation therapy is to be weighed indi‐
vidually. When limited in size and number of brain metastasis very good results can be
achieved in this case with regard to the local control of metastasis.
An indication for surgery in bone metastasis may present neurological deficits in a myelon
compression, pain, and fracture risk in instability of the bone. However survival time exten‐
sions are described in an osseous metastasis only in individual cases.
Metachronous adrenal metastasis without evidence of further metastasis should be surgical‐
ly removed.
6. Conclusion
Surgical therapy remains the only curative approach in the treatment of renal cell carcinoma
being resistant opposite radiation and chemotherapy. (Radical) nephrectomy was the stand‐
ard surgical procedure over a long period of time. The spread and further developments of
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imaging diagnostics resulted in an earlier diagnostic of incidentally detected small renal
masses therefore an increase of the performance of nephron-sparing procedures. In the
meantime partial nephrectomy represents the standard surgical technique in pT1a renal cell
carcinomas (size of tumour ≤ 4cm). Over the past years laparoscopic procedures (laparo‐
scopic nephrectomy and laparoscopic partial nephrectomy) showing similar results in con‐
sideration of the oncological outcome compared to open-surgical procedures gained in
importance. Long-term results of the rather new technique of robotic nephrectomy and par‐
tial nephrectomy are encouraging but remain to be seen. LESS (Laparoscopic Single Site Sur‐
gery) and NOTES (Natural Orifice Translumenal Endoscopic Surgery) are first steps
towards modifying established minimal invasive procedures.
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With regard to the surgical treatment of metastasis themselves this indication must be made
primarily in response to the location, size and extent of metastasis findings, the symptoms
and the overall situation of the affected patients.
Solitary pulmonary filiae should be checked for resectability. Are there only a few (up to
three) localized metastasis, then a nephrectomy plus complete resection of metastasis can
lead to a significant survival benefit. Basically patients with synchronous pulmonary meta‐
stasis have a significant worse prognosis than those with a metachronous metastasis. If it is
a disseminated metastasis the initiation of a targeted therapy for (long-term) stabilization of
the disease should be discussed with the patient. The basis for this inhibition of tumour
growth is a modification of growth signaling inside the tumour cell and the (neo)angiogene‐
sis. Currently seven substances (in different indications) are available: tyrosine kinase inhib‐
itors such as sunitinib, sorafenib, pazopanib and axitinib, antibody-based therapies such as
bevacizumab plus interferon-alpha and mTOR (“mamillian target of Rapamycin“) inhibitors
as temsirolimus and everolimus. The use of drugs in the adjuvant setting with advanced re‐
nal cell carcinoma with a high risk of disease progression is currently being evaluated in
clinical trials.
In case of hepatic filiae with a median survival rate of 6-18 months the indication for resec‐
tion in case of a solitary metastasis with a diameter <5 cm should be evaluated if liver func‐
tion is intact. It is essential to inform the patient about this procedure`s high morbidity. For
non-resectable liver metastasis it is possible to perform a CT-guided percutaneous radiofre‐
quency induced thermal ablation (RITA).
In the detection of brain metastasis a surgical approach is to be discussed especially with the
onset of neurological symptoms. The indication for resection of metastasis through stereo‐
tactic radiosurgery (GammaKnife, CyberKnife) or radiation therapy is to be weighed indi‐
vidually. When limited in size and number of brain metastasis very good results can be
achieved in this case with regard to the local control of metastasis.
An indication for surgery in bone metastasis may present neurological deficits in a myelon
compression, pain, and fracture risk in instability of the bone. However survival time exten‐
sions are described in an osseous metastasis only in individual cases.
Metachronous adrenal metastasis without evidence of further metastasis should be surgical‐
ly removed.
6. Conclusion
Surgical therapy remains the only curative approach in the treatment of renal cell carcinoma
being resistant opposite radiation and chemotherapy. (Radical) nephrectomy was the stand‐
ard surgical procedure over a long period of time. The spread and further developments of
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imaging diagnostics resulted in an earlier diagnostic of incidentally detected small renal
masses therefore an increase of the performance of nephron-sparing procedures. In the
meantime partial nephrectomy represents the standard surgical technique in pT1a renal cell
carcinomas (size of tumour ≤ 4cm). Over the past years laparoscopic procedures (laparo‐
scopic nephrectomy and laparoscopic partial nephrectomy) showing similar results in con‐
sideration of the oncological outcome compared to open-surgical procedures gained in
importance. Long-term results of the rather new technique of robotic nephrectomy and par‐
tial nephrectomy are encouraging but remain to be seen. LESS (Laparoscopic Single Site Sur‐
gery) and NOTES (Natural Orifice Translumenal Endoscopic Surgery) are first steps
towards modifying established minimal invasive procedures.
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1. Introduction
The incidence of kidney cancer is gradually increasing over the past 2–3 decades [1]. 60 920
new cases of RCC have been diagnosed in the US in 2011 and 13 120 died of cancer [2]. The
widespread use of modern radiological studies has substantially changed clinical presenta‐
tion of the renal tumors. Currently, there is a trend towards more frequent diagnosis of
asymptomatic, incidental, smaller lesions [1, 3]. Nephron sparing surgery (NSS) was initially
used in the treatment of renal cell carcinoma (RCC) only for absolute and relative indica‐
tions [4]. Excellent oncological outcome and reduced morbidity after NSS have led to more
frequent use of organ preserving surgery in many centers [4-7]. Elective NSS is currently the
treatment of choice for T1a tumors (<4 cm) in the patients with a normal contralateral kid‐
ney. Its safety and oncological results have been evaluated in numerous studies [3, 8-10].
The role of NSS in the tumors of 4–7 cm in size is less evaluated and controversial. It could
be technically challenging as well [10]. The existing studies suggest that this policy might be
feasible and safe. In this paper we present our single centre experience in using the NSS for
RCC of 4–7 cm in size.
2. Technique of nephron-sparing surgery
All patients were operated through extraperitoneal, extrapleural incision above the 12th rib
in 38 cases and above the 11th rib in 19 cases. The kidney was completely mobilized to ex‐
clude the presence of satellite tumors. Peritumoral fat was left in situ. Sharp incision of the
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renal capsule was performed 2 to 3 mm away from the tumor margin. The renal pedicle was
isolated completely and the renal artery was clamped just before beginning the incision on
the renal capsule. The venous clamping was not used in any case. For diminishing the out‐
comes of renal ischemia vigorous hydration, infusion of Mannitol before the arterial clamp‐
ing, and renal hypothermia was adopted in all cases. Tumors were enucleated without a
layer of normal parenchyma in 17 cases and enucleoresection was performed in 40 cases.
Tumor bed was inspected very carefully on the presense of residual tissue. Intraoperative
frozen section of tumor bed was routinely performed. The results of frozen section were
negative in all cases. The data of the patients who underwent nephrectomy due to positive
margins on the frozen section were not included in the study. The visible bleeding vessels
and opened calices were closed using running sutures. Finally, tumor bed was coagulated
carefully for haemostatic and partly for oncological reasons. The coagulation was performed
by means of diathermy. The parenchymal defect was closed using absorbable interrupted
sutures. In case of large capsular defect it was covered with free peritoneal graft.
The stained slides from all tumor specimens were reviewed by urological pathologist. Short‐
ly, the resected kidneys were evaluated macroscopically. The maximal tumor size was meas‐
ured and 1.5 x 2cm tissue samples were taken for further assessment. Specimens were fixed,
stained and evaluated by the same pathologist according to conventional technique. Patho‐
logical tumor staging was performed according to the 2002 TNM staging system [11] and
nuclear grade was assigned according to the Furhman’s grading system [12]. The removed
tumor specimen was always inspected by pathologists and the surgical margins were inked.
Patients were followed with renal functional tests, chest X-ray, abdominal ultrasound or CT
every 3 months during the first year, once in 6 months for the next two years and annually
thereafter. In terms of statistical analysis the probability of cumulative and cancer-specific
survival was estimated by the Kaplan-Meier method using the whole number of events.
3. Results
We retrospectively reviewed the records of 57 patients who underwent NSS at our institu‐
tion from 1994 to 2011. The table 1 describes the clinical and pathological features of 57 pa‐
tients operated at our institution. All patients were carefully evaluated to exclude the
presence of distant metastases. Preoperative evaluation included: ultrasonography of the
kidney, CT of the abdomen and chest X-ray in all patients. Renal function was assessed by
measuring serum creatinine level and creatinine clearance.
The mean follow-up was 70.1 months (range: 10-157 months). Out of the 57 patients 35
(61.4%) were male and 22 (38.6%) were female. The median patient age was 53.1 years
(range: 37-68 years). Left side tumor was detected in 34 (59.6%) cases and right side in 23
(40.4 %) cases. The tumor was located in the upper pole in 21 (36.8 %), in the mid kidney in 7
(12.2 %) and in the lower pole in 29 (51%) patients. Tumors were located peripherally in 46
(80.7%) cases and the central tumor location was detected in 11 (19.3%) cases. The peripheral
location was defined as: peripherally located and enveloped by cortical parenchyma tumor,
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without extension into the renal sinus. At the diagnosis 53 (92.9 %) tumors were detected
incidentally and 4 (7.1%) were associated with microscopic haematuria. The NSS was per‐
formed for absolute indications in 5 (8.7%) and for relative indications in 11 (19.9%) cases. 41
(71.9%) patients underwent NSS for elective indications.
Age at surgery (years) 53.1 (37-68)
Gender
Male 35 (61.4 %)
Female 22 (38.6 %)
Tumor location
Left 34 (59.6%)
Right 23 (40.4 %)
Upper pole 21 (36.8 %)
Mid kidney 7 (12.2 %)





Presented by haematuria, pain etc. 4 (7%)





G1 22 (38.6 %)
G2 27 (47.4 %)
G3 8 (14 %)
Histological subtype (%)
Clear cell 49 (85.9 %)
Pappilary 5 (8.7 %)
Chromophobe 2 (3.7 %)
Cystic RCC 1 (1.75 %)
Surgical complications
Bleeding 1(1.75 %)
Urinary leakage 4 (7%)
Disease Recurrence
Local recurrence 2 (3.5 %)
Distant metastases 4 (7%)
Table 1. Clinico-pathological characteristics of 57 patients operated with NSS.
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The mean tumour size was 48.1 mm. (range: 41-70 mm.). The mean tumor size in the patients
who underwent NSS for elective indications was 44.7 mm. and in the patients who underwent
NSS for absolute and relative indications was 65.8 mm (p<0.04). The difference between the lat‐
er two groups was not significant. Fifty three out of 57 tumors were pT1b (92.9 %) and 4 (7.1%)
were pT3a. Pathological T3a stage was confirmed by tumor microinvasion into the perirenal
fat. The final pathological evaluation did not reveal any case of tumor extension out of the
inked area of the surgical specimens. Grade I tumor was diagnosed in 22 (38.6%), Grade 2 in 27
(47,4%) and Grade 3 in 8 (14%) cases. Morphological evaluation revealed 49 (85.9%) clear cell, 5
papillary (8.7%), 2 chromophobe (3.7%) and 1 cystic (1.75%) RCCs.
The mean duration of renal ischemia was 22 minutes (range: 18-35 mm.). No perioperative
mortality and/or serious general complications (myocardial infarction, deep venous throm‐
bosis etc.) have been observed. Postoperative complications occurred in 5 (8.8%) patients in‐
cluding: one (1.7%) postoperative bleeding and 4 (7%) urinary fistulas. The bleeding was
observed in peripherally located, large (6 cm. in size) tumor operated for absolute indica‐
tion. Urinary leakage occurred in two patients operated for centrally located (18.1%) and in
two (4.2%) peripherially located tumors. This difference was statistically significant in favor
of peripherially located tumors (p<0.0001). All patients required a double “J” stenting. Peri‐
renal hematoma was observed in 2 (3.5%) cases but did not need any intervention and re‐
solved spontaneously. Renal functions were stable in all patients during the follow-up
period with a median postoperative creatinine level of 0.9 mg/dl (range: 0.7–1.4 mg/dl). The
median hospital stay was 6 days (range: 4-15 days).
The tumor has recurred in 6 (10.5%) patients. Of them, local recurrence was detected in 2
(3.5%) and systemic recurrence in 4 (7%) patients. At the end of the follow-up overall surviv‐
al was 85.8%, the disease-free survivals was 88.2 %. Both disease-free and overall survival
were significantly better in groups of relative and elective indications as compared with ab‐
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Figure 1. Cancer-specific survival in the patients with elective, relative and absolute indications for NSS.
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4. Discussion
The widespread use of modern radiological modalities substantially changed clinical pre‐
sentation of renal tumors in recent decades. Currently, there is a trend towards the diagnosis
of asymptomatic, incidental, smaller lesions at lower stages [1, 3, 10]. The local disease re‐
currence is the major drawback of NSS mostly due to the incomplete resection of the pri‐
mary tumor. In this due radical nephrectomy still remains the gold standard for the
treatment of RCC [4, 10].
Improved diagnostic and surgical techniques have led to wider use of NSS. Uzzo RG. and
Novick AC. in their review of the results of more than 1800 cases of NSS have showed that
the true biological significance of multicentric renal tumors and its implications for NSS re‐
mains to be elucidated [3]. In a prospective, randomized EORTC (European Organisation for
Research and Treatment of Cancer) phase 3 study comparing open partial nephrectomy
(OPN) with open radical nephrectomy (ORN) in small renal tumors (< 5 cm.) found compa‐
rable oncological results in the both arms [8, 9]. Moreover, excellent 5 and 10 year disease-
free survival rates of 98.5% and 96.7% have been reported after NSS in non-randomized
studies [5-7]. These data are now widely accepted. Finally, the recent evidence favoring the
NSS over radical nephrectomy in the prevention of chronic kidney disease and possibly
linking it to a better overall survival will constitute a strong argument for wider use of NSS.
On the other hand, NSS is technically more demanding than RN even for small renal tumors
[13]. The previous report of the EORTC 30904 trial revealed that complication rate in NSS
was slightly higher than in radical nephrectomy [8].
Based on the success of NSS in the tumors of ≤ 4 cm, it has been increasingly used for the
treatment of 4-7 cm. tumors in case of a normal contralateral kidney. Leibovich BC. Et al.
retrospectively compared the results of NSS and radical nephrectomy in the tumors of 4 to 7
cm in size. There were no statistically significant differences in cancer-specific survival and
distant metastases-free survival after adjusting for important pathological features. Thus,
the authors concluded that the NSS has excellent results for the treatment of 4 to 7 cm renal
tumors in appropriately selected patients [14].
Dash A. et al. compared the outcomes of the patients who had an elective partial or radi‐
cal  nephrectomy for  clear  cell  renal  cell  carcinoma of  4–7 cm.  in size.  With the median
follow-up of 21 months the authors failed to show that radical nephrectomy was associ‐
ated with a better cancer control than the NSS. In terms of functional results the authors
found that  the serum creatinine level  3  months after  surgery was significantly lower in
the patients who had NSS [15].
Becker F. et al. reported the excellent results of NSS performed for elective indications. 69
patients with the tumor size of more than 4 cm. underwent NSS. After a mean follow-up of
6.2 years seven patients (10.1%) have died, none of them due to the tumor-related causes.
Tumor recurrence was detected in four patients (5.8%). The 5-year overall survival was
94.9%. The 10-year and 15-year overall survival was 86.7%. Cancer-specific survival was
100% at 5, 10, and 15 years. The authors concluded that the selected patients with localized
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The mean tumour size was 48.1 mm. (range: 41-70 mm.). The mean tumor size in the patients
who underwent NSS for elective indications was 44.7 mm. and in the patients who underwent
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er two groups was not significant. Fifty three out of 57 tumors were pT1b (92.9 %) and 4 (7.1%)
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The mean duration of renal ischemia was 22 minutes (range: 18-35 mm.). No perioperative
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al was 85.8%, the disease-free survivals was 88.2 %. Both disease-free and overall survival
were significantly better in groups of relative and elective indications as compared with ab‐
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Figure 1. Cancer-specific survival in the patients with elective, relative and absolute indications for NSS.
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RCC of > 4 cm. can be treated with elective NSS providing optimal long-term outcome. The
surgeon’s decision for organ-preserving surgery should depend on the tumor location and
technical feasibility rather than on the tumor size [16].
Pahernick S. et al. compared the results of NSS for the tumors of less and more than 4 cm. in
size. Out of 474 treated patients 102 had the tumor of more than 4 cm. The mean follow-up
was 4.7 years. The 5 and 10-year cancer-specific survival for small and large tumors were:
97.9% and 95.8%, 94.9% and 95.8%, respectively. In contrast to the tumor size, stage pT3a
was associated with a significantly higher risk of tumor related death. The authors advocat‐
ed that the surgeon’s decision with regard to the organ preservation should consider the tu‐
mor location and safe surgical resectability, rather than the tumor size [17]. This conclusion
has been later supported by Antonelli A. et al. [18].
Joniau S. et al. presented their results of NSS for the patients with bigger than 4 cm renal
tumors. The following data have been collected and analyzed: surgical indication, tumor
characteristics, complications, serum creatinine level, time to recurrence and time to the pa‐
tient death. Local cancer control has been achieved in the vast majority of patients. The renal
function was preserved in the patients with elective indications. NSS for absolute indica‐
tions was significantly correlated with the loss of renal function but not with a cancer-specif‐
ic survival [19].
In our study the local disease recurrence was detected in 2 (3.5%) and the systemic recur‐
rence in 4 (7%) patients. We could not reveal any changes in the serum creatinine level pre-
and postoperatively in the both groups, despite cold ischemia which was used in all
patients. Both, the cancer-specific and overall survival was significantly better in the groups
of relative and elective indications as compared with the absolute indication (p<0.014 and
p<0.023, respectively). These data are similar to the results of the eight-institution multicen‐
tre review of 1048 NSS procedures [13].
It has been shown by Badalato GM. et al. in their recent publication that the oncological effi‐
cacy of NSS for pT1b renal tumors was comparable to that of radical nephrectomy [20]. The
authors compared the NSS with radical nephrectomy in the patients with T1b RCC using a
propensity scoring approach. 11 256 cases of 4-7 cm. tumors that underwent partial or radi‐
cal nephrectomy have been evaluated. The propensity score analysis was used to adjust for
the potential differences in the baseline characteristics of the patients between the two
groups. Overall and disease-free survival of the patients was compared in stratified and ad‐
justed analysis, controlling for propensity scores. For the entire patient cohort, no difference
in the survivals was found in the NSS and radical nephrectomy groups. The survival differ‐
ence between the groups in a propensity-adjusted cohort of patients could not be confirmed
even when stratified by the tumor size and patient age.
We’ve observed that the NSS for centrally located tumors was associated with a higher com‐
plication rate. This goes in accordance with the data of Ficarra V. et al. who recently pro‐
posed a new tumor scoring system [21]. According to the authors this system can better
predict the complications after NSS than linear tumor size.
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The weak points of our study are retrospective nature and absence of control group consist‐
ing of RN patients. However, the prospective randomized study is very difficult to conduct
especially in the era of minimally invasive approaches for the treatment of RCC.
5. Conclusion
In conclusion, the NSS is a feasible procedure for RCCs of 4-7 cm in size. The local cancer
control can be achieved in most patients. Oncological outcome of the treatment is negatively
related with the tumor size. Long-term prospective studies on the higher number of patients
are required to prove the similar oncological efficacy of NSS and radical nephrectomy in the
RCCs of 4-7 cm. in size.
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1. Introduction
Role of renal artery embolization (RAE) in strategy of treatment of renal carcinoma (RC) has
a multiyear history in scientific literature and in personal experience. In view of personal ex‐
perience we have a strong feeling that RAE is beneficial both in operable and advanced RC,
partially because of longer survival and stimulation of certain immune reactions [1].
RAE was introduced to clinical practice in the 70's of last century. The pioneers who devel‐
oped the technique of surgery were Lalli et al, in 1973 while Almgard et al. presented their
own experience with the application of RAE in renal cancer in humans [2,3]. At that time
arteriography was the basic diagnostic methods and identification of renal tumors was
made during the embolization. Today, vascular embolization procedures are becoming
widely used in the treatment of persistent bleeding, vascular defects and cancer.
In urology RAE is well established in the treatment of bleeding observed after jatrogennie
complications of NSS (nephron sparing surgery), PCN (percutaneous nephrostomy), ESWL
(extracorporeal shock wave lithotripsy), PCNL (percutaneous nephrolithotrypsy), closing
arteriovenous fistulas and the need to rempve kidney in the case of severe nephrotic syn‐
drome or secondary arterial hypertension [4, 7, 22].
Basic form of treatment of locoregional RC is surgical resection of kidney containing the
tumor (optionally with adrenal gland and extraperitoneal lymph nodules).  Recently it  is
adviced to introduce new, less  invasive surgical  techniques (laparoscopy and use of  ro‐
bots),  as  well  as  NSS  (nephron  sparing  surgery).  These  techniques  are  used  mostly  in
less advanced RC (T1) [25, 28, 29, 30].
In the strategy of treatment of more advanced RC frequently there is adviced application of
RAE [2,3]. RAE is a procedure based on introduction, with use of an angiographic catheter,
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Basic form of treatment of locoregional RC is surgical resection of kidney containing the
tumor (optionally with adrenal gland and extraperitoneal lymph nodules).  Recently it  is
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into blood vessel an obstruction material aimed to interrupt blood supply to an organ or to
its particular region. At present different coils, haemostatic spongues, cyanoacrylic glues
and alcohols are applied as materials for RAE [2, 11, 19]. This leads to acute necrosis of tis‐
sues where blood flow has been amputeed, which in turn results in development of acute
phase reaction in the organism.
RAE is applied in treatment of RC for about 40 years [3]. It may be evoked prior to surgery,
considered as a technique succouring the surgery, or used as palliative embolization in
large, inoperable RC, mostly with intensive bleedings and/or pains. RAE which preceedes
nephrectomy provides better conditions for the surgery and allows to shorten time of the
intervention [1,4]. There exist informations that RAE may lead to stabilization and/or regres‐
sion of distal metastases. These effects may be due to immunomodulating effects of RAE
suggested by some authors [1,5]. However, knowledge on influence of RAE on immune sta‐
tus and response of immunocompetent cells is still scarce and fragmentaric. Systematic stud‐
ies of this issue are needed.
In view of multiple limitations in efficacy and safety of RAE the present indications for ap‐
plication of this procedure include mostly [6, 7, 18]:
• Palliative RAE in advanced RC which results in relief of life-treatening haematuria and
lumbar pains;
• Embolization of  large,  highly  vascularized neoplasms prior  to  surgery  (effective  RAE
results  in  contraction  of  vascular  collaterals,  facilitates  dissection  of  the  tumour,  and
allows to change the sequence of affixing renal vascular pedicle, ie first artery and the
renal vein later);
• Embolization of highly vascularized RC metastases (e.g. vertebral metastases).
Opinions on the role of preoperative RAE in the management of patients with RC are con‐
troversial. Although a significant number of studies on RAE are reported in RC patients,
there is no consensus on the benefits and morbidity associated with the procedure [7, 22].
Moreover, many large studies on the use of RAE both prior to nephrectomy and in ad‐
vanced RC were conducted in the 1980s, before the development of improved techniques
and imaging. Most proponents of preoperative RAE report the facilitation of nephrectomy
through decreased operative blood loss, ease of dissection secondary to the development of
oedema in tissue planes, and decreased operative time [8,9]. For those patients with signifi‐
cant tumour thrombus there might be a beneficial effect of decreasing the size or extent of
tumour thrombus before surgery [10]. Interestingly, there might also be an advantage in the
form of immunomodulation, whereby RAE-induced tumour necrosis stimulates a tumour-
specific response from the immune system of the host [11-13].
Own experience [1] includes 474 patients with RC of which 118 had RAE before nephrec‐
tomy. It  was reported that RAE significantly prolonged survival  time in T2 and T3 RC.
Additionally,  it  was found preliminarly that  RAE exerted immunotropic  effects  and en‐
hanced immune status of the patients. This diminished risks of the surgery. Recently we‐
continued these  investigations  and performed series  of  studies  on  response  of  immune
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system in patients with RC undergoing RAE [14].  We analyzed 50 patients with RC ex‐
ceeding diameter of 7 cm (T≥2) and tested immune status of persons with less and more
advanced RC. 30 patients underwent palliative RAE and assessment of immune status at
different  times  after  embolization.  The  complex  assessment  of  immune  status  included
large battery of microculture tests of peripheral blood mononuclear cells (PBMC), estima‐
tion of levels of certain cytokines and cytometric measurement of lymphocyte subpopula‐
tions  in  peripheral  blood.  It  was  found  that  RAE  lowers  the  suppressive  action  of
neoplastic cells on the immune system, results in normalization of disordered proportion
of  lymphocyte  subpopulations  (CD4,  CD8)  and  enhances  the  antiinflamatory  response
(increases  levels  of  certain  cytokines-  IL-10  and  IL-1ra).  All  together,  the  result  reveal
stimulation of  certain  functions  of  immunocompetent  cells  isolated from blood of  RAE-
treated RC patients.  Clinical  relevance of  these findings and concluding whether  or  not
RAE improved immune status of patients needs further studies.
2. Techniques of renal artery embolization
The initial indications developed in the 1970s for RAE were limited to symptomatic haema‐
turia and palliation for metastatic renal cancer [2,3]. With technical advances and growing
experience the indications have broadened to include conditions such as vascular malforma‐
tions, medical renal disease, angiomyolipomas (AMLs), and preoperative infarction. The in‐
troduction of smaller delivery catheters and more precise embolic agents has drastically
improved the morbidity associated with this technique [4]. RAE has continued to gain popu‐
larity as a minimally invasive approach for various urological conditions.
The technique of embolising hypervascular renal carcinomas dates back to 1969 when first
reported by Lalli et al [2]. Since then, various techniques and embolic materials have been
described. RAE has been used pre-operatively to facilitate nephrectomy [8], or to stimulate a
possible systemic response in patients with metastases [5]. Renal embolisation has been es‐
tablished as a palliative treatment for unresectable renal carcinoma and in patients with less
advanced disease (stage I–III) who, for whatever reason, are unsuitable or unwilling to un‐
dergo surgery [18, 22, 24]. In this group of patients the technique reduces tumour bulk and
relieves local symptoms such as pain or intractable haematuria.
However, opinions on the role of preoperative RAE in the management of patients with
RC are controversial.  Although a significant  number of  studies  on RAE are reported in
these  patients,  there  is  no  consensus  on the  benefits  and morbidity  associated with  the
procedure [7-9].
Effective embolization induces acute ischemic necrosis zone to form infarct of the organ tis‐
sues, which results in the onset of symptoms called postembolization syndrome, which usu‐
ally occurs within the first few days after RAE [8]. Greater risk of developing the
postembolization syndrome occurs in patients with small tumors, developing peripherally,
when still remains a large part of the normal, not embolized part of the kidney [9]. The side
effects which occur after RAE include: pain in the lumbar region, nausea and vomiting, hy‐
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perthermia, and fluctuations of blood pressure. These symptoms are usually temporary and
transient, and their severity depends on the extent of ischemia in the kidney area. In a small
percentage RAE may also lead to serious complications that are associated primarily with
the movement (migration) or embolic material backflow [12, 22]. The consequence of this
may be embolization of contralateral artery, mesenteric arteries, arteries of the lower limbs,
and ischemic spinal cord injury. The risk of serious complications is low, if RAE is per‐
formed well and professionally. In our clinic material including hundreds of treatments was
observed and serious complications developed, except of various symptoms of postemboli‐
zation syndrome [1].
If there is a real benefit to be gained, most proponents of preoperative RAE cite the facilita‐
tion of nephrectomy through decreased operative blood loss, ease of dissection secondary to
the development of oedema in tissue planes, and decreased operative time [10, 11, 26]. For
those patients with significant tumour thrombus there might be a beneficial effect of de‐
creasing the size or extent of tumour thrombus before surgery [12]. Interestingly, there
might also be an advantage in the form of immunomodulation, whereby RAE-induced tu‐
mour necrosis stimulates a tumour-specific response [1,5,13]. It is likely that RAE is underu‐
tilized, perhaps because of a lack of prospective randomized studies demonstrating these
potential benefits.
In our Departament of Clinical Urology the treatment of REA is performed under local anes‐
thesia wit 1% xylocaine after puncturing the femoral artery under fluoroscopic control
[1,14]. Vascular catheter is inserted into the abdominal aorta (Seldinger method). Aorto‐
nephrography is performed as the first step of the procedure (Fig.1 - A). This is followed by
selective catheterisation of renal arteries and contrast agent (usually Omnipac) is applied us‐
ing an automatic syringe (Fig. 1 - B). Image of arterial and venous intermediate is obtained
with angiographic confirmation of following RC characteristics:
• Increased flow through the renal artery and the resulting expansion of the arteries,
• Presence of pathological vascularization in arterial phase (numerous, tortuous vessels
with impaired angioarchitectonics)
• Nephrograms with the image of tumorous discoloration occuring due to retention of con‐
trast in blood vessels,
• Loss of saturable renal parenchyma.
This  is  followed by injecting the  embolizing material  through a  vascular  catheter.  Most
frequently  used is  Spongostan which is  fragmented and placed at  the  end of  a  syringe
filled with 0.9% NaCl, and then injected into renal artery. Spongostan embolization often
supplemented with  different  coils.  In  case  of  confirmation in  renal  arteriography of  tu‐
mor vascularization by more  than one artery,  respectively  all  the  supplying vessels  are
embolized, as above.
The whole procedure of RAE (Fig. 1 A – D) lasts about 30 – 60 minutes and its effectiveness
(lack of blood flow in renal vessels) is confirmed in angiography after re-injection of contrast
medium through the catheter withdrawn to the aorta.
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Figure 1. Stages of vascular embolization of renal artery. A. arteriography; B. vascularization of renal tumour; C. mate‐
rial for embolization injected to renal artery; D. closed renal artery.
After completing the RAE procedure the femoral artery puncture site is deemed temporary
with pressure dressing. Few hours after RAE standard blood tests, monitoring of urine out‐
put and assessment of severity of postembolization symptoms (lumbar pain - a symptom
that occurs in nearly all patients after effective RAE, nausea, vomiting, fever, transient renal
failure and symptoms of gastrointestinal paralytic ileus). Medication (analgesic, antispas‐
modic, prokinetic agents, anticoagulants drugs and antibiotics) are prescribed appropriately
to symptoms and depending on the clinical situation. In the study group of 474 patients
there were no clinically significant complications (death, femoral hematoma, migration of
embolizing material or ischemic spinal cord injury) [1,14].
Time schedules of RAE and nephrectomy are not established precisely, usually RAE is made
few – several days before nephrectomy. In some cases RAE is made one only day before sur‐
gery to avoid acute postembolization syndrome.
3. Survival of renal cancer patients treated with renal artery embolization
Up to 30% of patients diagnosed with RC have metastatic disease at presentation [27]. De‐
spite its sometimes favourable course, patients with metastatic RC generally die within 2
years of diagnosis. DeKernion et al [20] found that cumulative survival in 86 patients with
metastatic RCC was 53% at 6 months, 43% at 1 year, 26% at 2 years and 13% at 5 years. The
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treatment of patients with metastatic RC has not improved over the years and continues to
pose a problem for clinicians. Surgery is not curative in this group; however, recent advan‐
ces in immunotherapy have rekindled interest in cytoreductive nephrectomy. A combined
analysis [21] of two prospective randomized trials, [15, 16], found a small survival advant‐
age (5.8 months) in patients who underwent nephrectomy followed by interferon-alpha
based immunotherapy compared with immunotherapy alone. This survival benefit relates
to patients with a good performance status whose primary tumour has been assessed to be
surgically operable and who are good candidates for subsequent immunotherapy. Unfortu‐
nately, many elderly patients with disseminated RC do not fit these criteria and have signifi‐
cant comorbidity. Radical nephrectomy may cause significant morbidity post-surgery,
particularly in elderly patients, and in some cases precludes the use of systemic therapy. It is
in this situation that renal artery embolisation appears to have a role.
Previous studies had reported that delayed nephrectomy following embolisation of RC may
be of clinical benefit to high risk patients with reduction in the size and vascularity of the
primary tumour prior to surgery [9]. Subsequent studies have, however, found no survival
benefit for patients with metastatic disease undergoing embolisation and nephrectomy [23].
The survey also indicated that a significant proportion of respondents (35%) still believed
that the technique had a role in palliation of haematuria or pain in unfit or inoperable cases,
or as the sole treatment modality in patients with metastatic disease.
Park et al [19] investigated the effectiveness of RAE with a mixture of ethanol and lipiodol
in 27 patients with unresectable RC. 10 of the patients had stage III disease with 15 of the 27
patients having stage IV disease. Overall the median survival of the 27 patients was 8.5
months. The median survival was 23 months in the 10 patients with stage III disease and 7
months in 15 patients with stage IV disease. A similar study by Onishi et al [24] compared
two groups of patients with unresectable RC with stage IV disease. 24 patients underwent
renal embolisation with ethanol while 30 patients did not have any intervention. The me‐
dian survival for the renal embolisation group was 229 days and for the control group 116
days. Those undergoing renal embolisation had a significantly better prognosis than those
who did not (p=0.019). Other authors [18, 25, 26] have reported median survival times for
patients treated with renal embolisation ranging from 4 months to 8.4 months. This equates
to a 1 year survival rate of 36.8% and a 2 year survival rate of 15.8%. Ridley et al. [28] sup‐
port the view that embolisation is not a curative treatment and probably only minimally al‐
ters the natural course of the disease, but it gives palliation of local symptoms related to
advanced renal malignancy and is a safe alternative to radical nephrectomy, with low mor‐
bidity and complication rate and shorter hospital stay.
In own studies [1] a series of 474 patients with RC, who had radical nephrectomy during a peri‐
od of 15 years, was studied to assess the prognostic significance of various pathologic parame‐
ters (tumor stage [pT], lymph node status, metastasis, tumor grade, venous involvement) and
value of preoperative RAE. There were: 20 (4%) pT1, 204 (43%) pT2, 245 (52%) pT3, and 5 (1%)
pT4 patients. All 474 patients underwent nephrectomy including a group of 118 (25%) patients
(24 pT2, 90 pT3, and 4 pT4) who underwent preoperative embolization of the renal artery. To
compare treatment outcomes in embolized patients with RC, a group of 116 (24%) nonembol‐
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ized patients with RC was selected. This group was matched for sex, age, stage, tumor size, and
tumor grade, with the embolized patients (p < 0.01). All important prognostic factors were
studied as to their influence on survival by the treatment group. The overall 5- and 10-year sur‐
vival was 62% and 47%, respectively (Figure 2). The 5- and 10-year survival rates were signifi‐
cantly better (p < 0.01) for patients with pT2 than for those with pT3 tumors (79% vs. 50% and
59% vs. 35%, respectively) (Figure 2). Involvement of regional lymph nodes (N+) was an impor‐
tant prognostic factor for survival in patients with pT3 tumors. The 5-year survival for pT3 N+
was 39%, compared with 66% in those with pT3N0 (p < 0.01). Preoperative embolization was
also an important factor influencing survival (Figure 3).
Figure 2. Estimated probability of survival from all causes of death by pathologic stage, pT2 vs. pT3. Open circles rep‐
resent death of a patient. Tick marks represent a patient who was alive at last follow-up.
Figure 3. Estimated probability of survival in the 118 patients treated with preoperative embolization as compared to
the 116 patients in radical nephrectomy alone group (matched patients).
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The overall 5- and 10-year survival for 118 patients embolized before nephrectomy was 62%
and 47%, respectively, and it was 35% and 23%, respectively, for the matched group of 116 pa‐
tients treated with surgery alone (p = 0.01). The most important finding of this study was an ap‐
parent importance of preoperative embolization in improving patients' survival. This finding
needs to be interpreted with caution and confirmed in a prospective randomized trial.
In conclusion, the available data suggest that RAE is a convenient, relatively tolerable man‐
agement option in patients with unresectable renal tumours and in patients unfit or unwill‐
ing to undergo surgery as a means of palliation of local symptoms and improving clinical
status. We believe there is also a role for this procedure in asymptomatic patients who have
potentially resectable disease who are unfit or unwilling to undergo surgery, and in asymp‐
tomatic patients with inoperable metastatic disease.
4. Reaction of immune system to renal artery embolization
RC, with the tumor growth, and then the spread of tumor tissue beyond the original lo‐
cation, begins to affect the activity of the immune system [14].  Nakano et al [5] indicate
the  importance  of  cell  proliferation  inhibitory  factor  present  in  the  serum  of  patients
with  RC.  Lymphocytes  in  RC  patients  without  any  therapy,  stimulated  in  vitro  with
PHA (phytohemagglutinin) in the presence of own serum responded very weakly to this
mitogen.  After  RAE  the  impact  of  this  inhibiting  factor  enhanced  and  proliferation  of
PHA-stimulated  lymphocyte  was  still  lowered [5].  Nephrectomy in  patients  not  treated
with RAE before surgery did not influence the ability of cells to stimulation by PHA. In
contrary,  patients who had RAE prior to nephrectomy the proliferation inhibitory factor
quickly disappeared and proliferative response to PHA was normal already 2 months af‐
ter surgery [5]. Catalona et al [34] reported that cell response to Con A (concanavalin A)
is impaired in case of urological cancers, including RC, and the cells have a high immu‐
no-suppressor  activity.  The  abolition  of  the  high  suppressor  activity  may  be  necessary
for effective treatment of RC [34]. Osada et al [35] in their study of 50 patients with RC
confirmed a  significant  increase  of  helper  and cytotoxic  NK lymphocytes  10-12  months
after  RAE.  This  was  very  impressive,  when  compared  to  lowered  values  of  these  cells
prior  to  RAE,  suggesting  that  RAE  enhanced  the  immune  status  [35].  Similar  results
were obtained by Bakke et al [13], who conducted a study of NK cell activity in patients
with RC after RAE. Blood samples of 30 patients were taken before RAE and 24, 48,  72
and 96  hours  after  surgery.  Surgery  was  performed to  remove  the  kidney  from 5  to  7
days after RAE. RAE resulted in increase in NK cells, with peak values observed after 48
hours  [13].  RAE in  patients  with  RC is  performed in  presence  of  potential  existence  of
immune deficiency caused by cancer itself. Therefore, in this case, the immune responses
(still  poorly  understood and inconsistent)  observed at  different  times after  embolization
(usually few-several days after RAE) will be the result of the two, often different operat‐
ing  mechanisms:  1.  response  to  ischemia  and  tissue  necrosis  and  inflammation  in  the
area  of  embolization  of  a  probable  stimulation  of  the  macrophage-monocyte  system;  2.
release from tumor tissues of various factors affecting the immune system, at least some
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of  which  appear  to  have  an  immunosuppressive  effect.  The  main  task  of  the  immune
system is  to  maintain  homeostasis.  The  basic  unit,  often  defined  as  "immune  orchestra
conductor" is thymus-dependent T lymphocyte,  which, based on the phenomenon of re‐
striction major histocompatibility complex I and II expresses the phenomenon of violence
against  its  own unnormal or  changed antigens,  and the phenomenon of  tolerance to its
own antigens  [32,  33].  Embolization  may  lead  to  stimulation  of  the  immune  system in
the  following  mechanism:  close  off  blood  supply  to  the  tumor  leads  to  necrosis  which
gives a chance to enhance antigenicity of cancer cells and evoke the potential amplifica‐
tion of the immune system [14]. This leads in turn to destruction of tumor tissue by infil‐
tration with cytolytic immunocompetent cells.
Recent studies in patients with metastatic RC have shown a small survival advantage in pa‐
tients undergoing radical nephrectomy followed by immunotherapy; however, these studies
are biased towards patients with good performance status aqccording to ECOG (Eastern Co‐
operative Oncology Group) scale status 0 or status 1. This small survival benefit should also
be viewed in light of the morbidity and mortality associated with a large surgical procedure.
The increased morbidity associated with radical nephrectomy may preclude or delay the ad‐
ministration of systemic immunotherapy, which has demonstrated reproducible response
rates of 10–20% [15].
In two randomized trials with identical design, patients who underwent nephrectomy fol‐
lowed by interferon alpha (IFN-α) therapy had improved survival (median 13.6 months)
compared with those treated with IFN-α alone (median 7.8 months) [15, 16]. The antivascu‐
lar endothelial growth factor (VEGF) antibody; the multityrosine kinase inhibitors, sorafe‐
nib, sunitinib, and pazopanib; and the mammalian target of rapamycin (mTOR) inhibitors,
temsirolimus and everolimus, have become the mainstay of therapy for the vast majority of
patients with metastatic renal cell carcinoma (mRCC). Large randomized controlled clinical
trials have shown improved progression-free survival with these agents and improved sur‐
vival in selected populations, but the majority of these study patients had prior nephrecto‐
my and good performance status [16, 17, 20, 21].
In  own  studies  [14]  we  examined  functional  status  of  immunocompetent  cells  isolated
from peripheral  blood of  patients  with  advanced RC treated  with  RAE.  Blood samples
were  collected  by  vein  puncture  and  peripheral  blood  mononuclear  cells  (PBMC)  were
isolated on Ficol-Paque gradient, and after determination of cell viability (usually no less
than 80% viable cells), the microcultures were set up in triplicates (105 cells/0.2 ml RPMI
+ 15% autologous inactivated serum) in Nuncoln microplates. Respective triplicates were
left without stimulation or stimulated with phytohemagglutinin (PHA, HA16, Murex Bio‐
tech Ltd Dartford U.K.,  0.4 μg/cult.)  or with concanavalin A (Con A, Sigma, 8 μg/cult.).
The  plates  were  placed  inside  the  anechoic  chamber  in  the  ASSAB  incubator  at  37o  C
and 5% CO2. An identical plate of control cultures was also set up and placed in the AS‐
SAB incubator beyond the chamber. At 24h of incubation, rearrangements of the cultures
were performed as described elsewhere [32,33].
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As a result of rearrangements of cultures performed at 24 h, the following parameters of
T cell  and monocyte  activities  were  measured at  the  end of  cultures:  T  lymphocyte  re‐
sponse  to  PHA  and  to  Con  A,  saturation  of  IL-2  receptors,  T  cell  suppressive  activity
(SAT index),  and the index of monocyte immunogenic activity (LM) related to the ratio
of produced monokines (IL-1β versus IL-1ra) [32]. For the last 18h of incubation, 3H-thy‐
midine  (3HTdR,  Amersham,  U.K.,  spec  act.  5Ci/mM)  was  added  into  the  cultures  in  a
dose of 0.4 μCi/cult.
At 72h the cultures were harvested and incorporation of 3HTdR was measured in Pack‐
ard Tri carb 2100 TR scintillation counter. The results were calculated as a mean value of
dpm (desintegrations per  minute)  per  triplicate  of  cultures  ±  SD.  The experiments  were
repeated 10 times, and the results observed in the exposed cultures were compared with
those  obtained  in  the  control  cultures.  The  data  were  analyzed  with  STATGRAPHICS
PLUS  6.0  version.  The  differences  between  the  mean  values  were  assumed  statistically
significant if  the p values, calculated withthe use of U Mann-Whitney’s test,  were lower
than 0.05.
The  results  obtained  in  this  study  are  summarized  in  Table  1  and  described  in  detail
elsewhere [14].
In the analysis of  50 patients with RC treated with RAE, we selected 30 patients where
RAE was the only form of treatment. In this group of patients the immune response was
studied at  different  times  after  the  palliative  RAE (output  test,  the  test  after  2-6  weeks
and at 12 weeks after RAE) successive assessment of significant differences in the magni‐
tude and direction of  change of  parameters  characterizing the efficiency of  the immune
system. It was found that RAE performed in patients with advanced RC exerts immuno‐
modulatory  effect  on the  immune response  manifested by the  increase  of  the  prolifera‐
tive response to PHA and the percentage of  CD4 + cells,  and significant increase in the
value of saturation of the receptors, IL-2, a cytokine with protrophic properties (Table 1).
After RAE significant increase was observed in inflammatory response manifested by the
increase of  T regulatory cells,  which can be a potential  source of  IL-10,  cytokine inhibi‐
tion of the function of the inflammatory response (Table 1).
It was found that RAE lowers the suppressive action of neoplastic cells on the immune sys‐
tem, results in normalization of disordered proportion of lymphocyte subpopulations (CD4,
CD8) and enhances the antiinflamatory response (increases levels of certain cytokines- IL-10
and IL-1ra). All together, the result reveal stimulation of certain functions of immunocompe‐
tent cells isolated from blood of RAE-treated RC patients. Clinical relevance of these find‐
ings and concluding whether or not RAE improved immune status of patients needs further
studies [1, 14].
The changes in the immune system may, however be heterogeneous and multidirectional
and individually changebale. This would indicate that the systemic inflammatory response
is not only associated with the release of cytokines from a kidney tumor, and it rather results
from the defective immune response in patients with advanced cancer [14].
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Investigated parameter
RAE-treated RC patients (T 3 and 4)
N=30
PHA
Lowering after 2-6 weeks *
Increase after 12 weeks
ConA
Lowering after 2-6 weeks *
Lowering after 12 weeks
IL-2
Lowering after 2-6 weeks
Increase after 12 weeks
LM
No significant differences after 2-6 weeks
Lowering after 12 weeks
SAT
Increase after 2-6 weeks
No significant differences after 12 weeks
CD3+
Increase after 2-6 weks
No significant differences after 12 weeks
CD4+
Increase after 2-6 weeks
Increase after 12 weeks
CD8+
Lowering after 2-6 weeks *
Lowering after 12 weeks
CD4+/CD25high
Increase after 2-6 weeks
Increase after 12 weeks
NK
No significant differences after 2-6 weeks
No significant differences after 12 weeks
IL-1β
Increase after 2-6 weeks
Lowering after 12 weeks
IL-6
Increase after 2-6 weeks
Lowering after 12 weeks
TGF-β
Lowering after 2-6 weeks *
Increase after 12 weeks
IL-1ra
Lowering after 2-6 weeks *
Increase after 12 weeks
IL-10
Lowering after 2-6 weeks *
Increase after 12 weeks
Table 1. Summary of changes in investigated functional parameters of immune system in a group of 30 patients with
advanced RC treated with RAE (p<0.05).
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5. Summary and conclusions
In summary, the present authors conclude that patients with advanced RC benefit from RAE
with longer survival. RAE applied prior to nephrectomy facilitates surgery and additionally
prolongs survival. Additionally, RAE appears to be a potent immunostimulatory agent. It is
our strong feeling that in specialistic urologic centers RAE is a safe procedure which suc‐
cours the complex therapeutic process in patients with RC.
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1. Introduction
Renal  cell  carcinoma  is  often  associated  with  paraneoplastic  syndromes  caused  by  the
secretion  of  tumor  cell  products  such  as  hormones,  cytokines,  growth  factors  and  tu‐
mor  antigens,  which  show  manifestations  including  impaired  glucose  metabolism,  hy‐
percalcemia,  hypertension,  Cushing  syndrome,  polycythemia,  thrombosis,  eosinophilia,
leukemoid  reactions  and  amyloidosis  [1].  It  has  been  reported  that  10-40%  of  patients
with  renal  cell  carcinoma  present  paraneoplastic  symptoms  [1].  However,  paraneoplas‐
tic  glomerulonephritis  associated  with  renal  cell  carcinoma  has  often  been  overlooked,
for  the  urinary  abnormalities  including proteinuria  and hematuria  are  often  interpreted
as  clinical  manifestations  of  the  tumor  itself,  especially  when  the  proteinuria  is  non-
nephrotic.
The  term of  paraneoplastic  glomerulopathy was  first  described by Galloway in  1922  in
a  case  of  nephrotic  syndrome  associated  with  Hodgkin’s  disease  [2].  Hodgkin’s  lym‐
phoma  is  associated  with  minimal  change  nephrotic  syndrome,  while  solid  carcinomas
including  lung  cancer  and  carcinomas  of  the  gastrointestinal  tract  frequently  develop
membranous  nephropathy,  which  is  the  most  common  paraneoplastic  glomerulopathy
[3,4].  Although renal  cell  carcinoma is  not  a  frequent  cause of  paraneoplastic  glomerul‐
opathy,  recent  advances  in  the  study of  the  molecular  mechanism of  renal  cell  carcino‐
ma  as  a  cytokine  producing  tumor  have  promoted  a  better  understanding  of  the
mechanism  of  paraneoplastic  nephropathy  associated  with  renal  cell  carcinoma.  In  this
chapter,  I  will  discuss  the  mechanisms  of  paraneoplastic  nephropathies  associated  with
renal  cell  carcinoma.
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1.1. Pathological types of renal cell carcinoma and molecular mechanisms of
paraneoplastic syndrome
Renal cell carcinoma accounts for 85 % of renal neoplasms, and 25% of patients with renal
cell carcinoma show advanced disease with local invasion or metastasis at the time of diag‐
nosis [5]. Renal cell carcinoma is classified pathologically into five types: clear cell (75%),
papillary (12%), chromophobe (4%), oncocytoma (4%), collecting duct carcinoma (<1%), and
unclassified (3-5%) [5]. The most common type, clear cell renal cell carcinoma, shows hyper‐
vascularity. About 60% of sporadic clear cell renal cell carcinoma have mutations in the von
Hippel-Lindau tumor suppressor gene (VHL) [6], which is a causative gene for von Hippel-
Lindau disease, an autosomal dominant familial cancer syndrome consisting retinal angio‐
ma, hemangioblastoma of the central nervous system, pheochromocytomas, and clear cell
renal cell carcinoma. VHL protein normally suppresses hypoxia-inducible genes by inhibit‐
ing HIF-1α [7] (Figure 1). However, when VHL protein is lost in clear cell renal cell carcino‐
ma, various cytokines and growth factors induced by HIF-1α are enhanced; vascular
endothelial growth factor (VEGF) which stimulates angiogenesis of carcinoma, platelet-de‐
rived growth factor (PDGF) and transforming growth factor alpha (TGF- α), which lead to
tumor growth, glucose transporter (GLUT-1) and carbonic anhydrase IX (CA IX), which
leads to tumor cell survival in an acidic environment [8-10]. NF-kB activity is also regulated
by VHL protein, and cytokine-inducible transcription factors including NF-kB and STAT3
are activated in renal cell carcinoma [11-15]. Renal cell carcinoma tissue and cell lines of the
tumor express mRNA of IL-6 and IL-6 receptor [16, 17], which may play a role in cancer cell
growth in an autocrine or paracrine manner.
Figure 1. Molecular mechanisms of renal cell carcinoma as a cytokine-producing tumor.
Renal Tumor110
The von Hippel-Lindau protein (pVHL) binds with hypoxia inducible factor 1α (HIF-1α)
transcription factor and promotes the ubiqutination of HIF-1α, resulting in degradation by
the proteasome under normoxic conditions. In renal cell carcinoma, the absence of wild type
pVHL stimulates the accumulation of HIF-1α and activates transcription at hypoxia-re‐
sponse elements (HREs) in genes including vascular endothelial growth factor (VEGF), pla‐
telet-derived growth factor (PDGF), transforming growth factor α (TGF-α) and TGF-β,
glucose transporter (GLUT-1) and carbonic anhydrase IX (CA IX).
MMP: matrix metalloproteinase; Ang-2: angiopoietin-2; Aglike-4: angiopoietin-like 4;
COX-2: cyclooxygenase-2; BNIP3: BCL2/adenovirus E1B 19 kD interacting protein 3; PAX2:
paired box gene 2.
The serum levels of VEGF and IL-6 are increased according to the stage of renal cell carcino‐
ma, whereas TNF-α and IL-1β showed a slight increase as they are probably produced by
infiltrating monocytes or macrophages (Figure 2) [18,19]. This indicates that clear cell renal
cell carcinoma is a cytokine-producing tumor, whose functions are linked to the develop‐
ment of the various features of the paraneoplastic syndrome [9,20].
Figure 2. Serum vascular endothelial growth factor (VEGF), interleukin-6 (IL-6), tumor necrosis factor α (TNF-α) and
interleukin-1β (IL-1β) in various stages of renal cell carcinoma. Adapted from [18] and [19].
2. Incidence of paraneoplastic syndrome and glomerulopathy in renal
cell carcinoma
The most frequent features of the paraneoplastic syndrome in renal cell carcinoma are hy‐
percalcemia, hypertension and polycythemia. Their prevalence and their causative hor‐
mones and cytokines are listed in Table1 [1].
Paraneoplastic Glomerulopathy Associated with Renal Cell Carcinoma
http://dx.doi.org/10.5772/53534
111
1.1. Pathological types of renal cell carcinoma and molecular mechanisms of
paraneoplastic syndrome
Renal cell carcinoma accounts for 85 % of renal neoplasms, and 25% of patients with renal
cell carcinoma show advanced disease with local invasion or metastasis at the time of diag‐
nosis [5]. Renal cell carcinoma is classified pathologically into five types: clear cell (75%),
papillary (12%), chromophobe (4%), oncocytoma (4%), collecting duct carcinoma (<1%), and
unclassified (3-5%) [5]. The most common type, clear cell renal cell carcinoma, shows hyper‐
vascularity. About 60% of sporadic clear cell renal cell carcinoma have mutations in the von
Hippel-Lindau tumor suppressor gene (VHL) [6], which is a causative gene for von Hippel-
Lindau disease, an autosomal dominant familial cancer syndrome consisting retinal angio‐
ma, hemangioblastoma of the central nervous system, pheochromocytomas, and clear cell
renal cell carcinoma. VHL protein normally suppresses hypoxia-inducible genes by inhibit‐
ing HIF-1α [7] (Figure 1). However, when VHL protein is lost in clear cell renal cell carcino‐
ma, various cytokines and growth factors induced by HIF-1α are enhanced; vascular
endothelial growth factor (VEGF) which stimulates angiogenesis of carcinoma, platelet-de‐
rived growth factor (PDGF) and transforming growth factor alpha (TGF- α), which lead to
tumor growth, glucose transporter (GLUT-1) and carbonic anhydrase IX (CA IX), which
leads to tumor cell survival in an acidic environment [8-10]. NF-kB activity is also regulated
by VHL protein, and cytokine-inducible transcription factors including NF-kB and STAT3
are activated in renal cell carcinoma [11-15]. Renal cell carcinoma tissue and cell lines of the
tumor express mRNA of IL-6 and IL-6 receptor [16, 17], which may play a role in cancer cell
growth in an autocrine or paracrine manner.
Figure 1. Molecular mechanisms of renal cell carcinoma as a cytokine-producing tumor.
Renal Tumor110
The von Hippel-Lindau protein (pVHL) binds with hypoxia inducible factor 1α (HIF-1α)
transcription factor and promotes the ubiqutination of HIF-1α, resulting in degradation by
the proteasome under normoxic conditions. In renal cell carcinoma, the absence of wild type
pVHL stimulates the accumulation of HIF-1α and activates transcription at hypoxia-re‐
sponse elements (HREs) in genes including vascular endothelial growth factor (VEGF), pla‐
telet-derived growth factor (PDGF), transforming growth factor α (TGF-α) and TGF-β,
glucose transporter (GLUT-1) and carbonic anhydrase IX (CA IX).
MMP: matrix metalloproteinase; Ang-2: angiopoietin-2; Aglike-4: angiopoietin-like 4;
COX-2: cyclooxygenase-2; BNIP3: BCL2/adenovirus E1B 19 kD interacting protein 3; PAX2:
paired box gene 2.
The serum levels of VEGF and IL-6 are increased according to the stage of renal cell carcino‐
ma, whereas TNF-α and IL-1β showed a slight increase as they are probably produced by
infiltrating monocytes or macrophages (Figure 2) [18,19]. This indicates that clear cell renal
cell carcinoma is a cytokine-producing tumor, whose functions are linked to the develop‐
ment of the various features of the paraneoplastic syndrome [9,20].
Figure 2. Serum vascular endothelial growth factor (VEGF), interleukin-6 (IL-6), tumor necrosis factor α (TNF-α) and
interleukin-1β (IL-1β) in various stages of renal cell carcinoma. Adapted from [18] and [19].
2. Incidence of paraneoplastic syndrome and glomerulopathy in renal
cell carcinoma
The most frequent features of the paraneoplastic syndrome in renal cell carcinoma are hy‐
percalcemia, hypertension and polycythemia. Their prevalence and their causative hor‐
mones and cytokines are listed in Table1 [1].
Paraneoplastic Glomerulopathy Associated with Renal Cell Carcinoma
http://dx.doi.org/10.5772/53534
111
Phenomenon Prevalence % Hormones and cytokines






3-20% Hepatotoxines, lysosomal enzymes stimulating hepatic
cathepsins or phosphatases, IL-6
Constitutional syndrome (fever, weight
loss, fatigue)
20-30% TNF-α, IL-6. IL-1, prostaglandins
6% β-HCG
Cushing’s syndrome 2% ACTH
Abnormal glucose metabolism Insulin, glucagon
Galactorrhea Prolactin





PTHrP: parathyroid hormone-related peptide, OAF: osteoclast activating factor, TNF: tumor necrosis factor, HCG: hu‐
man chorionic gonadotropin, ACTH: adrenocorticotropin, SAA: serum amyloid A.
Table 1. Prevalence and features of paraneoplastic syndromes in renal cell carcinoma.
Paraneoplastic glomerulopathy is believed to be a rare manifestation of the paraneoplastic
syndrome. However, immunohistochemical analysis of resected kidneys from 60 patients of
renal cell carcinoma revealed 27% of them had immune complex nephropathy including 11
patients (18%) with IgA nephropathy and 5 patients (8%) with focal segmental glomerulo‐
sclerosis [21]. Another immunofluorescence study revealed a positive staining for C3, IgM,
or IgA in the mesangial deposits in 35% (14/40) of patients with renal cell carcinoma versus
5.4% in the control subjects [22] (Table 2). Thus, the occurrence of glomerular diseases is not
so rare in renal cell carcinoma.
Renal Tumor112
Prevalence % Outcomes after resection of renal
carcinoma
Reference
IgA nephropathy 11/60 (18%) Remission 6, Azotemia 2 Magyarlaki [21]
FSGS 5/60 (8%) Azotemia 3
Diabetic nephropathy 3/60 (5%) Nephrotic /Azotemia 2
Nephrosclerosis 4/60 (7%) Nephrotic /Azotemia 2
Tubulointerstitial nephritis 16/60 (27) -
IgA/C3 deposition 1/40 (2.5%) N.D. Beaufils [22]
C3/IgM deposition 13/40 (33%)
CEA deposition 2/9 (22%)
HBs Ag/Ab deposition 6/29(21%)
Table 2. Evaluation of glomerulopathy in resected kidneys of renal cell carcinoma patients.
3. Diagnosis and mechanism of paraneoplastic glomerulopathy
associated with renal cell carcinoma
Recent development or worsening of diabetes mellitus, increased platelet or C-reactive pro‐
tein (CRP), and hypercalcemia also suggests the existence of paraneoplastic syndrome. Glo‐
merulonephritis is considered when urinalysis shows dysmorphic red blood cells and red
blood cell casts, as hematuria caused by renal cell carcinoma usually shows isomorphic red
blood cells. When proteinuria exceeds 1g per day, it is also better to speculate overlapping
glomerulonephritis and examine serological tests including immunoglobulins (IgG, IgA,
IgM), complements (CH50, C3, C4), anti-nuclear antibody, and anti-dsDNA antibody. A fi‐
nal diagnosis of glomerulonephritis can only be given by a renal biopsy. Renal cysts or
masses identified by renal ultrasonography at the time of renal biopsy should be further in‐
vestigated with CT and MRI. Renal cancer will progress rapidly after steroid therapy for
glomerulonephritis.
The diagnosis of paraneoplastic glomerulopathy will be suggested following the criteria; 1)
existence of a time relationship between the diagnosis of the glomerulopathy and cancer, 2)
no obvious etiology for glomerular diseases, 3) clinical or histological remission of glomerul‐
opathy after complete remission by surgical removal of carcinoma, 4) recurrence of the carci‐
noma associated with deterioration of glomerular diseases [3,23].
As mentioned above, inactivation of the VHL gene by frame-shift mutation is observed in
about 60% of sporadic RCC [5]. Activated HIF-1α without VHL protein stimulates hypoxia-
related proteins such as vascular endothelial growth factor (VEGF) and platelet-derived
growth factor (PDGF), which lead to tumor growth and trigger angiogenesis (Figure 1)
[8,10]. The increased VEGF accelerates glomerular permeability and causes proteinuria, and
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PDGF and IL-6 stimulates mesangial cell proliferation, and TGF-β increases the mesangial
matrix, contributing to the development of glomerulonephritis.
It is interesting that IgA nephropathy showed a higher prevalence than membranous nephr‐
opathy in renal cell carcinoma, whereas about 50% of glomerulopathies associated with gas‐
trointestinal neoplasias and lung cancers were membranous nephropathy (Table 3). The
mechanisms of paraneoplastic nephropathy may be different in renal cell carcinoma com‐
pared with gastrointestinal neoplasias and lung cancers. The paraneoplastic nephropathy of
renal cell carcinoma may depend more upon overproduction of cytokines rather than cross-








Membranous nephropathy 10 (20%) 26 (54%) 20 (49%)
IgA nephropathy 15 (31%) 1 (2%) 2 (5%)
Minimal change disease 6 (12%) 9 (19%) 9 (22%)
Focal segmental glomerulonephritis 5 (10%) 2 (4%) 1 (2%)
Membranoproliferative
glomerulonephritis
3 (6%) 2 (4%) 5 (12%)
Crescentic glomerulonephritis 10 (20%) 8 (17%) 4 (10%)
Table 3. Type of glomerulopathy in renal cell carcinoma compared with gastrointestinal neoplasia and lung cancer.
Modified from [3].
4. Types of paraneoplastic nephropathy
4.1. IgA nephropathy and renal cell carcinoma
Although IgA nephropathy is more common in younger patients, when it occurs in patients
older than 60 years, a high prevalence of malignancy (23%) is observed [24]. Solid tumors
that invade mucosal tissue like the respiratory tract, the buccal cavity, and the nasopharynx
increase circulating IgA levels and show deposition of IgA in the mesangium [24]. Several
cases of IgA nephropathy associated with renal cell carcinoma have been reported previous‐
ly [21,25-28]. In Figure 3, a 66 year-old male diagnosed IgA nephropathy with mesangial
IgA deposition but weak C3 staining showed a rapid increase in renal cyst during steroid
treatment, and a clear cell renal cell carcinoma was found in the resected kidney (Figure 3).
The infiltrating plasma cells around the renal cell carcinoma produced IL-6 and IgA (Figure
3). Elevated levels of IL-6 have been reported in 18 (25%) of 71 patients with renal cell carci‐
noma [29], and IL-6 increased in more than 50% of patients with metastatic renal cell carci‐
noma, playing a role as a prognostic marker [19,20,30,31]. IL-6 stimulates IgA production
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[32], thus, the elevated IL-6 in renal cell carcinoma may increase circulating IgA, which de‐
posits in the mesangial area causing IgA nephropathy.
Figure 3. Clear cell renal cell carcinoma in association with IgA nephropathy. (A) PAS staining of clear cell carcinoma
with a capsule. (B) immunostaining for IL-6 showing positive immunoreactivity in the infiltrating lymphocytes and
plasma cells around the clear cell carcinoma and capsule. (C) IgA immunoreactivity positive in the plasma cells around
renal cell carcinoma. (D) Renal biopsy sample showing segmental mesangial cell proliferation. (E) Immunofluores‐
cence showed positive staining of IgA in the mesangial area, and weak staining of C3 (F).
4.2. Membranous nephropathy and renal cell carcinoma
The most frequent paraneoplastic glomerulopathy associated with solid tumors is membra‐
nous nephropathy and it is easy to detect because most of the cases manifest the nephrotic
syndrome (paraneoplastic nephrotic syndrome) [3,23,33]. Since membranous nephropathy
associated with malignancy has been attributed to tumor antigen-antibody immune com‐
plex formation, the cancer related antigens have been identified in immune complex in some
cases including PSA in prostate cancer, CEA in gastrointestinal cancer [34]. Renal cell carci‐
noma has been reported to be associated with membranous nephropathy [35-43], but its
prevalence is lower compared with gastrointestinal cancer and lung cancer (Table 3). As an‐
tibodies against phospholipase A2 receptor antibody have been identified in 70 % of pa‐
tients with primary membranous nephropathy [44], a diagnosis of secondary membranous
nephropathy should be considered when it is negative. IgG subclass immunofluorescence is
useful to distinguish the primary membranous nephropathy in which IgG4 is stained pre‐
dominately. In a case of secondary membranous nephropathy associated with renal cell car‐
cinoma, showed predominantly IgG1 and IgG3 staining compared to IgG4 (Figure 4). The
renal tubular epithelial antigen (RTE) has been identified in one case of renal cell carcinoma
[45], but in most cases the tumor antigen-antibody complex were not identified in the serum
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PDGF and IL-6 stimulates mesangial cell proliferation, and TGF-β increases the mesangial
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Table 3. Type of glomerulopathy in renal cell carcinoma compared with gastrointestinal neoplasia and lung cancer.
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older than 60 years, a high prevalence of malignancy (23%) is observed [24]. Solid tumors
that invade mucosal tissue like the respiratory tract, the buccal cavity, and the nasopharynx
increase circulating IgA levels and show deposition of IgA in the mesangium [24]. Several
cases of IgA nephropathy associated with renal cell carcinoma have been reported previous‐
ly [21,25-28]. In Figure 3, a 66 year-old male diagnosed IgA nephropathy with mesangial
IgA deposition but weak C3 staining showed a rapid increase in renal cyst during steroid
treatment, and a clear cell renal cell carcinoma was found in the resected kidney (Figure 3).
The infiltrating plasma cells around the renal cell carcinoma produced IL-6 and IgA (Figure
3). Elevated levels of IL-6 have been reported in 18 (25%) of 71 patients with renal cell carci‐
noma [29], and IL-6 increased in more than 50% of patients with metastatic renal cell carci‐
noma, playing a role as a prognostic marker [19,20,30,31]. IL-6 stimulates IgA production
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[32], thus, the elevated IL-6 in renal cell carcinoma may increase circulating IgA, which de‐
posits in the mesangial area causing IgA nephropathy.
Figure 3. Clear cell renal cell carcinoma in association with IgA nephropathy. (A) PAS staining of clear cell carcinoma
with a capsule. (B) immunostaining for IL-6 showing positive immunoreactivity in the infiltrating lymphocytes and
plasma cells around the clear cell carcinoma and capsule. (C) IgA immunoreactivity positive in the plasma cells around
renal cell carcinoma. (D) Renal biopsy sample showing segmental mesangial cell proliferation. (E) Immunofluores‐
cence showed positive staining of IgA in the mesangial area, and weak staining of C3 (F).
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nous nephropathy and it is easy to detect because most of the cases manifest the nephrotic
syndrome (paraneoplastic nephrotic syndrome) [3,23,33]. Since membranous nephropathy
associated with malignancy has been attributed to tumor antigen-antibody immune com‐
plex formation, the cancer related antigens have been identified in immune complex in some
cases including PSA in prostate cancer, CEA in gastrointestinal cancer [34]. Renal cell carci‐
noma has been reported to be associated with membranous nephropathy [35-43], but its
prevalence is lower compared with gastrointestinal cancer and lung cancer (Table 3). As an‐
tibodies against phospholipase A2 receptor antibody have been identified in 70 % of pa‐
tients with primary membranous nephropathy [44], a diagnosis of secondary membranous
nephropathy should be considered when it is negative. IgG subclass immunofluorescence is
useful to distinguish the primary membranous nephropathy in which IgG4 is stained pre‐
dominately. In a case of secondary membranous nephropathy associated with renal cell car‐
cinoma, showed predominantly IgG1 and IgG3 staining compared to IgG4 (Figure 4). The
renal tubular epithelial antigen (RTE) has been identified in one case of renal cell carcinoma
[45], but in most cases the tumor antigen-antibody complex were not identified in the serum
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and elutes of glomeruli in patients with membranous nephropathy associated with renal cell
carcinoma [35,40].
Even though tumor antigen-antibodies have not been identified yet, renal tumors may have
some contribution to the pathogenesis of membranous nephropathy because nephrotic syn‐
drome is transiently ameliorated after tumor excision [40-43].
Figure 4. Secondary membranous nephropathy associated with clear cell renal cell carcinoma.
Light microscopy of PAM staining demonstrated thickening of the glomerular basement
membrane, and electron microscopy revealed subepithelial electron dense deposits with
spike formation. IgG1 and IgG3 were more strongly stained along the capillary wall than
IgG4, suggesting secondary membranous nephropathy.
4.3. Minimal change disease and focal segmental glomerulosclerosis with renal cell
carcinoma
In contrast to Hodgkin’s disease, renal cell carcinoma associated with minimal change neph‐
rotic syndrome is rare [46,47]. The onset of nephrotic syndrome is simultaneous [48,49] or
precedes the diagnosis of renal tumor by 3-4 weeks [47,50], and there was a case in which
complete remission was achieved after nephrectomy without steroids [49]. These lines of
evidence suggest that occurrence of minimal change nephrotic syndrome may be a paraneo‐
plastic syndrome associated with renal cell carcinoma. Renal oncocytoma, characterized by
increased cytoplasmic volume containing abundant fine eosinophilic granules and mito‐
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chondria, also show the paraneoplastic minimal change nephrotic syndrome [51]. The
pathogenesis of minimal change nephrotic syndrome in not clear, but T cell-mediated im‐
mune response has been postulated. The increased secretion of VEGF from renal cell carci‐
noma may alter glomerular permeability and induce minimal change nephrotic syndrome.
Magyarlaki et al [21] reported 5 cases (8%) of focal segmental glomerulosclerosis in 60 au‐
topsy cases of renal cell carcinoma, however, there are only a few reports of focal segmental
glomerulosclerosis with renal cell carcinoma [52] and Wilms’ tumor [53]. Glomerulosclerotic
lesions are often observed in the renal parenchyma adjacent to a tumor, so parenchymal
compression and urinary outflow obstruction by renal tumor may be involved in the devel‐
opment of focal segmental glomerulosclerosis.
4.4. Crescentic rapidly progressive glomerulonephritis and vasculitis with renal cell
carcinoma
Crescentic glomerulonephritis with rapid progressive renal failure in conjunction with renal
cell carcinoma has been reported previously [54-57]. The prevalence of renal cell carcinoma
is significantly higher in patients with ANCA-positive Wegener’s granulomatosis (7 in 477
patients) than in those with rheumatoid arthritis (1 in 479 patients) with an odds-ratio for
development of renal cell carcinoma of 8.73 (p=0.0464, 95% CI 1.04-73.69) [58]. In most of the
7 cases, Wegener’s granulomatosis was developed shortly after or simultaneously with the
diagnosis of renal cell carcinoma [58]. There are many infiltrating cells around the clear cell
renal cell carcinoma (Figure 5), and the chronic inflammation observed in renal cell carcino‐
ma may induce anti-neutrophil cytoplasmic antibodies (ANCA) or the renal cancer cells
may serve as an antigen source [59]. The renal prognosis in crescentic glomerulonephritis
with renal cell carcinoma becomes poor when an anti-GBM antibody exists, and a rapid pro‐
gression to end-stage renal failure with need of hemodialysis has been reported [54].
Figure 5. ANCA-related crescentic nephritis associated with renal cell carcinoma. A) The clear cell renal cell carcinoma
was surrounded by many infiltrating inflammatory cells including lymphocytes, plasma cells and some neutrophils. B)
Some glomeruli around the renal cell carcinoma demonstrated crescents, and the MPO-ANCA level was decreased
from 217 EU to 99 EU after nephrectomy.
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plastic syndrome associated with renal cell carcinoma. Renal oncocytoma, characterized by
increased cytoplasmic volume containing abundant fine eosinophilic granules and mito‐
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topsy cases of renal cell carcinoma, however, there are only a few reports of focal segmental
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lesions are often observed in the renal parenchyma adjacent to a tumor, so parenchymal
compression and urinary outflow obstruction by renal tumor may be involved in the devel‐
opment of focal segmental glomerulosclerosis.
4.4. Crescentic rapidly progressive glomerulonephritis and vasculitis with renal cell
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Crescentic glomerulonephritis with rapid progressive renal failure in conjunction with renal
cell carcinoma has been reported previously [54-57]. The prevalence of renal cell carcinoma
is significantly higher in patients with ANCA-positive Wegener’s granulomatosis (7 in 477
patients) than in those with rheumatoid arthritis (1 in 479 patients) with an odds-ratio for
development of renal cell carcinoma of 8.73 (p=0.0464, 95% CI 1.04-73.69) [58]. In most of the
7 cases, Wegener’s granulomatosis was developed shortly after or simultaneously with the
diagnosis of renal cell carcinoma [58]. There are many infiltrating cells around the clear cell
renal cell carcinoma (Figure 5), and the chronic inflammation observed in renal cell carcino‐
ma may induce anti-neutrophil cytoplasmic antibodies (ANCA) or the renal cancer cells
may serve as an antigen source [59]. The renal prognosis in crescentic glomerulonephritis
with renal cell carcinoma becomes poor when an anti-GBM antibody exists, and a rapid pro‐
gression to end-stage renal failure with need of hemodialysis has been reported [54].
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Membranoproliferative glomerulonephritis with crescents has been reported in patients
with renal cell carcinoma, and elective nephrectomy improved both proteinuria and renal
function after seven months [60]. Henoch-Schönlein purpura with leukocytoclastic vasculitis
was also observed in a 25-year-old man with a small size (0.9x0.8cm) clear cell renal cell car‐
cinoma [61]. Vasculitis associated with cancer is common in lymphoma and leukemia, but
only 37 cases associated with solid tumor malignancies have been reported [62], including
lung cancer, prostate cancer, colon cancer, renal cell carcinoma, breast cancer and squamous
cell carcinoma [63]. Cytokine production by malignant cells, like renal cell carcinoma, may
contribute to the development of vasculitis.
4.5. Scleroderma and lupus erythematosus with renal cell carcinoma
Renal cell carcinoma has an immunogenic feature. An interesting case was reported recently
where clinical manifestations of scleroderma and proteinuria associated with renal cell carci‐
noma and membranous nephropathy in a 55-year-old man improved after heminephrecto‐
my of the renal cell carcinoma [43]. Similarly, lupus nephritis developed in a 64 year-old
male with clear cell renal carcinoma with para-aortic lymph node metastasis. After one year
of partial nephrectomy, the renal cell carcinoma recurred with nephrotic syndrome and per‐
icarditis, and laboratory examination showed an increase in IgG (3449 mg/dL), IgA (371 mg/
dL), IgM (715 mg/dL), anti-nuclear antibody (x320) and anti-double strand DNA antibody
(41 IU/mL) with low complement levels (CH50 10 U/mL, C3 60, C4 10 mg/dL). Immunohis‐
tochemical examination of the resected kidney and para-aortic lymph nodes revealed in‐
creased infiltration of plasma cells producing IgG, IgM and IgA around the tumor (Figure
6), suggesting that renal cell carcinoma may have some role in the development of lupus er‐
ythematosus.
Figure 6. Immunohistochemistry for IgG, IgM, and IgA in the resected kidney of renal cell carcinoma and its para-aort‐
ic lymph node metastasis. The patient developed lupus erythematosus and nephrotic syndrome when renal cell carci‐
noma recurred and progressed.
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4.6. Amyloidosis associated with renal cell carcinoma
About 3% of patients with renal cell carcinoma develop systemic amyloidosis [64], and the
amyloid is composed of AA protein [65,66]. The renal cell carcinoma may be involved in the
stimulation of hepatic production of acute phase reaction proteins including serum amyloid
A protein, and the modification of amyloidogenic proteins by the monocyte-macrophage
system in the chronic inflammatory lesion of renal cell carcinoma, causing the secondary
amyloidosis. Remission of amyloidosis and nephrotic syndrome has been reported after
nephrectomy [65,67,68].
4.7. Tubulointerstitial nephritis
Tubulointerstitial nephritis is often difficult to identify because it does not show obvious ab‐
normalities in urine. However, 27% of patients with renal cell carcinoma showed tubuloin‐
terstitial nephritis in resected kidney (Table 2) [21]. Recently, as a mechanism of
tubulointerstitial nephritis, the antibody against carbonic anhydrase II (CAII) was identified
in Sjögren syndrome with renal tubular acidosis [69] and IgG4 related tubulointerstitial
nephritis [70]. Carbonic anhydrase is a zinc metalloenzyme that catalyzes the hydration of
carbon dioxide and the dehydration of bicarbonate in the proximal tubules and the distal
nephron including the intercalated cells of the collecting duct. CA has 15 isoforms and CAII
accounts for more than 95 % of CA activity in the kidney and exists in the cytosol, and the
remaining 5% renal CA is membrane associated CAIV and CAXII [71]. CAIX is not ex‐
pressed in the normal kidney, however, in renal cell carcinoma CAIX is induced by hypoxia
as a tumor-associated antigen [72,73]. Inactivation of the VHL gene complex leads to the sta‐
bilization of hypoxia inducible factor-1α which activates CAIX gene expression [74]. CAIX
may promote tumor growth and survival in hypoxic and acidic environments [73]. Serum
levels of CAIX are higher in clear cell renal cell carcinoma than non-clear cell renal cell carci‐
noma and it is a useful marker for the differential diagnosis of renal cell carcinoma and also
as a maker of tumor size [75]. It could be possible that an autoantibody against CAIX could
be induced and cause tubulointerstitial nephritis in renal cell carcinoma.
5. Treatment of paraneoplastic glomerulopathy associated with renal cell
carcinoma
The primary treatment for renal cell carcinoma is surgical excision including radical neph‐
rectomy, nephron-sparing partial nephrectomy, laparoscopic nephrectomy and percutane‐
ous ablation by radiofrequency heat or cryoablation [5]. Most cases of nephrotic syndrome
associated with renal cell carcinoma showed remission or transient reduction of proteinuria
just after nephrectomy as summarized in Table 4. It is interesting that only nephrectomy can
achieve remission of nephropathy with amyloidosis [65,67,68], which is usually refractory to
treatment. Some cases of IgA nephropathy, membranous nephropathy, crescentic glomeru‐
lonephritis and focal segmental nephrosclerosis associated with renal cell carcinoma pro‐
gressed to end stage renal failure. In addition to nephrectomy, treatment with prednisolone
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amyloidosis. Remission of amyloidosis and nephrotic syndrome has been reported after
nephrectomy [65,67,68].
4.7. Tubulointerstitial nephritis
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may promote tumor growth and survival in hypoxic and acidic environments [73]. Serum
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noma and it is a useful marker for the differential diagnosis of renal cell carcinoma and also
as a maker of tumor size [75]. It could be possible that an autoantibody against CAIX could
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5. Treatment of paraneoplastic glomerulopathy associated with renal cell
carcinoma
The primary treatment for renal cell carcinoma is surgical excision including radical neph‐
rectomy, nephron-sparing partial nephrectomy, laparoscopic nephrectomy and percutane‐
ous ablation by radiofrequency heat or cryoablation [5]. Most cases of nephrotic syndrome
associated with renal cell carcinoma showed remission or transient reduction of proteinuria
just after nephrectomy as summarized in Table 4. It is interesting that only nephrectomy can
achieve remission of nephropathy with amyloidosis [65,67,68], which is usually refractory to
treatment. Some cases of IgA nephropathy, membranous nephropathy, crescentic glomeru‐
lonephritis and focal segmental nephrosclerosis associated with renal cell carcinoma pro‐
gressed to end stage renal failure. In addition to nephrectomy, treatment with prednisolone
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was attempted in some cases, especially in minimal change nephrotic syndrome, and
showed reduction of proteinuria. However, it is noteworthy to recognize that the cyst at the
time of biopsy rapidly enlarged after treatment with prednisolone for IgA nephropathy, and
a diagnosis of renal cell carcinoma was made later [28]. Thus, the first line of treatment of
paraneoplastic glomerulopathy associated with renal cell carcinoma is nephrectomy, and
the use of steroids should be limited only to cases of controlled renal cell carcinoma.
Glomerulopathy Age, sex Treatment Outcomes References
IgAN 61 M nephrectomy Remission Tanaka [26]
IgAN 8 cases nephrectomy Remission (6/8) Magyarlaki [21]






Remission ESRD Remission Mimura [28]
MN 76 F nephrectomy Died (33 days) Stein [37]
MN 69 M steroid 50mg Died (6 months) Nishihara [38]
MN 62 M Partial nephrectomy PR Fujita [39]
MN 57 M nephrectomy TR/relapse Togawa [40]
MN 72M nephrectomy TR/ESRD Kapolas [41]
MN 77 F nephrectomy remission Kuroda [42]
MN 55 M nephrectomy remission Nunez [43]
MCNS 49 M Nephrectomy, steroid PR Forland [51]
MCNS 70 M nephrectomy Remission after biopsy Lee [49]
MCNS 69 M Steroid 80mg,
CPM150mg
Died of infection Abouchacra [48]
MCNS 64 F Nephrectomy, steroid
60mg
PR Woodrow [50]
MCNS 78 M nephrectomy, steroid
1mg/kg
Complete remission Auguet [47]
FSGS 48 M nephrectomy Worsened sCr Ejaz [52]
CresGN /GBM-Ab 74 M nephrectomy ESRD Hatakeyama [54]
CresGN/MPO-ANCA 68 F nephrectomy, steroid Remission Karim [56]
CresGN 35 F HD ESRD died on HD Jain [ 57]
MPGN 26 F nephrectomy remission Tydings [76]
MPGN 65 M nephrectomy remission Ahmed [60]
amyloidosis 66 F diuretics NS, Died (respiratory
failure)
Pras [66]
amyloidosis 58 F Nephrectomy,
splenectomy
Remission (7months) Vanatta [65]
amyloidosis 62 M nephrectomy Remission (3years) Karsenty [67]
amyloidosis 54 F nephrectomy Remission (5years) died of
relapse
Tang [68]
IgAN: IgA nephropathy, MN: membranous nephropathy, MCNS: minimal change nephrotic syndrome, FSGS: focal seg‐
mental glomerulosclerosis, cresGN: crescentic glomerulonephritis, MPGN: Membranoproliferative glomerulonephritis,
PR: partial remission, ESRD: end-stage renal disease, TR transient remission, CPM cyclophosphamide, HD: hemodialysis,
NS: nephrotic syndrome.
Table 4. Treatment and outcomes of glomerulopathy with renal cell carcinoma
Renal Tumor120
6. Molecular-target therapy related nephropathy in renal cell carcinoma
About  30%  patients  will  have  distant  metastasis  at  the  time  of  diagnosis,  and  medical
therapies including interleukin-2,  interferons,  and molecular-target  therapy are generally
offered  for  advanced  renal  cancer  as  listed  in  Table  5.  Interleukin-2  showed  transient
proteinuria  and  renal  dysfunction,  but  these  changes  are  reversible  and  did  not  cause
long-term intrinsic renal damage [77-79]. Interferons are well known to show proteinuria
in  15-20% of  patients  [80].  The  nephrotic  syndrome and acute  renal  failure  induced by
interferon therapy are histologically due to minimal change disease and acute tubuloin‐
terstitial nephritis [80-82].
Bevacizumab, a humanized monoclonal anti-vascular endothelial growth factor antibody,
is  used for  the treatment  of  metastatic  renal  cell  carcinoma,  but  adverse effects  such as
hypertension, anorexia and proteinuria are increased with combination therapy of bevaci‐
zumab  and  interferon  α  compared  with  interferon  α  monotherapy  [83,84].  High-dose
bevacizumab therapy showed proteinuria of more than 1+ in 64% of patients with renal
cell  carcinoma and nephrotic  range proteinuria  of  more than 3.5  g/day in 7.7% patients
[85].  Renal  biopsy  revealed  thrombotic  microangiopathy  in  two  patients  treated  with
Bevacizumab and interferon-α [86]. As VEGF is expressed in the podocyte and its recep‐
tors  are  found in glomerular  endothelial  cells,  blocking VEGF may disturb the function
of  VEGF  to  maintain  the  glomerular  capillary  permeability  barrier,  causing  thrombotic
microangiopathy [87,88].
Treatment of renal cell carcinoma with sunitinib or sorafenib, which inhibit the VEGF re‐
ceptor  and multi-tyrosine  kinases,  induced severe  nephrotic  syndrome with  acute  renal
failure,  and renal  biopsy revealed minimal change disease and thrombotic  microangiop‐
athy with acute tubular necrosis [89,90]. Sunitinib also develops other pathological forms
of renal diseases including acute interstitial nephritis [91], acute nephritic syndrome with
subendothelial  C3  deposition  [92],  FSGS [93],  and sorafenib  is  also  associated with  IgA
nephropathy  [94],  and  interstitial  nephritis  [95].  Withdrawal  of  sunitinib  or  sorafenib
with or  without  use  of  steroids  ameliorated increased serum creatinine  and proteinuria
as well as hypertension and edema [91,93-95],  but in some advanced cases hemodialysis
was needed [89,  92]  or proteinuria persisted [90].  Thus,  early detection of renal  adverse
effects of these drugs is necessary.
Temsirolimus is a highly specific inhibitor of the mammalian target of rapamycin, which is a
central regulator of intracellular signaling pathways and an inhibitor of angiogenesis. Tem‐
sirolimus has prolonged overall survival in patients with advanced renal cell carcinoma
compared to interferon-α [96]. However, temsirolimus reduced synaptopodin and nephrin
expression in podocytes and induced nephrotic syndrome caused by focal segmental glo‐
merulosclerosis [97]. The amount of proteinuria decreased after withdrawal of temsirolimus,
so it is necessary to notice the nephrotic adverse effects of this drug.
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was attempted in some cases, especially in minimal change nephrotic syndrome, and
showed reduction of proteinuria. However, it is noteworthy to recognize that the cyst at the
time of biopsy rapidly enlarged after treatment with prednisolone for IgA nephropathy, and
a diagnosis of renal cell carcinoma was made later [28]. Thus, the first line of treatment of
paraneoplastic glomerulopathy associated with renal cell carcinoma is nephrectomy, and
the use of steroids should be limited only to cases of controlled renal cell carcinoma.
Glomerulopathy Age, sex Treatment Outcomes References
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CresGN 35 F HD ESRD died on HD Jain [ 57]
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PR: partial remission, ESRD: end-stage renal disease, TR transient remission, CPM cyclophosphamide, HD: hemodialysis,
NS: nephrotic syndrome.
Table 4. Treatment and outcomes of glomerulopathy with renal cell carcinoma
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6. Molecular-target therapy related nephropathy in renal cell carcinoma
About  30%  patients  will  have  distant  metastasis  at  the  time  of  diagnosis,  and  medical
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hypertension, anorexia and proteinuria are increased with combination therapy of bevaci‐
zumab  and  interferon  α  compared  with  interferon  α  monotherapy  [83,84].  High-dose
bevacizumab therapy showed proteinuria of more than 1+ in 64% of patients with renal
cell  carcinoma and nephrotic  range proteinuria  of  more than 3.5  g/day in 7.7% patients
[85].  Renal  biopsy  revealed  thrombotic  microangiopathy  in  two  patients  treated  with
Bevacizumab and interferon-α [86]. As VEGF is expressed in the podocyte and its recep‐
tors  are  found in glomerular  endothelial  cells,  blocking VEGF may disturb the function
of  VEGF  to  maintain  the  glomerular  capillary  permeability  barrier,  causing  thrombotic
microangiopathy [87,88].
Treatment of renal cell carcinoma with sunitinib or sorafenib, which inhibit the VEGF re‐
ceptor  and multi-tyrosine  kinases,  induced severe  nephrotic  syndrome with  acute  renal
failure,  and renal  biopsy revealed minimal change disease and thrombotic  microangiop‐
athy with acute tubular necrosis [89,90]. Sunitinib also develops other pathological forms
of renal diseases including acute interstitial nephritis [91], acute nephritic syndrome with
subendothelial  C3  deposition  [92],  FSGS [93],  and sorafenib  is  also  associated with  IgA
nephropathy  [94],  and  interstitial  nephritis  [95].  Withdrawal  of  sunitinib  or  sorafenib
with or  without  use  of  steroids  ameliorated increased serum creatinine  and proteinuria
as well as hypertension and edema [91,93-95],  but in some advanced cases hemodialysis
was needed [89,  92]  or proteinuria persisted [90].  Thus,  early detection of renal  adverse
effects of these drugs is necessary.
Temsirolimus is a highly specific inhibitor of the mammalian target of rapamycin, which is a
central regulator of intracellular signaling pathways and an inhibitor of angiogenesis. Tem‐
sirolimus has prolonged overall survival in patients with advanced renal cell carcinoma
compared to interferon-α [96]. However, temsirolimus reduced synaptopodin and nephrin
expression in podocytes and induced nephrotic syndrome caused by focal segmental glo‐
merulosclerosis [97]. The amount of proteinuria decreased after withdrawal of temsirolimus,
so it is necessary to notice the nephrotic adverse effects of this drug.
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Medical therapy Mechanism Renal diseases References





Interferon α, γ immunomodulatory cytokine proteinuria, MCNS, IN,
ARF
INF-α: Quesada [80]
IFN-γ: Nair [81], Tashiro [82]
Bevacizumab Humanized VEGF-neutralizing
antibody
Proteinuria, TMA Rini [83], Summers [84],
Roncone [86]
Sunitinib VEGF receptor and multiple
tyrosine kinase inhibitor
MCNS, iATN Chen [89]
AIN Winn [91]
AGN Rolleman [92]
FSGS, TMA Costero [93]
Sorafenib VEGF receptor and multiple
tyrosine kinase inhibitor
TMA, MCNS Overkleeft [90]
IgAN Jonkers [94]
AIN Izzedine [95]
Temsirolimus Inhibitor of the mammalian
target of rapamycin
FSGS Izzedine [97]
MCNS: minimal change nephrotic syndrome, IN: interstitial nephritis, ARF: acute renal failure, TMA: thrombotic micro‐
angiopathy, iATN: ischemic acute tubular necrosis, AGN:acute glomerulonephritis.
Table 5. Interleukin, interferon and molecular-target drugs related nephropathy in the renal cell carcinoma
7. Summary
Recent advances in the molecular understanding of renal cell carcinoma have shed light on
the mechanism of paraneoplastic glomerulopathy. Clear cell renal cell carcinoma with a
VHL gene mutation stimulates HIF-1α transcription, and produces various cytokines and
growth factors including VEGF, PDGF, TGF−α/β, IL-6, CAIX and EPO. Renal cell carcinoma
has a feature of cytokine disease or immunogenic disease, and enhanced cytokines and
growth factors stimulate lymphocytes and plasma cells, and the latter works as a causative
factor for various forms of paraneoplastic glomerulopathies. The precise mechanism of glo‐
merulonephritis has not been completely elucidated, and further investigation of renal cell
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1. Introduction
Urooncological diseases account about 40% of all oncological pathologies in men and more
than 10% in women. Renal cell carcinoma (RCC) accounts for about 4% of all adult malig‐
nancies and is the most lethal urological cancer. 60 920 new cases of RCC have been diag‐
nosed in the US in 2011 and 13 120 died of cancer [1]. The patient death rate from RCC has
decreased in the last 15 years due to the improvements in early diagnosis and surgical treat‐
ment of the disease [1]. However, it is estimated that 1/3 of the patients with localized cancer
will develop distant metastasis after radical treatment [2]. Therefore, early identification of
metastatic disease, timely and proper treatment is the main goal in the management of RCC.
The most common sites of metastases of RCC are: lymph nodes, lungs, liver, bones and
brain [3]. It is known that the disease can metastasize to almost every organ. Adrenal meta‐
stasis of RCC is relatively rare. It can be: synchronous or metachronous; ipsilateral, contrala‐
teral or bilateral; solitary or part of a massive metastatic spread. Malignant involvement of
the ipsilateral adrenal gland has been detected in up to 10% of the radical nephrectomy
specimens [4-8]. Contralateral adrenal metastasis however, is uncommon. In the autopsy
study of more than 400 patients who had undergone nephrectomy for RCC, the solitary con‐
tralateral adrenal metastasis has been detected in only 2.5% of cases [9].
The predisposing factors for the disease spread and the optimal treatment of this rare com‐
plication are not fully understood. It is well-known that some patients with isolated meta‐
stasis may benefit from surgical treatment. However, the optimal diagnosis and treatment of
the contralateral adrenal metastasis from RCC is not yet well defined. The available infor‐
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mation on the outcomes of various treatment options of this complication is limited and
mainly based on a sporadic case reports.
In this chapter we analyze all 65 cases of the contralateral adrenal metastases of RCC report‐
ed in the literature [10-32]. Our single center experience of treatment of four patients with
this complication is also presented. The chapter describes the current view on the pathogen‐
esis, diagnosis and management as well as the surgical, pathological and oncological results
of treatment of this rare complication.
The natural course of the RCC is unpredictable. The disease can metastasize to any organ,
any time even many years after the operation [33, 10]. Metastasis from the RCC has been
discovered as late as 23 and 31 years after radical nephrectomy [33, 34]. The contralateral
adrenal metastasis from RCC is extremely rare. Only 69 cases (including our series) can be
found in the literature.
The exact reasons of late development of the adrenal metastasis are not completely clear.
One of the possible explanations could be that some metastases, especially those of low
grade, can grow very slowly. Besides, improper patient follow-up i.e. not using a routine
imaging studies for a long time might explain the late detection of some metastasis.
Adrenal metastasis from renal tumors is more common to the ipsilateral adrenal gland. The
pathological mechanisms for secondary involvement of the contralateral adrenal gland are
unknown. It is thought that the disease spreads via hematogenous route as in case of other
organ metastases. However, the autopsy studies illustrate that contralateral adrenal metasta‐
ses occur far more often than should be expected on the basis of organ size [18]. Explanation
of this fact can be a rich blood supply of the adrenal gland and its high blood volume-to-unit
weight ratio [35]. It has been speculated that as far as the contralateral adrenal metastasis
has occurred the adrenal gland will have a higher affinity to the RCC cells than other organ
tissues [4]. In another words, if the tumor cell reaches the adrenal gland the later acts as a
fertile soil and stimulates raise of these cells [18]. In consistent with this theory some studies
are showing that the adrenal metastases from the contralateral primary RCC grew to a con‐
siderable size without metastasing to other organs. Utsumi T, et al. describe a huge
(85X90mm) contralateral adrenal metastasis that had invaded the kidney, renal vein, and in‐
ferior vena cava but without any involevement of other organs [32].
The risk-factors for development of the adrenal metastasis have been analyzed by some of
the studies. Importance of the several clinicopathological features of the primary RCC has
been reported. These are: tumor size, left sided tumor, advanced T-stage, and upper-pole tu‐
mor location [4, 36].
Adrenal metastases are usually anatomically and functionally silent and patients rarely have
symptoms or signs of adrenal insufficiency. Therefore, abdominal imaging is not routinely
used for follow-up and the isolated contralateral adrenal metastasis from RCC is rarely diag‐
nosed during a lifetime. This should contribute to the late disease diagnosis, treatment and
the worse prognosis.
Due to rare occurrence, the optimal diagnostic approach to a solitary contralateral adrenal
metastasis in the patients with a history of RCC is controversial. It can be different from the
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adrenal incidentalomas. Imaging studies usually cannot verify with certainty the adrenal
masses detected in the patients previously operated due to the RCC. It is always difficult to
determine whether the mass is: primary adrenal tumor (carcinoma), benign tumor (i.e. an
adrenal cortical adenoma) or metastasis. Preoperative diagnosis of synchronous adrenal
metastases is relatively easy and is mainly based on radiological findings from abdominal
CT and/or MRI. The finding of solitary adrenal mass without elevated serum adrenocortical
hormones is strongly suggestive of a metastatic lesion. Metastatic adrenal tumors are usual‐
ly well-vascularized as compared with the adrenal cortical adenoma or primary adrenal car‐
cinoma. The later ones are more hypovascular [30].
CT is a highly specific in diagnosing adrenal metastases. In 82% of cases reported in the lit‐
erature, contralateral adrenal metastases have been diagnosed by abdominal CT. Antonelli
et al. reviewed clinical records of 1179 surgically treated RCC patients and found that 15 had
suspicious findings in the contralateral adrenal glands on CT. Only one of the 15 surgically
removed adrenals was found to be free of tumor. The authors reported positive and nega‐
tive predictive value of CT as 73% and 96% in detecting the adrenal metastases. Remarkably,
the positive predictive value of CT in diagnosing the contralateral adrenal metastases was
higher [32]. It should be noted that accuracy of CT for distinguishing between benign and
malignant contralateral adrenal nodules has improved recently using CT protocols to evalu‐
ate the wash-out of contrast media [37].
We’ve analyzed the records of six hundred twenty nine patients who underwent radical
nephrectomy for RCC in our center between 1991 and 2005. The mean patient age was
55.7±11.3 years (range: 12-85 years). 422 (67.2%) were man and 207 (32.8%) were women.
The mean follow-up is 60.5±1.7 months (range: 1-187 months). The pathological stage distri‐
bution of the tumor was the following: T1 –132 (21%); T2 – 229 (36.4%); T3 – 256 (40.7%); T4 -
12 (1.9%) patients. 123 (19.4%) cancers were G1, 277 (44.1%) - G2 and 229 (36.5 %) - G3.
Morphological evaluation revealed clear cell RCC in 475 patients (75.6%). 38 (6.1%) patients
had lymph node and 28 (4.5%) patient had distant metastases at the time of surgery. 170
(27%) tumors were discovered incidentally, 332 (52.8%) were locally symptomatic and 127
patients (20.2%) had a systemic disease symptoms.
Four cases  (0.6%) of  isolated contralateral  adrenal  metastasis  have been diagnosed with
the mean follow-up of 83.3 months (range: 23-196 months). In accordance with the exist‐
ing data from the literature all  four metastases have been detected by CT. The metasta‐
ses  have  been  diagnosed  synchronously  in  one  (0.1%)  and  metachronously  in  three
(0.5%) cases. Mean age of the patients was 56 years (range: 47-68 years). All the patients
underwent adrenalectomy through flank incision above the 11th rib. No patient received
any form of adjuvant systemic therapy.
All  four  patients  had  undergone  contralateral  radical  nephrectomy  due  to  the  conven‐
tional RCC. All removed kidneys and adrenal were sent to the department of pathology
of the same institution (National Centre of Urology). The same team of personnel accord‐
ing to the single protocol has technically processed all the tissue specimens. The surgical
margins  of  the  primary  nephrectomy  specimens  were  recorded  as  positive  or  negative
based on the gross and microscopic examination of the specimen. The adrenal gland was
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examined macroscopically,  sliced in 2- to 3-mm cross sections and processed for further
microscopical evaluation.
Morphological parameters assessed for both the primary and metastatic tumors included:
stage, histological subtype, nuclear grade and presence of tumor necrosis. The stained slides
from all tumor and metastases specimens were reviewed by urological pathologist, as de‐
scribed previously [38]. Shortly, the resected kidneys and adrenals were evaluated macro‐
scopically. The maximal tumor size was measured and 1.5 x 2cm tissue samples were taken
for further assessment. Specimens were fixed, stained and evaluated by the same patholo‐
gist according to conventional technique. The tumors were staged according to the AJCC
classification system and graded according to Fuhrman’s grading system.
The mean (range) diameter of the primary renal tumor was 76±27.9 mm (12-200 mm) and
the mean diameter of the adrenal metastases was 6.4 cm (range: 3–9 cm). The clinical and
pathological features of the primary tumors for the 4 patients with contralateral adrenal
metastasis are summarized in Table 1. The pathological stage of the adrenal metastasis was
pT2N0 and pT3aN0 in two patients each. Grade 2 tumor was detected in one and grade 3 in
three cases.




Stage Grade Follow-up Patient
status
1 47 M 18 Right T3a 3 31 Dead
2 58 M 64 Right T2 3 78 Dead
3 57 F 24 Right T3a 3 165 Alive
4 73 F 156 Left T2 2 180 Alive
Table 1. The characteristics of four patients with contralateral adrenal metastasis.
One patient had synchronous contralateral adrenal metastasis. The mean time from the pri‐
mary nephrectomy to contralateral adrenal metastasis for the remaining three patients was
65.5 months (range: 18–156 months).
Adrenal biopsy can be advocated in some cases. The biopsies of RCC has been lately aban‐
doned due to the following reasons: a) the predictive value of the imaging findings usually
is so high that a negative biopsy result would not alter the management strategy; b) 10-20%
of biopsies are reported to be non-conclusive; c) high risk of complications associated with
the biopsy [39].
Early diagnosis and treatment of metachronous adrenal metastases is more challenging as it
can occur many years after the operation. This depends on the mode of follow-up, diagnos‐
tic techniques used and early referral of the patient to the specialized clinic. In our study the
adrenal metastases have been detected at the mean 65.5 months after radical nephrectomy.
A wide variability of latency in diagnosis of the metastases has been reported by others as
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well. These data indicate on the necessity of prolonged surveillance, especially in the high
risk patients i.e. with advanced disease stage [31, 40].
The survival of patients with RCC mainly depends on the disease spread. Widely metastatic
RCC usually have a poor prognosis with a mean survival of 11 months. On the contrary, in
the patients with solitary or limited metastases resection of the metastases can be associated
with prolonged survival (30% survival at 5 years) [39]. Reports of successful outcomes and
subsequent long-term survival after treatment of solitary metastases of the RCC justify an
aggressive surgical approach [10]. In light of the existing data, complete resection of the pri‐
mary renal and metastatic adrenal tumors should be the main clinical strategy in these pa‐
tients. Thus, in case of adrenal metastases whether it is synchronous or metachronous,
ipsilateral or contralateral, complete removal of adrenal gland is a treatment of choice pro‐
viding the best results [30].
Adrenalectomy can be performed either laparoscopically, retroperitoneoscopically or by ro‐
botic surgery, decreasing the surgery-associated morbidity and hospital stay [20]. We’ve
performed open adrenalectomy in all our patients. The operation was uneventful in all of
them. The mean operation time was 136 minutes (range: 110-160 minutes). All metastases
were clear cell RCC tumors. The mean blood loss was 175 ml (range: 50-350 ml). The mean
hospital stay was 6 days (range: 4-10 days). No patient had positive surgical margins from
the adrenalectomy. There are no data on the efficacy of any form of systemic therapy in the
treatment of solitary adrenal metastasis.
The available data on the outcome of the surgical treatment of the contralateral adrenal
metastases form RCC are limited and biased. Table 2 summarizes the data of 65 patients
with contralateral adrenal metastasis reported in the literature [10-32]. Characteristics of the
patients (age, sex), interval between the primary surgery and diagnosis of the adrenal meta‐
stasis, and clinical outcome of the patients are described.
These are mainly the case reports of 1-2 cases. The biggest series of 11 cases has been report‐
ed by Lau WK, et al. from the Mayo clinic in 2003. In this report 82% of the metastases were
metachronous, diagnosed at the mean 4.2 years (0-9.2 years) after the nephrectomy. Other
relatively big series of 7 and 8 patients have been reported by Plawner J. and Antonelli A. in
1991 and 2006, respectively.
57% of all metastases reported up to now have been detected synchronously and 43% were
discovered metachronously at the mean 2.8 years (0-23 years) after the radical nephrectomy.
58% of the patients were male and 42% were female. The majority (62%) of metastases de‐
veloped on the left side. Abdominal CT was the preferred method of diagnosis in the vast
majority of cases (82%) followed-up by arteriography (6%) and IVP (2%).
At the mean follow-up of 6.8 years (0.3-14.3 years) 29 patients (55%) were alive without evi‐
dence of disease and 18 patients (34%) were dead of disease. Surgical removal of the adrenal
gland was the only treatment used in these patients. None of the patients received any form
of adjuvant systemic therapy.
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of adjuvant systemic therapy.
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Art, arteriography; AWD, alive with disease; DOC, dead of other causes; DOD, dead of disease; DU, dead of unknown
cause; F, female; IVP, intravenous pyelogram; L, left; m, metachronous; M, male; NED, no evidence of disease; NS, not
stated; R, right; s, synchronous.
Table 2. Characteristics of the patients treated for the contralateral adrenal metastasis published in the literature.
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From our series of four patients, two are alive 141 and 24 months after adrenalectomy with‐
out signs of disease recurrence. Two patients died from multiple metastases 13 and 14
months after adrenalectomy, including the patient with synchronous contralateral adrenal
metastasis.
For the entire group of patients, the 5 and 10 years disease–specific survival rates were 61.5
% and 25.6%, respectively. The 5-year overall survival for metastatic (N+ and M+) disease
was significantly worse as compared with the non-metastatic disease (6.25% and 72.8%, re‐
spectively) (p=0.0001).
There was no statistically significant difference when the survival of patients with solita‐
ry  adrenal  lesions  was  compared  to  that  of  the  patients  with  organ–confined  primary
RCC.  Furthermore,  no  differences  in  survival  have  been  detected  between  the  patients
with  synchronous  or  metachronous  adrenal  metastasis  (p=0.346  for  overall  survival;
p=0.256 for disease-specific survival). With multivariate statistical analysis the presence of
solitary  adrenal  metastases  was  not  predictive  of  the  clinical  prognosis  of  the  patients
following adrenalectomy.
The biggest number of the patients with contralateral adrenal metastasis from RCC reported
in the literature is 11 [30]. This number is small for making the strong conclusions. Majority
of the available studies indicate that the surgical treatment of the complication is worth‐
while in selected patients [22, 23]. One study demonstrated that patients in whom RCC
metastases (both synchronous and metachronous) were clinically confined to the adrenal
gland had statistically better survival rates than those with diffuse metastasis [31]. In about
one-third of the RCC patients with isolated adrenal metastasis, surgical resection of the
metastasis led to an apparently curative outcome [32]. The longest disease-free survival after
removing a contralateral adrenal metastases form RCC is 12.1 years [41], and the longest
overall survival is 14.3 years [20]. In accordance with the literature, we didn’t find statistical‐
ly significant survival difference between the patients with localized RCC and solitary con‐
tralateral adrenal metastasis. Furthermore, with multivariate statistical analysis the presence
of solitary adrenal metastases was not predictive of the clinical prognosis of the patients fol‐
lowing adrenalectomy.
The exact reason why do these patients survive longer remains unclear. The several possible
explanations exist. It has been speculated that this is a localized disease and that complete
removal of the tumor improves prognosis. Another explanation is that the patient’s immune
system can probably inhibit microscopic disease after tumor debulking. Finally, it has been
postulated that this may be a naturally selected group of patients with slow-growing cancer
which is not very aggressive and does not metastasize readily [19].
2. Conclusion
In conclusion, the solitary contralateral adrenal metastasis from RCC is an extremely rare
clinical complication that can occur very late after the radical nephrectomy. The increased
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in the literature is 11 [30]. This number is small for making the strong conclusions. Majority
of the available studies indicate that the surgical treatment of the complication is worth‐
while in selected patients [22, 23]. One study demonstrated that patients in whom RCC
metastases (both synchronous and metachronous) were clinically confined to the adrenal
gland had statistically better survival rates than those with diffuse metastasis [31]. In about
one-third of the RCC patients with isolated adrenal metastasis, surgical resection of the
metastasis led to an apparently curative outcome [32]. The longest disease-free survival after
removing a contralateral adrenal metastases form RCC is 12.1 years [41], and the longest
overall survival is 14.3 years [20]. In accordance with the literature, we didn’t find statistical‐
ly significant survival difference between the patients with localized RCC and solitary con‐
tralateral adrenal metastasis. Furthermore, with multivariate statistical analysis the presence
of solitary adrenal metastases was not predictive of the clinical prognosis of the patients fol‐
lowing adrenalectomy.
The exact reason why do these patients survive longer remains unclear. The several possible
explanations exist. It has been speculated that this is a localized disease and that complete
removal of the tumor improves prognosis. Another explanation is that the patient’s immune
system can probably inhibit microscopic disease after tumor debulking. Finally, it has been
postulated that this may be a naturally selected group of patients with slow-growing cancer
which is not very aggressive and does not metastasize readily [19].
2. Conclusion
In conclusion, the solitary contralateral adrenal metastasis from RCC is an extremely rare
clinical complication that can occur very late after the radical nephrectomy. The increased




use of radiological diagnostic tests like: ultrasound, CT and/or MRI has led to more efficient
detection of these lesions. Aggressive surgery remains the treatment of choice in these cases
improving prognosis in some of the patients. There is no doubt that the existing data are
limited and we need more studies to define the optimal management strategy in the patients
with contralateral adrenal metastasis from RCC.
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1. Introduction
Renal cell carcinoma (RCC) accounts for approximately 3% of adult malignancies and close to
90% of all renal neoplasms. Renal cell carcinomas, by definition, are tumors that originate in
the renal cortex. These tumors are often asymptomatic, have diverse clinical manifestations,
and can be associated with hereditary syndromes. Surgery is the treatment of choice for
localized RCC. In localized RCC, partial nephrectomy for small tumors and radical nephrec‐
tomy for larger tumors continue to be the gold standard. Surgical practice has reduced
morbidity and has advanced toward more limited and less invasive resection approaches. In
addition, cytoreductive nephrectomy is often indicated before embarking on systemic
treatment in patients with metastatic disease.
In recent years, there has been a shift from radical nephrectomy toward more nephron-sparing
approaches. RCC still remains a predominantly surgical disease because RCCs are frequently
characterized as tumors that are resistant to chemotherapy and radiation. However, advances
in the treatment of metastatic RCC have evolved, primarily with biologic response modifiers.
The management of RCC has undergone the most significant transformation. Scientific
understanding of the molecular basis of cancer and the role of growth factors have resulted in
the identification of signaling pathways relevant in the pathogenesis of renal cell carcinoma.
This knowledge provided the impetus for developing new drugs that target and inhibit these
diff e rent pathways. Previously, systemic therapy for renal cancer has been limited to the use
of interleukin-2 and the off-label use of interferon. These drugs formulated an immunothera‐
peutic approach to the treatment of advanced renal cancer. Translational research and
participation of patients with advanced renal cell carcinoma in clinical trials have resulted in
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the approval of six systemic targeted therapies. These include sorafenib tosylate, sunitinib
malate, temsirolimus, everolimus, bevacizumab in combination with interferon, and most
recently, pazopanib. Each of these drugs has increased therapeutic options and appears to
prolong survival for patients with advanced renal cancer.
2. Biologic basis of targeted therapy
Recent advancements in the understanding of the genetics of RCC have led to a new patho‐
logical classification of five different subtypes of RCCs: clear cell, papillary, chromophobe,
collecting duct carcinoma (Bellini Duct tumor), and renal carcinoma unclassified (renal
medullary carcinoma). This classification is primarily based on cytologic appearance and the
cell origin in combination with growth pattern and genetic alterations [1].
The grading of RCC is based on the morphology of a neoplasm with hematoxylin and eosin
(H&E) staining on microscopy. The most popular and widely used system for grading RCC is
a nuclear grading system described by Fuhrman, Lasky, and Limas in 1982. This system
categorizes RCC into one of four grades based on nuclear characteristics and has been shown
to correlate with prognosis.
Adenocarcinomas represent the great majority (85%) of renal cell cancers. Adenocarcinomas
may be subdivided into clear cell renal carcinomas, the most common form of kidney cancer;
Many cases of clear cell carcinoma are linked to inactivation of the von Hippel-Lindau tumor
suppressor protein (pVHL), [2]. VHL is a 213 amino acid protein that polyubiquinates hypoxia-
inducible factor 1 alpha (HIF1alpha) which marks it for destruction by the cellular proteosome.
Normally, low oxygen conditions allow HIF1alpha to accumulate and bind to HIF1beta
thereby creating a complex that transcriptionally activates genes. In patients with aberrant
VHL, HIF1alpha is left to accumulate freely without degradation even under normal oxygen
conditions and thus the transcription of genes related to glucose metabolism, apoptosis,
angiogenesis and endothelial stabilization are abnormally promoted. This disordered response
to hypoxia activates over 100 HIF-responsive genes which include growth factors and their
receptors such as VEGF, platelet-derived growth factor (PDGF), and transforming growth
factor alpha/beta (TGF), [3].
1nactivation of the VHL gene is an early step in clear cell renal carcinogenesis, at least for those
tumors associated with VHL disease. Subsequent studies have shown that VHL inactivation
is also common in non-hereditary clear cell renal carcinoma. Approximately 50% of sporadic
clear cell renal carcinomas harbor somatic mutations affecting the maternal and paternal VHL
locus.
Another downstream effect of the VEGF receptor (VEGFR) pathway is the activation of PI3
kinase and Akt which in turn promote mTOR kinase [4]. mTOR is a central component of
intracellular pathways that promote tumor growth and proliferation, cellular metabolism and
is a mediator of the hypoxic response as an upstream activator of HIF1alpha. When mTOR
and raptor combine to form an activated complex, they phosphorylate and thus activate the
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eukaryotic translation initiation factor 4E binding protein-1 (eIF-4BP1) and ribosomal S6 kinase
(p70s6k). This leads to the synthesis of cellular proliferation proteins such as cyclin D1,
angiogenesis mediators such as VEGF, and hypoxia response regulators such as HIF1alpha [5].
3. Targeted therapies
Systematic studies of cell lines in which pVHL or HIF status has been manipulated suggest
that as many as 100 HIF-responsive genes might be dysregulated when pVHL is crippled [6].
A number of these genes encode proteins that are implicated in tumorigenesis. This makes
them amenable to pharmacologic attack. Evidence now indicates that targeting these HIF-
responsive genes can alter the natural history of human renal carcinoma.
Fortunately, a number of drugs have been identified that indirectly downregulate HIF protein
levels. One such drug, rapamycin, inhibits mTOR, which plays a critical role in the regulation
of protein translation. This in turn affects HIFα, which is very sensitive to changes in protein
translation due in part to its high metabolic turnover rate. Inhibitors of mammalian target of
rapamycin (mTOR) like rapamycin, downregulate HIF, [7].
4. Targeting HIF-responsive growth factors
4.1. Vascular endothelial growth factor
Clear cell renal carcinomas are notoriously angiogenic. Indeed, prior to the availability of
computed tomography, renal angiograms were often used to diagnose these tumors. Renal
carcinomas overproduce a variety of angiogenic moieties including vascular endothelial
growth factor (VEGF), the product of a HIF-responsive gene. In addition to promoting
angiogenesis, VEGF might suppress antitumor immune responses as well. It has also been
suggested that VEGF has direct stimulatory effects on renal carcinoma cells, although these
findings await further corroboration, [8, 9].
Several drugs that inhibit VEGF, or its kinase insert domain-containing receptor (KDR), have
activity against clear cell renal carcinomas. In a randomized phase II study, patients with
metastatic renal carcinoma who were treated with 10 mg/kg (but not 3 mg/kg) bevacizumab,
a neutralizing antibody against VEGF, exhibited a significant delay in time-to-disease pro‐
gression, [10]. Other unrelated KDR inhibitors such as SU11248 (sunitinib maleate),
BAY43-9006 (sorafenib), and AG-013736 also appear to have significant activity against this
tumor subtype, [11, 12].
5. VEGFR tyrosine kinase inhibitors
VEGF stimulates endothelial cell proliferation and survival. Immature blood vessels appear
to be exquisitely sensitive to VEGF withdrawal. In contrast, mature blood vessels are less
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sensitive to VEGF withdrawal because their endothelial cells are responsive to additional
survival factors such as platelet-derived growth factor (PDGF) released from surrounding
pericytes. Ongoing efforts to improve our understanding of the basic biology of RCC have
identified several potential targets for therapeutic modulation. One particularly promising
area of investigation is the role of VEGF in the pathogenesis of renal cell carcinoma. VEGF is
a tumor-secreted cytokine that plays an important role in both normal and tumor-associated
angiogenesis. VEGF exerts its biologic effect by binding to cell surface VEGF receptors, thereby
inducing dimerization and autophosphorylation of intracellular receptor tyrosine kinases,
leading to activation of downstream signal transduction elements. There are several forms of
VEGF receptors (VEGFR), but VEGFR-2 appears to be the main receptor responsible for the
proangiogenic effects of VEGF. The relevance of VEGF to tumor biology is supported by the
high incidence of von Hippel-Lindau tumor suppressor gene mutations in patients with RCC,
which subsequently leads to increases in VEGF expression. Receptor tyrosine kinases (RTKs)
play an integral role in the signaling cascade of VEGF and PDGF [12].
RTKs have an extracellular domain that binds to their respective ligand and an intracellular
domain that holds the tyrosine kinase responsible for downstream signaling. Upon ligand
binding, the RTKs dimerize or multimerize to induce a conformational change that allows ATP
binding resulting in autophosphorylation and transphosphorylation. These tyrosine domains
are then able to phosphorylate and activate various proteins in the downstream signal
transduction cascade.
6. Sunitinib
Sunitinib is an oral drug with inhibitory activity against several related protein tyrosine kinase
receptors, including the platelet-derived growth factor receptor (PDGFR)–ß, stem cell factor
receptor (KIT), and Fms-like tyrosine kinase-3, as well as the vascular endothelial growth factor
(VEGF) receptors 1, 2 and 3, [13]. Two initial phase II trials of sunitinib 50 mg/day for 4 weeks
followed by 2 weeks rest in 169 metastatic renal cell carcinoma (RCC) patients who had failed
previous cytokine-based therapy demonstrated an investigator-assessed objective response
rate of 45%, a median duration of response of 11.9 months, and a median progression-free
survival (PFS) of 8.4 months [14, 15]. Recently, a survival analysis of these patients was
reported, suggesting a trend for improved median overall survival (OS) with sunitinib therapy
(26.4 vs 21.8 months; hazard ratio: 0.821; 95% confidence interval: 0.673-1.001; P =.051.Based
on these data, sunitinib has emerged as a frontline standard of care for patients with metastatic
RCC. Common toxicities associated with sunitinib have included fatigue, hand-foot syndrome,
diarrhea, mucositis, hypertension and hypothyroidism. Cardiotoxicity has been reported and
thus monitoring may be required in patients with preexisting heart disease [16].
In a population-based retrospective analysis comparing patients treated in the IFN era (n=131)
versus those treated in the sunitinib era (n=69), the patients treated with first-line sunitinib had
an associated doubling in OS compared to those treated with interferon (17.3 versus 8.7
months, p=0.004) [17]. When adjusted for Memorial Sloan Kettering Cancer Center (MSKCC)
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prognostic criteria, the HR of death for sunitinib versus IFN was 0.049 (p=0.001). Even those
patients classified as having a poor prognosis by MSKCC criteria had a survival advantage.
Current treatment algorithm for patients with met (10.7 versus 4.1 months, p=0.0329), sug‐
gesting that use of sunitinib is beneficial in this population as well.
7. Sorafenib
Sorafenib is an oral multikinase inhibitor that inhibits vascular endothelial growth factor
(VEGF) receptors 1-3, platelet-derived growth factor receptor (PDGFR)–ß, and the serine
threonine kinase Raf-1 [18]. A phase III trial of sorafenib randomized 905 treatment-refractory
metastatic RCC patients to sorafenib 400 mg orally twice daily or placebo [19]. In the sorafenib
arm, a progression-free survival (PFS) advantage of 5.5 months vs 2.8 months was observed
(hazard ratio for disease progression: 0.44; 95% confidence interval: 0.35-0.55; P <.01). The
median overall survival was also increased for patients in the sorafenib group (19.3 vs 15.9
months) but did not reach prespecified statistical boundaries for significance. The common
toxicities experienced with sorafenib are similar to sunitinib except that the hand-foot syn‐
drome may be more pronounced and cardiotoxicity and fatigue appears to occur less fre‐
quently. Based on these data, sorafenib has been FDA approved and become a standard of care
for second-line treatment of mRCC after immunotherapy failure. However, a smaller, random‐
ized phase II of sorafenib vs interferon alfa-2b in 189 previously untreated metastatic RCC
patients failed to demonstrate a PFS advantage over IFN. Compared with interferon alfa-2b,
sorafenib did not significantly improve the median PFS (5.6 vs 5.7 months, respectively), [20].
Although the reason for the lack of significant effect when compared with interferon alfa-2b
in the frontline setting remains unclear, one possibility is that it is because of a weaker
inhibition of VEGF receptor compared with sunitinib. Although there may be patients in whom
sorafenib is a preferred initial agent because of the toxicity profile or other considerations,
sorafenib has largely been relegated to second-line and later therapy. The identification of
those patients for whom sorafenib would be the preferred frontline treatment is needed.
8. Mammalian Target of Rapamycin (mTOR) inhibitors
Temsirolimus is an inhibitor of mammalian target of rapamycin (mTOR), a molecule impli‐
cated in multiple tumor-promoting intracellular signaling pathways.
Activation of the mTOR protein, through cellular stimuli-triggered activation of the PI3K/Akt
pathway, can also result in HIF accumulation. mTOR phosphorylates and activates p70S6K,
which results in enhanced translation of certain proteins, including HIF. Activated HIF
translocates into the nucleus, where it triggers the transcription of a large number of hypoxia-
inducible genes; among these are the growth factors vascular endothelial growth factor (VEGF)
and PDGF. These growth factors interact with their respective cell-surface receptors, leading
to cell migration, proliferation, and permeability. Temsirolimus and everolimus bind to the
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FK506-binding protein; this resultant protein-drug complex inhibits the kinase activity of
mTOR within the mTORC1 complex.
Temsirolimus was initially evaluated for patients with mRCC in a randomized phase II study
of three different dose levels [21]. When patients were retrospectively stratified into MSKCC
prognostic risk groups, the poor risk group appeared to have a better than expected OS, leading
to further evaluation in this population.
The subsequent phase III trial with temsirolimus had a primary endpoint of OS. Six hundred
and twenty-six previously untreated patients with poor prognostic criteria were randomized
to temsirolimus 25mg IV weekly, IFN alpha 18 million units (MU) three times a week or
temsirolimus 15 mg IV weekly plus IFN 6 MU three times a week [22]. To be considered poor
risk, patients were required to have three or more of the following adverse risk features:
Karnofsky performance status less than 80%, lactate dehydrogenase over 1.5 times the upper
limit of normal, hemoglobin below the lower limit of normal, serum corrected calcium more
than 10 mg/dl, time from first diagnosis of RCC to start of therapy of less than a year and three
or more metastatic sites. Of patients included in this trial, 19% had nonclear cell or unknown
histology. Temsirolimus monotherapy demonstrated an OS advantage compared to IFN alpha
(10.9 months versus 7.3 months, log rank p<0.008). The objective response rates were 8.6% for
temsirolimus and 4.8% for IFN, which was not statistically significant. The median PFS for the
temsirolimus monotherapy arm and interferon arm was 3.8 months (95% confidence interval
(CI): 1.9–2.2) and 1.9 months (95% CI: 3.6–5.2), respectively. Common side effects include
fatigue, hypercholesteremia and hyperglycemia. Temsirolimus has become a first-line option
for patients with metastatic RCC of any histologic subtype, appropriately applied to patients
with poor prognostic criteria.
Another  mTOR  inhibitor,  everolimus  (RAD001)  has  recently  been  reported  to  improve
progression-free survival in a phase III trial of patients with mRCC who had progressed
on sunitinib, sorafenib or both [23]. These patients were randomized to receive either ev‐
erolimus 10mg orally daily or placebo and were stratified by the number of previous ty‐
rosine  kinase  inhibitors  (TKI)  and  MSKCC  'previously  treated'  risk  groups  (one  point
each for anemia, hypercalcemia, and Karnofsky performance status <80; 0 points=favora‐
ble, 1 point=intermediate, 2 +points=poor risk group). The primary endpoint was PFS and
in the everolimus and placebo groups it was 4.9 months and 1.87 months (p<0.0001), re‐
spectively.  The PFS benefit  was seen in all  three MSKCC risk groups.  Common side ef‐
fects  included asthenia,  anemia and stomatitis.  Up to 14% of  patients experienced some
form  of  pneumonitis.  OS  was  14.79  and  14.39  months  (p=0.117)  respectively,  however
crossover  to  everolimus  was  permitted  in  this  study.  One  hundred  and  six  patients
randomized to  placebo  crossed  over  to  receive  everolimus  after  initial  progression.  For
this group, the median PFS was 5.09 months, which is similar to the PFS of the original
everolimus group. This is the first agent tested in a second-line trial after initial TKI fail‐
ure to demonstrate benefit. US FDA approval has recently been granted.
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9. Axitinib (AG013736)
AG013736 is another orally bioavailable small-molecule TKI of VEGFR-2 and PDGFR-B that
has shown activity in metastatic RCC. Preclinical data from Inai and colleagues suggested that
AG013736 inhibited angiogenesis and caused regression of existing tumor vessels.A phase II
trial enrolled 62 treatment-refractory patients with RCC that had progressed on sorafenib [24].
They were treated with oral axitinib 5mg twice daily. Of 62 patients, 13 (21%) patients exhibited
a partial response and the median PFS was 7.4 months. Another phase II trial with axitinib
enrolled cytokine-refractory, nephrectomized patients and demonstrated a response rate of
44.2% and a median time to progression of 15.7 months (25]. Grade 1/2 toxicity included
hypertension (33%), fatigue (29%), nausea (29%), diarrhea (27%), hoarseness (19%), anorexia
(17%), and weight loss (15%). Grade 3/4 toxicity included hypertension (18%), diarrhea (6%),
fatigue (6%), blister (4%), and limb pain (4%). These studies confirm that AG-013736 produces
a substantial objective response rate in cytokine-refractory, metastatic RCC.
10. Pazopanib (GW786034)
Pazopanib hydrochloride is an oral, angiogenesis inhibitor targeting vascular endothelial
growth factor receptor, platelet-derived growth factor receptor, and c-kit. In October 2009, the
US Food and Drug Administration–approved pazopanib for the treatment of patients with
advanced renal cell carcinoma. In the international, multicenter, randomized, double-blind
trial, 435 patients were randomly assigned (2:1) to receive pazopanib (n = 290) or placebo (n =
145), [26]. The study demonstrated a median progression-free survival (the primary endpoint)
of 9.2 months in the pazopanib arm vs 4.2 months in the placebo arm (hazard ratio [HR]: 0.46;
P <.001). This effect was observed both in patients who had not received previous treatment
(HR: 0.40) as well as patients pretreated with cytokine therapy (HR: 0.54). The median duration
of responses was 13.5 months. The overall survival results were not mature yet and 40% of
patients died by the time of final data cut-off. Based on this study, the recommended dose of
pazopanib for the treatment of advanced renal cell carcinoma is 800 mg administered orally
once daily without food (at least 1 hour before or 2 hours after a meal).
11. BAY 73-4506
BAY 73-4506 is an orally active, potent multikinase inhibitor targeting both tumor cell
proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases
(VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (RAF and p38MAPK).
Previously untreated patients with predominantly clear cell RCC and measurable disease
according to RECIST were enrolled in this multicenter, open-label, phase II study. Eligibility
criteria included ECOG performance status 0–1, low or intermediate risk MSKCCC prognostic
profiles, and adequate bone marrow and organ function. Treatment consisted of BAY 73-4506
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FK506-binding protein; this resultant protein-drug complex inhibits the kinase activity of
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limit of normal, hemoglobin below the lower limit of normal, serum corrected calcium more
than 10 mg/dl, time from first diagnosis of RCC to start of therapy of less than a year and three
or more metastatic sites. Of patients included in this trial, 19% had nonclear cell or unknown
histology. Temsirolimus monotherapy demonstrated an OS advantage compared to IFN alpha
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everolimus group. This is the first agent tested in a second-line trial after initial TKI fail‐
ure to demonstrate benefit. US FDA approval has recently been granted.
Renal Tumor150
9. Axitinib (AG013736)
AG013736 is another orally bioavailable small-molecule TKI of VEGFR-2 and PDGFR-B that
has shown activity in metastatic RCC. Preclinical data from Inai and colleagues suggested that
AG013736 inhibited angiogenesis and caused regression of existing tumor vessels.A phase II
trial enrolled 62 treatment-refractory patients with RCC that had progressed on sorafenib [24].
They were treated with oral axitinib 5mg twice daily. Of 62 patients, 13 (21%) patients exhibited
a partial response and the median PFS was 7.4 months. Another phase II trial with axitinib
enrolled cytokine-refractory, nephrectomized patients and demonstrated a response rate of
44.2% and a median time to progression of 15.7 months (25]. Grade 1/2 toxicity included
hypertension (33%), fatigue (29%), nausea (29%), diarrhea (27%), hoarseness (19%), anorexia
(17%), and weight loss (15%). Grade 3/4 toxicity included hypertension (18%), diarrhea (6%),
fatigue (6%), blister (4%), and limb pain (4%). These studies confirm that AG-013736 produces
a substantial objective response rate in cytokine-refractory, metastatic RCC.
10. Pazopanib (GW786034)
Pazopanib hydrochloride is an oral, angiogenesis inhibitor targeting vascular endothelial
growth factor receptor, platelet-derived growth factor receptor, and c-kit. In October 2009, the
US Food and Drug Administration–approved pazopanib for the treatment of patients with
advanced renal cell carcinoma. In the international, multicenter, randomized, double-blind
trial, 435 patients were randomly assigned (2:1) to receive pazopanib (n = 290) or placebo (n =
145), [26]. The study demonstrated a median progression-free survival (the primary endpoint)
of 9.2 months in the pazopanib arm vs 4.2 months in the placebo arm (hazard ratio [HR]: 0.46;
P <.001). This effect was observed both in patients who had not received previous treatment
(HR: 0.40) as well as patients pretreated with cytokine therapy (HR: 0.54). The median duration
of responses was 13.5 months. The overall survival results were not mature yet and 40% of
patients died by the time of final data cut-off. Based on this study, the recommended dose of
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BAY 73-4506 is an orally active, potent multikinase inhibitor targeting both tumor cell
proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases
(VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (RAF and p38MAPK).
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160mg once daily on a 3 weeks on/1 week off schedule. The primary endpoint was overall
response rate. Preliminary efficacy data of the 33 patients evaluable for response show a 27%
partial response (PR) and a 42% stable disease (SD) rate [27].
12. Sequence of targeted therapy
Currently, we have the fortunate problem of having several agents demonstrating effica‐
cy in the first- and second-line setting, with a number of other small molecule inhibitors
that target VEGFR tyrosine kinase being evaluated in mRCC consistently showing activi‐
ty.  With similar  mechanisms of  action,  clinical  responses have been observed,  including
in  patients  that  have  previously  received TKI  therapy.  Part  of  the  challenge  in  moving
forward is  the  lack  of  understanding of  the  biologic  underpinnings  of  resistance  to  the
currently approved agents and uniform clinical definitions of what truly constitutes treat‐
ment resistance.
Studies combining targeted therapies are being performed with the known caveat that
combinations are associated with high financial cost and risk of increased toxicity due to
additive and overlapping side effect profiles. Rational combinations of active agents continue
to be evaluated. Currently, combinations of targeted therapy remain experimental and they
should only be employed in the context of a clinical trial.
Targeted agents are also being studied in the adjuvant setting for patients with resected
highrisk  RCC.  The  Adjuvant  Sorafenib  or  Sunitinib  for  Unfavorable  Renal  Carcinoma
(ASSURE) intergroup trial randomizes high-risk nephrectomized patients to 1 year of sor‐
afenib,  sunitinib  or  placebo  (estimated  enrolment:  1332,  primary  endpoint:  disease-free
survival (DFS)) (NCT00326898). Other trials such as the phase III sunitinib versus placebo
study for the treatment of patients at high risk of recurrent RCC (S-TRAC: estimated en‐
rolment 236, primary endpoint: DFS) (NCT00375674) and the sorafenib versus placebo tri‐
al in patients with resected intermediate or high-risk RCC (SORCE: estimated enrolment
1656,  primary  endpoint:  DFS)  (NCT00492258)  will  further  help  elucidate  the  effect  of
these agents in the adjuvant setting.
13. Combination therapy
One of the next directions in the therapy of advanced RCC involves the combination of several
targeted agents to better inhibit a single pathway at several different levels or inhibition at the
same level of several pathways mediating different effects. As combinations of targeted agents
undergo investigation, it will be critical for these combinations to demonstrate clinical benefit
above and beyond those of sequential monotherapy with the same agents, in order to justify
the added toxicity and risk. Thus, prospective data in this regard are critical, and some data
have recently emerged.
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Combinations of VEGF-targeting agents have undergone initial testing. Several combina‐
tions of these targeted agents were studied, including temsirolimus with either bevacizu‐
mab  or  sorafenib.  Bevacizumab  was  also  combined  with  sunitinib,  and  PTK787/
ZK222584. These combinations have frequently demonstrated enhanced toxicity, prevent‐
ing  the  use  of  the  maximum single-agent  doses.  However,  temsirolimus  and  bevacizu‐
mab in combination could be given at full doses of each agent without enhanced toxicity
and with encouraging clinical activity.
The combination of sorafenib and bevacizumab showed preliminary evidence of antitumor
activity, but the full doses of each agents were not reached due to dose-limiting toxicity related
primarily to hand-foot syndrome, functional stomatitis, anorexia, and fatigue.
Additional preclinical data have described potentially favorable immunomodulation with
sunitinib therapy. Such data may provide a rationale for combination strategies with immu‐
notherapy to optimize antitumor effect.
At this point, such combinations cannot be recommended for routine use outside of a clinical
trial setting.A greater understanding of the pleiotropic effects of targeted agents is needed to
rationally build combinations.
14. Future directions and conclusions
Surgery is the mainstay of therapy across renal cell carcinoma stages, and surgical innovation
has resulted in less invasive approaches to localized disease while preserving oncologic
efficacy. Renal cell carcinoma has become a model for solid tumors in which a better under‐
standing of biologic pathways has led to systemic therapies that have dramatically improved
patient outcomes. Given the availability of multiple treatment options, each with a slightly
different profile of risk and benefit, there are currently multiple options for therapy. The
approach to treatment requires appreciation of the risks and benefits of each of these agents,
as well as knowledge of the limitations of the current data.
The goal for every metastatic renal cell carcinoma patient upon presentation is to maximize
overall therapeutic benefit, meaning delaying for as long possible a lethal burden of disease
while maximizing quality of life and patient convenience.
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1. Introduction
Kidney cancer comprises 2-3% of all cancers according to Cancer Research UK statistics. (http://
info.cancerresearchuk.org). Renal Cell Carcinomas (RCC) is the most common subtype
(around 90%) with clear-cell variant constituting up to 75% of all RCCs. Non clear-cell variant
are less common and consist of papillary (Type I and II; 10-15%), chromophobe (4%) and
collecting duct (including the rare medullary variant; <1%). [1, 2] At initial diagnosis, one third
of patients have evidence of distant metastases, and amongst patients who undergo curative
nephrectomy, a third will have a recurrence within 5 years. Historically, treatment options
have been limited in metastatic RCC, as cytotoxic chemotherapy is not effective in this disease
and immunotherapy is of modest benefit. [1] The treatment outlook for metastatic RCC has
changed in the past decade, with the introduction of new therapeutic agents which target
molecular pathways involved in tumour angiogenesis.
2. Molecular pathogenesis
2.1. Clear- cell variants renal cell carcinoma
The discovery of von Hippel–Lindau (VHL) / hypoxia-inducible factor (HIF) oxygen-sensing
pathway and its role in the pathogenesis of RCC (clear-cell as well as some of the non-clear-
cell variant), has led to a new approach in the systemic therapy for RCC. [1, 3] Tumour
suppressor gene VHL encodes the VHL protein (pVHL), which interacts with hypoxia-
inducible factor (HIF) to regulate cellular response to oxygen deprivation. HIF is a gene
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transcription factor and consists of two subunits: HIF α-subunit and the HIF β-subunit (also
known as aryl hydrocarbon receptor nuclear translocator (ARNT) protein). In the presence of
normal oxygen tension (or normoxic state), HIF-α is hydroxylated. pVHL-E3 ubiquitin ligase
complex targets the hydroxylated HIF-α for proteosomal degradation. [4] VHL protein
functions as the substrate-recognition subunit of this complex. [5, 6]
VHL gene mutation or hypermethylation leads to intracellular accumulation of HIF-α subu‐
nits. [7] HIF-α subunits, after translocation into the nucleus, act in concert with the HIF-β subunits,
and form transcriptional factor complexes that induce transcription of hypoxia-response genes.
[8] The endpoint is an increase in the production of pro-angiogenic factors including vascular
endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and transforming
growth factor alpha and beta (TGF-α and TGF-β). [9] By increasing angiogenesis through VHL-
HIF pathway the tumour increases its potential to survive and progress. [10]
2.2. Non clear-cell variant
Papillary carcinomas are commonly bilateral, multifocal and frequently present as small, early
stage tumours. [11] They can be further subdivided histologically into papillary types I and II
with underlying different genetics and molecular pathways. [12] Type I papillary renal cancers
are linked to activating mutations of the methyl-nitroso-nitroguanidine induced (MET)
oncogene. [13] The MET oncogene mutations activate the intracellular kinase domains and
subsequently trigger the hepatocyte growth / MET pathway. [13] Type II papillary renal
cancers on the other hand are associated with mutations of the fumarate hydratase (FH)
tumour suppressor gene. [14] Mutational inactivation of the FH tumour suppressor gene leads
to a pseudo-hypoxic state and up-regulation of the HIF α-subunits. The accumulation of
fumarate is induced by the mutated FH enzyme. That in turn causes inhibition of HIF-prolyl
hydroxylase(HPH), an enzymatic regulator of the intracellular HIF-α. Inactivation of the HPH
disrupts the hydroxylation of HIF leading to failure of recognition by pVHL and subsequent
VHL-dependent proteosomal degradation of HIFs. Accumulation of HIF leads to over-
expression of pro-angiogenic factors and tumour proliferation. [15]
Chromophobe renal cell cancers accounts for 4% of all RCCs. [1] The exact pathogenesis is not
established. It is thought that the VEGF-angiogenic pathway is implicated based on the
elevated levels of VEGF and its receptors in this type of RCC. The KIT oncogene and the
folliculin gene linked to the familial form of chromophobe/oncocytic RCC hybrid (Brit-Hogg-
Dubé-Syndrome), are extra molecular targets identified in this variant [16, 17] Collecting duct
RCC are very rare and the underlying pathogenesis has not been established. [18]
3. Systemic treatment of metastatic renal cell carcinoma
The current guidelines from the National Comprehensive Cancer Network Metastatic (NCCN)
continue to identify nephrectomy as an important initial consideration, even in the context of
metastatic disease. [19] The current recommendations are to consider patients for nephrectomy
and/or oligmetastatectomy prior to initiation of systemic therapy whenever appropriate. [20]
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The traditional teaching is that cytoreductive nephrectomy lead to improved outcome from
systemic therapy. This is based on phase III data that showed an improvement in response to
IFN-α following nephrectomy in the metastatic setting. In the era of targeted therapy / anti-
VEGF therapies, the validity of this practice has been called into question. [20] Clinical trials
are underway to address this very question.
Beyond surgery, the only systemic options available prior to the era of targeted therapy
consisted of interleukin-2 (IL-2) and interferon-α (IFN-α). Other treatments that had been
trialed included chemo- and hormonal therapy have all been discouraging. [21]
IFN-α classically caused flu-like syndrome, depression and in some cases suicidal ideation and
is certainly onerous especially in the patients with poorer performance status. [1, 22] IL-2, the
other cytokine has a small long term survival benefit of 4%. This is however at the cost of
potentially life threatening toxicities such as hypotension, oliguria, capillary leak syndrome with
secondary multi-organ failure, somnolence and confusion. [23] Not surprisingly, the underly‐
ing enthusiasm for cytokine agents as frontline therapy in metastatic RCC has been replaced by
tyrosine kinase inhibitors / targeted therapy which has a more favourable toxicity profile. [24]
The targeted therapies used in metastatic RCC consist of 1. Anti-VEGFs, which are monoclonal
antibodies that bind directly to VEGF and related peptides and therefore removing them from
the circulation (bevacizumab) and 2. Small molecule tyrosine kinase inhibitors (SMTKIs) that
target the down-stream tyrosine kinase signaling pathways, are involved in promotion of
tumour angiogenesis, endothelial growth, proliferation and ultimately tumour survival and
metastasis. [25] The SMTKIs that have been approved for use in 2012 include sunitinib,
sorafenib, pazopanib and axitinib.
3.1. Small molecular tyrosine kinase inhibitors
3.1.1. Sunitinib
Sunitinib is a multi-kinase inhibitor targeting numerous VEGF receptors (VEGF-1, 2, 3) and
additional tyrosine kinase receptors (PDGFR, c-Kit, FLT-3, CSF-1R, and RET) [26-29] Early trials
showed sunitinib to be effective in patients with advanced malignancies including RCC. [30]
3.1.1.1. Sunitinib intermittent dosing
A phase II study of sunitinib in patients with cytokine-refractory metastatic RCC assessed the
clinical efficacy and safety of sunitinib as second-line therapy. [31] Sixty three patients who
previously failed cytokine-based therapy received 50mg of sunitinib for 4 weeks followed by
a 2 week scheduled break, in a 6 week cycle. A partial response of 40% (n=25) (PR) and a stable
disease response for ≥ 3 months in 27% (n=17) of the patients were reported. The median time
to progression and survival were 8.7 months and 16.4 months respectively. [31]
A second but larger phase II trial of 106 patients similarly confirmed promising activities of
sunitinib in cytokine refractory, metastatic RCC. An overall objective response of 44% was
observed with 1% (n=1) of patients demonstrated a CR and 44% showed PR. [32] A further
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22% (n=23) of patients showed SD for ≥ 3 months. The median response for the 46 responders
was 10 months whilst the median progression free survival (PFS) was 8.3 months [32]
These results led to a phase III trial comparing sunitinib with INF-α that was deemed standard
of care at the time for patients with metastatic clear cell RCC. [33] Seven hundred and fifty
treatment naїve patients with clear-cell histology and good performance status (ECOG 0 or 1)
were randomized in a 1:1 ratio to receive either sunitinib (dose as per earlier studies) or INF-
α (9 × 106 units subcutaneously thrice weekly). [32, 34] The median duration of treatment was
6 months (1-15 months) in the sunitinib group and 4 months (1-13 months) in the IFN-α group.
The median PFS assessed by an independent third-party review was 11 months in the sunitinib
group and 5 months in the IFN-α group, corresponding to a hazard ratio (HR) of 0.42 (95% CI
0.32–0.54; p < 0.001). [33] The investigators’ assessment showed similar results. An updated
analysis published in 2009 has shown the ORR of 47% for sunitinib and 12% for IFN-α (p <
0.000001), with a median PFS of 11 months and 5 months, respectively, for sunitinib and IFN-
α (p < 0.000001), similar to the original report. [35] These results were uniformly seen, regard‐
less of the patients’ age, gender and prognostic category. Patients on sunitinib also experienced
a median OS in excess of 2 years. The OS was 26.4 months for sunitinib and 21.8 months for
IFN-α (p = 0.051). [33] However, a dedicated exploratory analysis of patients on both treatment
arms who did not receive post-study cancer treatment showed the median OS with sunitinib
was twice as long as IFN-α (28.1 months versus 14.1 months respectively, p=0.003). [33] Based
on these significant findings, sunitinib replaced IFN-α as first line treatment for stage IV RCC.
In a real-world setting, sunitinib has proven its efficacy in an expanded-access program,
designed to allocate access to sunitinib in patients with metastatic RCC who would otherwise
be excluded from clinical trials. [33, 36] Four thousand five hundred patients were enrolled in
this international, open labeled study. The cohort importantly included older patients (≥ 65
years old; n=1414), those with poorer ECOG status (≥ 2; n=582), non clear-cell histology (n=288)
and with brain metastases (n=320). [36] Patients with poor performance status and brain
metastases prior to this had been excluded in all sunitinib trials.
The median number of treatment cycles and treatment duration were 5 cycles and 15.6 months
respectively. 56% of patients received more than 6 months of sunitinib treatment. The survival
data closely resembled the phase III study with an observed median PFS and OS of 10.9 months
and 18.4 months respectively. [33] No differences were noted in median PFS and OS between
patients with or without prior cytokine therapy. Importantly, the subgroup analysis of i.
elderly patients demonstrated median PFS and OS of 11.3 and 18.2 months respectively. [33]
ii. patients with poorer performance status, the median PFS and OS were 5.1 months and 6.7
months respectively and finally in patients with brain metastases with an overall poorer
prognosis, a median PFS of 5.6 months and median OS of 9.2 months were observed. [33]
3.1.1.2. Sunitinib continuous dosing
The efficacy of continuous sunitinib dosing was examined in an open-label multicenter phase
II trial. [37] In this study 107 patients were randomly assigned to either morning or evening
daily dose of 37.5mg for a median duration of 8.3 months. 43% of patients had their dose
reduced due to grade 3-4 adverse events. The ORR was 20% with a median duration of
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response of 7.2 months. The median PFS observed was 8.2 months and the OS was 19.8 months.
Tolerability and QOL between the morning and evening dose were similar. However, grade
3 diarrhea, fatigue and hand-foot syndrome were more common in the evening dosing
patients. The continuous schedule may benefit patients who are not able to tolerate the
intermittent sunitinib 50mg regimen. [33]
Another trial assessing continuous vs. intermittent sunitinib dosing was the EFFECT phase II
study. In this trial patients with locally recurrent clear-cell RCC or metastatic RCC, treatment
naïve patients, were randomly assigned to standard dosing (50mg/day; 4 weeks on, 2 weeks
off) and continuous dosing (37.5mg/day). The intermittent schedule when compared with the
continuous schedule showed a trend to improved ORR (32.2% vs. 28.1%; p=0.444) and median
PFS (8.5 months vs. 7.0 months; p=0.070). No difference were noted between the median OS
(23.1 months vs. 23.5 months, p=0.615). [38] Interestingly the median OS was lower than the
phase III sunitinib vs. INF-α trial which had a median OS of 26 months. The phase III trial had
a higher number of patients with better baseline prognostic features (better performance status
and more patients had underwent nephrectomy), which may account for better survival
results. [33, 38]
3.1.2. Sorafenib
Sorafenib (Nexavar, BAY 43-9006) is an oral multi-kinase inhibitor that targets multiple non-
receptor as well as receptor kinases. These include BRAF and CRAF, non-receptor serine
threonine kinases which belong to the RAF/Mek/ERK signaling pathway and also receptor
tyrosine kinases including VEGFR2, VEGFR3, PDGFR, fetal liver tyrosine kinase 3 (FLT-3)…
and c-kit. [2] In a phase II randomized discontinuation trial of patients with metastatic RCC
who had failed previous systemic therapies, sorafenib at a dose of 400 mg BD showed
significant disease-stabilizing activity. [39] In another phase II trial, patients with metastatic
RCC on sorafenib (initial starting dose of 400mg BD and escalating to 600mg BD on progres‐
sion) were compared with INF-α in the first line setting. PFS was similar in both arms, although
in the sorafenib arm, patients experienced greater rates of tumour size reduction, superior
quality of life and better treatment tolerance. [40] Subsequently in a phase 3 trial (TARGET)
903 patients with metastatic clear-cell RCC who had progressed on previous treatment were
randomized to receive either placebo or sorafenib (400mg BD). Compared with the placebo
group, the sorafenib group demonstrated a higher ORR (57% vs. 34%) and PFS was signifi‐
cantly longer (5.5 months vs. 2.8 months; HR=0.44; p<0.01). [41] This improvement was
independent of age (over or under 70 years), prognostic risk, prior cytokine therapy, and
previous cardiovascular disease. [41] In this trial, patients in the placebo arm crossed over to
sorafenib when progression of disease was diagnosed. In the first interim analysis, a trend
towards better OS was noted in patients taking sorafenib, and this was unchanged in the final
analysis (17.8 vs. 15.2 months, respectively, HR= 0.88; p = 0.146). [42] After censoring for the
patients who had crossed over on progression from the placebo arm, the OS was significantly
longer in the sorafenib arm (17.8 vs. 14.3 months; HR = 0.78; p = 0.029). [41] Sorafenib has also
been accessed in a real-world setting through open-label expanded access studies in Europe
(The European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCS) and North America
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towards better OS was noted in patients taking sorafenib, and this was unchanged in the final
analysis (17.8 vs. 15.2 months, respectively, HR= 0.88; p = 0.146). [42] After censoring for the
patients who had crossed over on progression from the placebo arm, the OS was significantly
longer in the sorafenib arm (17.8 vs. 14.3 months; HR = 0.78; p = 0.029). [41] Sorafenib has also
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(The European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCS) and North America
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(NA-ARCCS). Both studies showed that sorafenib provides similar benefits in first- and
second- or later line patient populations and the safety profile was similar to that reported in
clinical trials. [43-45] Ongoing clinical trials comparing sorafenib with other treatment options
in the first line setting are currently being undertaken. [46]
The role of sorafenib as second line treatment for advanced RCC has also generated significant
interest. Sorafenib was compared directly with temsirolimus in the INTORSECT trial. [47] This
is the first head-to-head trial comparing a VEGF inhibitor to an mTOR inhibitor. This trial
enrolled 551 patients with advanced RCC with good performance status who had progressed
after first-line sunitinib therapy. The median PFS with temsirolimus was 4.28 months and 3.91
months with sorafenib. The median OS for temsirolimus cohort was 12.7 months compared to
16.6 months in the sorafenib arm. These results highlighted that temsirolimus did not show
superiority over sorafenib in the primary end-point of PFS and the secondary end-point of OS.
[47] To date, sorafenib is considered a reasonable first-line treatment option especially in
elderly patients or patients with cardiovascular diseases or other co-morbidities. [46, 48]
3.1.3. Pazopanib
Pazopanib is an oral tyrosine kinase inhibitor that targets VEGF-1, -2, and -3 receptors, PDGF-
α and -β receptors, and c-kit. [49] A phase II study enrolled 225 patients with metastatic RCC:
(69% were treatment naïve, and 31% had received previous treatment with cytokine- or
bevacizumab-containing regimen). In this study, the ORR was 35%, median duration of
response was 68 weeks and median PFS was 52 weeks. This trial showed durable activity and
tolerability of pazopanib in patients with advanced RCC. (Hutson et al, 2010) In a phase III
study, 435 patients with locally advanced, and/or metastatic RCC were randomized to receive
oral pazopanib or placebo (54% were treatment naïve and 46% were cytokine pretreated). The
PFS was significantly prolonged with pazopanib compared with placebo (median PFS 9.2 vs.
4.2 months; HR=0.46; 95% CI, 0.34 to 0.62; p < 0.0001), with similar results shown in both the
Treatment naïve subpopulation (median PFS 11.1 v 2.8 months; HR, 0.40; 95% CI, 0.27 to 0.60;
P <.0001), and the cytokine-pretreated subpopulation (median PFS, 7.4 v 4.2 months; HR, 0.54;
95% CI, 0.35 to 0.84; p < 0.001). In the pazopanib arm, the ORR was 30% compared with 3% in
the placebo arm (p < 0.001). The median duration of response was longer than 1 year. [50] The
final median OS were 22.9 vs. 20.5 months in the pazopanib and placebo arms respectively
(p=0.224). The lack of significant difference could be due to the early, frequent, and prolonged
crossover to pazopanib in patients originally randomized to placebo. [50, 51] Whilst the role
of pazopanib as a frontline agent for metastatic RCC is being established, it remains unclear
how it compares with sunitinib in terms of efficacy. This was addressed in an open-label study
(COMPARZ) where pazopanib was compared head-to-head with sunitinib in 1100 patients
with locally advanced and/or metastatic RCC. Pazopanib demonstrated similar efficacy or
non-inferiority to sunitinib in terms of PFS with duration of more than 10 months. Both agents
resulted in side-effects, however fatigue and skin ulcers occurred less frequently for pazopanib
than with sunitinib. The quality of life (QoL) favoured pazopanib and demonstrated better
tolerance for pazopanib than sunitinib. [52]
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3.1.4. Axitinib
Axitinib, an oral agent that inhibits VEGF receptor-1, -2 and -3, is active in cytokine-refractory
metastatic RCC. Two complete and 21 partial responses (ORR of 44.2%) were reported in 52
patients taking axitinib 5mg twice daily in a second line treatment study. The median response
duration was 23 months and median OS was 29.9 months. [53] The 5 year survival rate was
20.6%. The ten patients surviving for more than five years had an ORR of 100% compared with
30% in <5 year survivors. They took axitinib for longer (median 5.8 years vs. 0.67 years) and
were fitter, with baseline ECOG PS of 0 in 80% of the longer term survivors compared with
53% in <5 year survivors. [54]
In a phase II trial, 213 patients were allocated on axitinib 5mg BD for four weeks, after which
some eligible patients were randomly assigned to further stepwise dose titration (5 to 7 to 10mg
BD) according to tolerability of either axitinib or placebo. Individuals who did not meet the
eligibility criteria were treated in a separate arm without dose titration. [55] The inclusion
criteria for randomisation after the initial dose schedule of axitinib for 4 weeks were blood
pressure ≤ 150/90 mmHg and less or equal to 2 concurrent anti-hypertensive medications. No
grade 3 or 4 toxicities from the initial dose and no dose reductions required in the first 4 weeks
of axitinib.
The most important outcomes of this study were a higher drug exposure, of more or equal
150 ng-h/ml serum concentration, and was associated with a higher RR (59% vs. 40%) and an
improvement in PFS (14 vs. 11 months). Patients with a higher diastolic blood pressure
(90mmHg) and an increase in diastolic blood pressure on day 15 of the first cycle had better
outcomes in ORR and PFS. The final results of this phase II trial are pending and will determine
if the titratrion strategy is associated with improved clinical outcomes
In a phase III second line treatment study (AXIS), 723 patients with progressive disease after
one first line treatment (sunitinib, bevacizumab, temsirolimus or cytokines) randomly received
axitinib at doses titrated from 5mg up to 10mg BD or sorafenib 400mg BD. [56] The ORR was
19.4% for axitinib vs. 9.4% for sorafenib (p=0.0001) and a significantly longer median PFS (6.7
versus 4.7 months, p<0.0001) was seen in patients on the axitinib arm. In patients who had
previously received cytokines PFS with axitinib was 12.1 months vs. 6.5 months with sorafenib,
which was significant (p<0.0001). This also occurred in those having prior sunitinib (4.8 vs. 3.4
months, p=0.0107). As part of the same trial, patient-reported kidney specific symptom and
function assessments were secondary endpoints. [57] Outcomes were similar for both drugs
during treatment, however due to the significantly longer PFS with axitinib, this delayed
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95% CI, 0.35 to 0.84; p < 0.001). In the pazopanib arm, the ORR was 30% compared with 3% in
the placebo arm (p < 0.001). The median duration of response was longer than 1 year. [50] The
final median OS were 22.9 vs. 20.5 months in the pazopanib and placebo arms respectively
(p=0.224). The lack of significant difference could be due to the early, frequent, and prolonged
crossover to pazopanib in patients originally randomized to placebo. [50, 51] Whilst the role
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how it compares with sunitinib in terms of efficacy. This was addressed in an open-label study
(COMPARZ) where pazopanib was compared head-to-head with sunitinib in 1100 patients
with locally advanced and/or metastatic RCC. Pazopanib demonstrated similar efficacy or
non-inferiority to sunitinib in terms of PFS with duration of more than 10 months. Both agents
resulted in side-effects, however fatigue and skin ulcers occurred less frequently for pazopanib
than with sunitinib. The quality of life (QoL) favoured pazopanib and demonstrated better
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II trial of 116 patients (placebo controlled, low-dose 3mg/kg or high dose 10mg/kg) showed
that bevacizumab significantly prolonged the time to progression of disease in patients with
metastatic RCC. [59, 60]
In a phase III trial (AVOREN), 649 patients with previously untreated metastatic RCC were
randomized to receive bevacizumab (10 mg/kg infusion) and interferon alfa-2a versus placebo
and interferon alfa-2a (IFN). A significant improvement in PFS, (10.2 vs. 5.4 months) and also
ORR (31% vs. 13%, respectively; p < 0.0001) was observed in the bevacizumab arm compared
with the IFN-α monotherapy arm. [61] Final OS analysis of this trial showed a trend towards
improved OS (Median OS was 23.3 months with bevacizumab plus IFN and 21.3 months with
IFN plus placebo). Patients (> 55%) in both arms received at least one post-protocol anti-
neoplastic treatment, which could confound the OS analysis. [61]
Another concurrent phase III trial (CALGB 90206) but in a non-blinded fashion, randomized
732 patients previously untreated metastatic RCC to receive bevacizumab and IFN-α versus
monotherapy with IFN-α. In this trial, the median PFS was 8.5 months in patients receiving
bevacizumab plus IFN compared with 5.2 months for IFN monotherapy (p < 0.0001) and the
ORR was similarly higher in the bevacizumab plus IFN arm than in the IFN monotherapy arm
(25.5% vs. 13.1%, respectively; p< 0.0001). [62] Final analysis of this trial showed a median OS
time of 18.3 months (95% CI, 16.5 to 22.5 months) for bevacizumab plus IFN-alpha and 17.4
months (95% CI, 14.4 to 20.0 months) for IFN-alpha monotherapy (unstratified log-rank p =
0.097) Grade 3 and 4 toxicity (hypertension (HTN), anorexia, fatigue, and proteinuria) were
significantly higher in the bevacizumab plus IFN-alpha arm. Patients who developed HTN on
bevacizumab plus IFN-alpha had a significantly improved PFS and OS versus patients without
HTN. [62]
Both of these trials showed clear benefits in the median PFS arms with an overlapping HR and
doubling of PFS when comparing the placebo/IFN-α arm with bevacizumab/IFN-α arm. [63]
The effects of crossover to the active bevacizumab arm in the AVOREN trial, as well as the
permission of second-line therapies in both trials would account for the dilution of the actual
OS benefit in both trials. [63] Based on the results of these trials, regulatory approval of
bevacizumab plus IFN in advanced RCC has occurred in Europe in the United States.
3.3. mTOR inhibitors
The mammalian target of rapamycin (mTOR) pathway is regulated by the PTEN tumour
suppressor gene. It plays a significant role in angiogenesis and regulation of cell cycle. [8]
mTOR activity is dependent on different factors, in particular to cellular stresses such as
hypoxia, heat shock, oxidative stress, DNA damage and finally a change in the pH or osmotic
cell pressure. [8] The mTOR pathway is downstream to phosphoinositide 3-kinase and akt
pathway which is dysregulated in many malignancies. [8, 64] Activation of this pathway
promotes mRNA translation and subsequent entry into the G1 phase of cell cycle. Another
different  but  important  function  of  mTOR  is  the  production  of  HIF-1α  which  drives
angiogenesis, survival and growth of malignant cells. The selective inhibition of this pathway
by the mTOR inhibitors is facilitated by binding to the intracellular protein FK506 binding
protein 12 (FKBP-12) resulting in inhibition of the kinase activity of the mTOR. [8] There are
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two mTOR inhibitors registered for the treatment of metastatic RCC, namely temsirolimus
and everolimus.
3.3.1. Temsirolimus
Temsirolimus is an analogue to sirolimus (rapamycin) which has been used with success as
an immunosuppressive agent in renal transplantation. [65] Temsirolimus is a parenteral
preparation and is administered as a weekly intravenous infusion at 25mg. It is metabolised
by CYP3A4 to active metabolite sirolimus and has a half-life of about 9 to 27 hours. [65]
Based on the encouraging results from Phase I and II trials of temsirolimus either alone, or in
combination with IFN-α, an international multicentre phase III trial was conducted. [8, 66] Six
hundred and twenty six treatment naïve patients with poor prognostic factors were rando‐
mised to temsirolimus (25 mg i.v. weekly), IFN-α (3 × 106 units, with an increase to 18 × 106
units s.c. thrice weekly) or the combination of temsirolimus (15 mg weekly) and IFN-α (6 ×
106 thrice weekly). Patients were required to have least three the following 6 predictors short
survival: a serum lactate dehydrogenase level of more than 1.5 times the upper limit of the
normal range, a hemoglobin level below the lower limit of the normal range; a corrected serum
calcium level of more than 10 mg per deciliter (2.5 mmol per liter), a time from initial diagnosis
of RCC to randomization of less than 1 year, a Karnofsky performance score of 60 or 70, or
metastases in multiple organs. An important characteristic of recruitment of this study is the
inclusion of up to 20% of non clear-cell renal cell histological subtype. This is the only rando‐
mised study available to date for patients with non clear-cell histology. Patients who received
temsirolimus monotherapy had a longer median OS (10.9 vs. 7.3 months; p = 0.008) and PFS
(3.8 vs. 1.9months; p<0.001) compared with those who received INF-α alone. [65] Finally those
in the combination treatment arm had the most grade 3 or 4 adverse events leading to more
dose reductions and delays. The median PFS in the temsirolimus, combination treatment and
IFN-α alone were 3.8, 3.7 and 1.9 months, respectively, and the median OS was 10.9 months,
8.4 months and 7.3 months. [65] In this trial, older patients and patients with a higher serum
LDH (> 1.5 fold the upper limit of normal) had better OS. [65]
This trial did not address the role of temsirolimus as second-line agent in patients refractory
to VGEF therapy. The only published prospective randomised trial looking at this cohort of
patients was RECORD-1 which examined everolimus vs. placebo. [67] The data supporting
the use of temsirolimus in second line treatment post VEGF agents are all derived from single
institution case series which demonstrated only a modest PFS of ~4 months.
3.3.2. Everolimus
Everolimus is an oral mTOR inhibitor. It has activity against advanced clear-cell RCC in
patients who have failed sorafenib, sunitinib or both. [67] In a double-blind, placebo controlled
phase III trial (RECORD-1, in which 410 patients with advanced clear cell RCC who had
progressed after sunitinib, sorafenib or both were randomized in a 2:1 ratio to everolimus 10
mg once daily or placebo with best supportive care. Independent of gender, age, previous
treatment with sorafenib, sunitinib or both, prolongation of PFS (4.9 vs. 1.9 months; p< 0.0001)
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was found with everolimus over placebo. [67] However there was no statistically significant
difference for median OS (14.8 months vs. 14.4 months) as majority (80%) of patients in the
placebo plus best supportive arm were allowed to cross over after the unbinding at the second
interim analysis. RECORD-1 trial proved the efficacy of mTOR inhibitors following VGEF
therapy and as such received FDA approval for patients who have progressed following
sunitinib / sorafenib. [67]
4. New agents in clinical development
The results with early TKIs in metastatic RCC has led to a number of small molecules multi-
targeted agents being investigated in phase II and III studies. [68] These include tivozanib
which targets VEGFR -1, -2, and -3, PDGFR and c-kit, dovitinib (VEGFR -1, -2, -3 and PDGFR-
beta) and regorafenib. [69]
4.1. Tivozanib
In a phase II study, two hundred and seventy two patients with advanced RCC treated who
had not received prior VEGF targeted therapy received tivozanib. [70] Patients took tivozanib
1.5 mg daily for 16 weeks, and according to response were then stratified into stopping or
continuing tivozanib. Those with stable disease were randomised between tivozanib and
placebo (and this group could re-start tivozanib if they developed progressive disease, or
completed the double blind phase). Overall, by week 16, 84% of patients demonstrated PR or
SD, ORR was 30%, disease control rate (DCR) was 85% and median PFS 11.7 months. Best
results were achieved in patients with clear-cell histology who had undergone a nephrectomy.
These patients achieved an ORR of 36%, DCR of 88% and median PFS of 14.8 months. Com‐
monest adverse effects included hypertension (45%) which was grade 3-4 in 12%, and dys‐
phonia (22%). [70]
Twenty-eight patients with advanced RCC and clear-cell variant, who had failed up to one
prior VEGF-targeted therapy, were treated in a phase Ib open-label study of tivozanib
combined with temsirolimus. [71] Tivozanib was administered orally daily for 3 weeks on and
1 week off. Intravenous temsirolimus was given once weekly. A standard 3+3 dose escalation
design was used at four levels from 0.5 mg to 1.5 mg per day and 15 to 25 mg per week of
tivozanib and temsirolimus, respectively. Twenty-eight patients (26 male) of median age 62
years and Karnofsky Performance Status from 100 to 80 were participated in the study. Median
duration of treatment was 21.1 weeks. PR was seen in 28%, SD in 64% and DCR (PR and SD >
24 weeks) in 48% of the treated population. Treatment-related adverse events seen in ≥ 10% of
patients were: fatigue, decreased appetite, stomatitis, thrombocytopenia, diarrhea, nausea,
constipation and dyspnea. There were no grade 4 events, and no dose limiting toxicities. [71]
Preliminary results of a phase III trial comparing tivozanib to sorafenib in stage IV RCC as first
line treatment were made available at the ASCO 2012 annual meeting. [72] Tivozanib in
comparison with sorefenib resulted in an improvement in PFS (HR 0.80; median 12 vs. 10
months respectively; p=0.04) and higher ORR (33 vs. 23%). Patients on tivozanib experienced
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a higher incidence of grade 3 or 4 hypertension (26 vs. 17%), higher rates of dysphonia (21 vs.
5 %) and back pain (14 vs. 7%). However, tivozanib had less diarrhea (24 vs. 38%), hand and
foot syndrome (15 vs. 71%) and alopecia (2 vs. 21%). [72]
4.2. Dovitinib
The highest tolerated dose of dovitinib is 500 mg daily on a 5-day on/ 2 day off schedule in 28-
day cycles. A phase II study of dovitinib in clear-cell metastatic RCC and in patients previously
treated with a VEGFR inhibitor and/or mTOR inhibitor was reported in 2011. [73] In 51 patients
overall responses were PR in 8%, and SD ≥ 4 months in 37%. Median PFS and OS were 6.1 and
16 months respectively. The most common adverse events were nausea (73%; grade 3:9%),
diarrhea (64%; grade 3:9%), vomiting (56%; grade 3: 5%), decreased appetite (48%; grade 3:7%),
asthenia (36%; grade 3:12%), and fatigue (36%; grade 3: 10%). An on-going phase 3 trials is
comparing dovitinib with sorafenib in patients who have had one previous VEGF- and mTOR-
targeted therapy.
4.3. Regorafenib
A phase II of regorafenib in previously untreated metastatic or unresectable RCC patients has
recently been published. [69]. Forty-eight of 49 patients enrolled were available for assessment
of tumour response. Nineteen of these had an objective response (partial); (39.6%, 90% CI
27.7-52.5). Side-effects were noted in 98% of patients, and 35% experienced serious drug-
related events. Two patients had grade 4 adverse events related to treatment including two
cardiac ischaemia or infraction, one hypomagnesaemia, and one chest/thoracic pain. The
authors advise close monitoring. [69]
5. Combination therapy in metastatic RCC
With the  increasing use  of  VEGF and mTOR inhibitors,  it  has  been noted that  patients
eventually develop resistance / relapse after 6 months to 3 years of therapy. [25] This has
been the driving force for the development of more novel anti-angiogenic agents or treat‐
ment strategies such as combination of the various targeted agents (combination of anti-
angiogenic  agents  or  with  mTOR  inhibitors,  chemotherapy  or  immunotherapy).  [74]
Combination therapies may lead to a more complete blockade of aberrant signaling and
potentially  delay  /  prevent  the  development  of  resistance  observed  with  single-agent
treatment. [74] Unfortunately, this invariably leads to increased toxicities as experienced in
some of the phase I trials. [75]
5.1. VEGF-ligands or receptor inhibitors / mTOR plus immunotherapy combination
Two single arm phase II studies using sorafenib in combination with standard dose IFN-α
showed higher ORR (approximately 30%) and longer PFS (7 – 12 months) when compared
with phase III data of sorafenib monotherapy. [76, 77] However, in a randomized phase II trial
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was found with everolimus over placebo. [67] However there was no statistically significant
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completed the double blind phase). Overall, by week 16, 84% of patients demonstrated PR or
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These patients achieved an ORR of 36%, DCR of 88% and median PFS of 14.8 months. Com‐
monest adverse effects included hypertension (45%) which was grade 3-4 in 12%, and dys‐
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Twenty-eight patients with advanced RCC and clear-cell variant, who had failed up to one
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design was used at four levels from 0.5 mg to 1.5 mg per day and 15 to 25 mg per week of
tivozanib and temsirolimus, respectively. Twenty-eight patients (26 male) of median age 62
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duration of treatment was 21.1 weeks. PR was seen in 28%, SD in 64% and DCR (PR and SD >
24 weeks) in 48% of the treated population. Treatment-related adverse events seen in ≥ 10% of
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Preliminary results of a phase III trial comparing tivozanib to sorafenib in stage IV RCC as first
line treatment were made available at the ASCO 2012 annual meeting. [72] Tivozanib in
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months respectively; p=0.04) and higher ORR (33 vs. 23%). Patients on tivozanib experienced
Renal Tumor166
a higher incidence of grade 3 or 4 hypertension (26 vs. 17%), higher rates of dysphonia (21 vs.
5 %) and back pain (14 vs. 7%). However, tivozanib had less diarrhea (24 vs. 38%), hand and
foot syndrome (15 vs. 71%) and alopecia (2 vs. 21%). [72]
4.2. Dovitinib
The highest tolerated dose of dovitinib is 500 mg daily on a 5-day on/ 2 day off schedule in 28-
day cycles. A phase II study of dovitinib in clear-cell metastatic RCC and in patients previously
treated with a VEGFR inhibitor and/or mTOR inhibitor was reported in 2011. [73] In 51 patients
overall responses were PR in 8%, and SD ≥ 4 months in 37%. Median PFS and OS were 6.1 and
16 months respectively. The most common adverse events were nausea (73%; grade 3:9%),
diarrhea (64%; grade 3:9%), vomiting (56%; grade 3: 5%), decreased appetite (48%; grade 3:7%),
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4.3. Regorafenib
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recently been published. [69]. Forty-eight of 49 patients enrolled were available for assessment
of tumour response. Nineteen of these had an objective response (partial); (39.6%, 90% CI
27.7-52.5). Side-effects were noted in 98% of patients, and 35% experienced serious drug-
related events. Two patients had grade 4 adverse events related to treatment including two
cardiac ischaemia or infraction, one hypomagnesaemia, and one chest/thoracic pain. The
authors advise close monitoring. [69]
5. Combination therapy in metastatic RCC
With the  increasing use  of  VEGF and mTOR inhibitors,  it  has  been noted that  patients
eventually develop resistance / relapse after 6 months to 3 years of therapy. [25] This has
been the driving force for the development of more novel anti-angiogenic agents or treat‐
ment strategies such as combination of the various targeted agents (combination of anti-
angiogenic  agents  or  with  mTOR  inhibitors,  chemotherapy  or  immunotherapy).  [74]
Combination therapies may lead to a more complete blockade of aberrant signaling and
potentially  delay  /  prevent  the  development  of  resistance  observed  with  single-agent
treatment. [74] Unfortunately, this invariably leads to increased toxicities as experienced in
some of the phase I trials. [75]
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Two single arm phase II studies using sorafenib in combination with standard dose IFN-α
showed higher ORR (approximately 30%) and longer PFS (7 – 12 months) when compared
with phase III data of sorafenib monotherapy. [76, 77] However, in a randomized phase II trial
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of sorafenib vs. sorafenib and low-dose IFN-α in patients with advanced RCC, no statistically
significant difference in ORR and PFS was noted in the two arms. [78] These results should be
interpreted cautiously given the small number of patients in these studies. [78]
Both AVOREN (n = 649) [79] and CALGB 90206 (n = 732) [80] compared bevacizumab / IFN-
α combination with IFN-α demonstrated that the PFS interval was significantly longer with
bevacizumab plus IFN-α than with the IFN-α alone (AVOREN: 10.2 months versus 5.4 months,
respectively; p = 0.0001; CALGB 90206: 8.5 months versus 5.2 months, respectively; p < 0.0001).
The ORRs were 31% with bevacizumab plus IFN-α and 13% with placebo plus IFN-α (p =
0.0001) in the AVOREN study. In the CALGB 90206 trial, the ORRs were 25.5% with bevaci‐
zumab plus IFN-α and 13.1% with IFN-α (p < 0.0001). [74, 79, 80] The design of these trials
however did not have a bevacizumab monotherapy arm and therefore the clinical efficacy of
bevacizumab monotherapy remained unanswered. In an open-label phase 2 study (TORAVA),
171 patients with metastatic RCC were randomly assigned (2:1:1) to receive the combination
of bevacizumab (10 mg/kg every 2 weeks) and temsirolimus (25 mg weekly) or sunitinib (50
mg/day for 4 weeks followed by 2 weeks off) or the combination of IFN-α (9 x 106 IU three
times per week) and bevacizumab (10 mg/kg every 2 weeks). PFS at 48 weeks was 29.5% (26
of 88 patients, 95% CI 20.0-39.1) in group A, 35.7% (15 of 42, 21.2-50.2) in group B, and 61.0%
(25 of 41, 46.0-75.9) in group C. Median PFS was 8.2 months (95% CI 7.0-9.6) in group A, 8.2
months (5.5-11.7) in group B, and 16.8 months (6.0-26.0) in group C. The toxicity of the
experimental regimen was high with over 50% of patients not able to tolerate the combination
of bevacizumab and temsirolimus over several months. This combination failed to show any
beneficial activity and was more toxic than the treatments used in the other arms, and therefore
was not recommended as first line treatment in these patients. [81]
The combination of temsirolimus and IFN-α was studied in a phase III trial. Six hundred and
twenty six patients were randomized to receive of IFN-α alone, temsirolimus alone, or a
combination of the two drugs. Median OS times in the IFN-α arm, the temsirolimus arm, and
the combination-therapy arm were 7.3, 10.9, and 8.4 months, respectively. Unlike temsirolimus
alone, the combination of temsirolimus plus IFN-α did not improve OS. Therefore the
temsirolimus / IFN-α combination is not recommended as standard practice for treatment of
advanced RCC. [65]
Lastly, in a global, open-labelled multi-centre phase IIIb trial (INTORACT), temsirolimus and
bevacizumab was compared with interferon and bevacizumab as first-line treatment in 791
patients with predominantly clear-cell metastatic RCC. [82] At the interim analysis, 489
patients were assessed PFS events. Median PFS with temsirolimus / bevacizumab combination
was 9.1 month compared to 9.3 months in the interferon / bevacizumab group. The median
OS was 25.8 months in the temsirolimus and 25.5 months for the interferon group. [82]
5.2. VEGF-ligands or receptor inhibitors / mTOR combination
Bevacizumab in combination with sorafenib and sunitinib has been evaluated in two phase I
trials. In these trials although there were some promising results regarding the median time
to progression and partial response rates in the combination arms, the adverse effects observed
in the latter were prominent. [83, 84] The combination arm in both trials required dose
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reduction of both agents and resulted in a considerably lower maximum tolerated dose in
contrast to the maximal tolerated dose of the single agent. Bevacizumab potentiated the side-
effects of sorafenib such as hypertension and hand-foot syndrome; hematological, vascular
toxicities (including microangiopathic hemolytic anaemia) and hypertension in the sunitinib
combination. [75] Finally, a phase II study assessing the tolerability and efficacy of multiple
combinations of currently available therapies, is being processed in the Eastern Cooperative
Oncology BeST trial. The four arms are bevacizumab (10mg/kg), bevacizumab (5mg/kg) /
temsirolimus (25 mg), bevacizumab (5mg/kg) and sorafenib (200mg twice daily)/ temsirolimus
(25mg). [85]. The results are currently pending.
6. Sequencing therapy in metastatic RCC
Sequential use of targeted agents has several potential benefits. Firstly, this approach could
lead to a treatment continuum, secondly, it provides patients the opportunity to receive full
doses of the targeted agents without affecting tolerability and finally, sequential targeting of
different molecular pathways could potentially overcome any resistance that would arise from
single target inhibition. [86]
6.1. Anti-angiogenic therapy after immunotherapy
Few phase II trials using anti-angiogenic agents after progression on immunotherapy lead to
promising results. [32, 59, 87] In a phase III trial (TARGET) patient who had progressed on
cytokine therapy after receiving sorafenib, there was a notable doubling of PFS from 2.8 to 5.6
months. [41] Likewise, the utilization of axitinib post progression on cytokine in a phase II
trial, lead to a TTP of 15.7 months. [77] There are no head-to-head data present to guide which
agent is best utilized post cytokine therapy and a properly conducted phase III trial are
required to share further insight into this treatment strategy.
6.2. mTOR blockade after anti-angiogenic therapy
In this strategy, the RECORD-1 trial investigated the efficacy of everolimus vs. placebo with
best supportive care post progression on sunitinib, sorafenib or both. Seventy one per cent of
patients included in the trial had received prior sunitinib treatment and 55% sorafenib therapy.
Patient on everolimus achieved addition of 3-month in terms of PFS regardless of prior
treatment. No overall survival benefit was observed due to large numbers of cross over from
placebo to everolimus arm (80%). [67]
RECORD-3, a phase III clinical trial recently closed to patient recruitment, randomly assigned
patients to either everolimus or sunitinib. Upon first sign of progression, patients would cross
over to sunitinib if they were on everolimus and to everolimus if previously on sunitinib. The
primary end point of this trial was to evaluate whether PFS post first-line treatment for patients
who received everolimus will be non-inferior to patients who receive sunitinib. [52]
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of sorafenib vs. sorafenib and low-dose IFN-α in patients with advanced RCC, no statistically
significant difference in ORR and PFS was noted in the two arms. [78] These results should be
interpreted cautiously given the small number of patients in these studies. [78]
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α combination with IFN-α demonstrated that the PFS interval was significantly longer with
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of bevacizumab and temsirolimus over several months. This combination failed to show any
beneficial activity and was more toxic than the treatments used in the other arms, and therefore
was not recommended as first line treatment in these patients. [81]
The combination of temsirolimus and IFN-α was studied in a phase III trial. Six hundred and
twenty six patients were randomized to receive of IFN-α alone, temsirolimus alone, or a
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the combination-therapy arm were 7.3, 10.9, and 8.4 months, respectively. Unlike temsirolimus
alone, the combination of temsirolimus plus IFN-α did not improve OS. Therefore the
temsirolimus / IFN-α combination is not recommended as standard practice for treatment of
advanced RCC. [65]
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bevacizumab was compared with interferon and bevacizumab as first-line treatment in 791
patients with predominantly clear-cell metastatic RCC. [82] At the interim analysis, 489
patients were assessed PFS events. Median PFS with temsirolimus / bevacizumab combination
was 9.1 month compared to 9.3 months in the interferon / bevacizumab group. The median
OS was 25.8 months in the temsirolimus and 25.5 months for the interferon group. [82]
5.2. VEGF-ligands or receptor inhibitors / mTOR combination
Bevacizumab in combination with sorafenib and sunitinib has been evaluated in two phase I
trials. In these trials although there were some promising results regarding the median time
to progression and partial response rates in the combination arms, the adverse effects observed
in the latter were prominent. [83, 84] The combination arm in both trials required dose
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promising results. [32, 59, 87] In a phase III trial (TARGET) patient who had progressed on
cytokine therapy after receiving sorafenib, there was a notable doubling of PFS from 2.8 to 5.6
months. [41] Likewise, the utilization of axitinib post progression on cytokine in a phase II
trial, lead to a TTP of 15.7 months. [77] There are no head-to-head data present to guide which
agent is best utilized post cytokine therapy and a properly conducted phase III trial are
required to share further insight into this treatment strategy.
6.2. mTOR blockade after anti-angiogenic therapy
In this strategy, the RECORD-1 trial investigated the efficacy of everolimus vs. placebo with
best supportive care post progression on sunitinib, sorafenib or both. Seventy one per cent of
patients included in the trial had received prior sunitinib treatment and 55% sorafenib therapy.
Patient on everolimus achieved addition of 3-month in terms of PFS regardless of prior
treatment. No overall survival benefit was observed due to large numbers of cross over from
placebo to everolimus arm (80%). [67]
RECORD-3, a phase III clinical trial recently closed to patient recruitment, randomly assigned
patients to either everolimus or sunitinib. Upon first sign of progression, patients would cross
over to sunitinib if they were on everolimus and to everolimus if previously on sunitinib. The
primary end point of this trial was to evaluate whether PFS post first-line treatment for patients
who received everolimus will be non-inferior to patients who receive sunitinib. [52]
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6.3. Serial anti-angiogenic agents
With the availability of multiple SMTKIs, an important focus ahead is in the identification of
how to best utilize the TKIs in sequence. There is now increasing evidence supporting the
sequential use of VEGF-targeted therapies.
In both phase II and III trials, axitinib has shown encouraging results in second-line setting in
advanced RCC. [88] In an ongoing study, the Sequential Two-agent Assessment in Renal Cell
Carcinoma Therapy (START), two hundred and forty treatment-naïve patients with clear-cell
component metastatic RCC will be randomized into 6 arms to receive different 2-drug
"sequences" of everolimus, bevacizumab, or pazopanib. The primary end point is the detection
of the longest combination of the TTP. [89]
A retrospective study on RCC patients treated with sunitinib and sorafenib evaluated the
effectiveness of switching from one TKI agent to the other after disease progression. In this
study patients who received sunitinib followed by sorafenib experienced a shorter time to
progression than patients who received sorafenib followed by sunitinib (risk ratio (RR) 3.0; p
= 0.016). Similarly, the median OS was 102 weeks in patients who received sorafenib followed
by sunitinib compared with 45 weeks in patients who received sunitinib followed by sorafenib
(p = 0.061).[90]
An ongoing phase III trial (SWITCH trial) is currently being undertaken comparing sorafenib
until progression followed by sunitinib and sunitinib until progression followed by sorafenib
in the first line advanced RCC setting. The primary end point is the PFS and hopefully this
trial will show further insight into which anti-VEGF treatment sequence will confer better
clinical outcome in patients with metastatic RCC. [91]
7. Systemic treatment for non-clear cell renal cell carcinoma
With clear-cell RCC being the predominant histological subtypes and non clear-cell (papillary
and chromophobe) being represented only in ~10% of clinical trials, there is consequently a
paucity of data regarding treatment for advance non-clear-cell RCC. [92] Novel target therapies
have demonstrated promising results in clear-cell histologies, however their activities re‐
mained undefined in the non-clear-cell counterpart. Majority of the data is derived from
expanded access trials, retrospective series, and subset analyses of major trials. [93] Patients
with non clear-cell RCC were both excluded from the landmark phase III trials of sunitinib
and sorafenib. The largest non clear-cell series were derived from the sunitinib and sorafenib
expanded access trials, which allowed entry of non-clear-cell histologies. Gore and colleagues
demonstrated sunitinib activity in the multi-centre, international, non-randomised expanded
access compassionate trial. Of the 4500 patients enrolled, approximately 10% (n=437) had non
clear-cell histology (not further characterized) were evaluated. An ORR of 11% was demon‐
strated (N=48) with 46 partial responders and 2 complete responders. Fifty sever percent had
stable disease (N=250) for a t least 3 months. [36] The median OS was reported as 13.4 months.
The ORR was notable lower, 11% compared to the reported 42 to 47% in the phase III trial. The
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non-stringent reporting of disease progression and the reliance of local practice may well
account for the discrepancy in the results.
The Advanced Renal Cell Carcinoma Sorafenib (ARCS) expanded access trial recruited patient
with advanced RCC who were not eligible for other clinical trials. One hundred and fifty eight
patients with papillary RCC were enrolled. Partial response of 3.4% and 5.6% were noted for
patients with papillary and chromophobe RCC respectively. Eighty-seven patients (77.1% of
the papillary RCC and 88.8% of the chromophobe RCC) demonstrated disease stability for a
duration of more than 8 weeks. Despite only modest activity being noted, this trial has at least
shared insight into the activity of sorafenib into the two most common non clear-cell variant.
[44] Another trial that demonstrated TKI activity across the different histological subtypes
were reported in a retrospective analysis of patients with metastatic papillary and chromo‐
phobe RCC who received either sunitinib and sorafenib as their initial frontline therapy. The
reported ORR, PFS and OS were 10%, 8.9 months and 12.2 months respectively. A sub-analysis
revealed a longer higher response rate for chromophobe variant (25%) compared to papillary
variant (4.8%); (p=0.007). Similarly the PFS in the chromophobe population was longer (9.3
months) when compared with papillary population 6.6 months (p=0.07). There were no
differences between the OS across both histologies. When stratified according to TKI type, the
papillary population had a statistically longer PFS (11.9 months) with sunitinib compared to
sorafenib (5.1 months; p<0.001). [3]
Temsirolimus has demonstrated promising activity in both clear-cell and non-clear-cell RCC.
The phase III trial undertaken by Hudes and colleagues, examined the efficacy of temsirolimus,
IFN-α or combination of both in patients with poor MSKCC prognostic features. [65] Although
majority of patients had clear-cell histology, approximately 20% of non-clear-cell variant were
included in the clinical trial. An improvement in median OS and median PFS were seen in
temsirolimus arm, across all histologies with a significant advantage in hazard ratio for OS in
the temsirolimus. An updated sub-analysis of the study showed a hazard ratio of 0.55 and 0.36
for median OS and PFS respectively, clearly favouring temsirolimus over IFN-α monotherapy
and IFN-α / temsirolimus combination arms. [94] The analysis also showed that 75% of the
non clear-cell variant consisted of papillary subtype. This has led to subsequent FDA approval
of temsirolimus as treatment for non-clear-cell histology in advanced RCC.
Everolimus through RECORD-1 trial has reported efficacy in patient who progressed on one
or two line of TKI. This has led to the development of an open-label, single arm, multi-centre
phase II examining the efficacy of everolimus as first-line systemic therapy for patients with
advanced papillary RCC. [8] This trial will stratify the histology into type I and II, and
recruitment will hopefully show further insight into the treatment of papillary variant of RCC.
Epidermal growth factor receptor (EGFR) has been investigated as potential therapeutic target
in metastatic RCC. Erlotinib, an anti-EGFR was examined in a phase II study of treatment naïve
patients with locally advanced or metastatic papillary RCC. [95] Fifty two patients were
registered and 45 were evaluable. The ORR was reported as 11% and the disease control rate
was 64% with 5 partial responders and 24 patients with stable disease. The six month PFS was
30% and median survival of 27 months was documented. [95]
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In both phase II and III trials, axitinib has shown encouraging results in second-line setting in
advanced RCC. [88] In an ongoing study, the Sequential Two-agent Assessment in Renal Cell
Carcinoma Therapy (START), two hundred and forty treatment-naïve patients with clear-cell
component metastatic RCC will be randomized into 6 arms to receive different 2-drug
"sequences" of everolimus, bevacizumab, or pazopanib. The primary end point is the detection
of the longest combination of the TTP. [89]
A retrospective study on RCC patients treated with sunitinib and sorafenib evaluated the
effectiveness of switching from one TKI agent to the other after disease progression. In this
study patients who received sunitinib followed by sorafenib experienced a shorter time to
progression than patients who received sorafenib followed by sunitinib (risk ratio (RR) 3.0; p
= 0.016). Similarly, the median OS was 102 weeks in patients who received sorafenib followed
by sunitinib compared with 45 weeks in patients who received sunitinib followed by sorafenib
(p = 0.061).[90]
An ongoing phase III trial (SWITCH trial) is currently being undertaken comparing sorafenib
until progression followed by sunitinib and sunitinib until progression followed by sorafenib
in the first line advanced RCC setting. The primary end point is the PFS and hopefully this
trial will show further insight into which anti-VEGF treatment sequence will confer better
clinical outcome in patients with metastatic RCC. [91]
7. Systemic treatment for non-clear cell renal cell carcinoma
With clear-cell RCC being the predominant histological subtypes and non clear-cell (papillary
and chromophobe) being represented only in ~10% of clinical trials, there is consequently a
paucity of data regarding treatment for advance non-clear-cell RCC. [92] Novel target therapies
have demonstrated promising results in clear-cell histologies, however their activities re‐
mained undefined in the non-clear-cell counterpart. Majority of the data is derived from
expanded access trials, retrospective series, and subset analyses of major trials. [93] Patients
with non clear-cell RCC were both excluded from the landmark phase III trials of sunitinib
and sorafenib. The largest non clear-cell series were derived from the sunitinib and sorafenib
expanded access trials, which allowed entry of non-clear-cell histologies. Gore and colleagues
demonstrated sunitinib activity in the multi-centre, international, non-randomised expanded
access compassionate trial. Of the 4500 patients enrolled, approximately 10% (n=437) had non
clear-cell histology (not further characterized) were evaluated. An ORR of 11% was demon‐
strated (N=48) with 46 partial responders and 2 complete responders. Fifty sever percent had
stable disease (N=250) for a t least 3 months. [36] The median OS was reported as 13.4 months.
The ORR was notable lower, 11% compared to the reported 42 to 47% in the phase III trial. The
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non-stringent reporting of disease progression and the reliance of local practice may well
account for the discrepancy in the results.
The Advanced Renal Cell Carcinoma Sorafenib (ARCS) expanded access trial recruited patient
with advanced RCC who were not eligible for other clinical trials. One hundred and fifty eight
patients with papillary RCC were enrolled. Partial response of 3.4% and 5.6% were noted for
patients with papillary and chromophobe RCC respectively. Eighty-seven patients (77.1% of
the papillary RCC and 88.8% of the chromophobe RCC) demonstrated disease stability for a
duration of more than 8 weeks. Despite only modest activity being noted, this trial has at least
shared insight into the activity of sorafenib into the two most common non clear-cell variant.
[44] Another trial that demonstrated TKI activity across the different histological subtypes
were reported in a retrospective analysis of patients with metastatic papillary and chromo‐
phobe RCC who received either sunitinib and sorafenib as their initial frontline therapy. The
reported ORR, PFS and OS were 10%, 8.9 months and 12.2 months respectively. A sub-analysis
revealed a longer higher response rate for chromophobe variant (25%) compared to papillary
variant (4.8%); (p=0.007). Similarly the PFS in the chromophobe population was longer (9.3
months) when compared with papillary population 6.6 months (p=0.07). There were no
differences between the OS across both histologies. When stratified according to TKI type, the
papillary population had a statistically longer PFS (11.9 months) with sunitinib compared to
sorafenib (5.1 months; p<0.001). [3]
Temsirolimus has demonstrated promising activity in both clear-cell and non-clear-cell RCC.
The phase III trial undertaken by Hudes and colleagues, examined the efficacy of temsirolimus,
IFN-α or combination of both in patients with poor MSKCC prognostic features. [65] Although
majority of patients had clear-cell histology, approximately 20% of non-clear-cell variant were
included in the clinical trial. An improvement in median OS and median PFS were seen in
temsirolimus arm, across all histologies with a significant advantage in hazard ratio for OS in
the temsirolimus. An updated sub-analysis of the study showed a hazard ratio of 0.55 and 0.36
for median OS and PFS respectively, clearly favouring temsirolimus over IFN-α monotherapy
and IFN-α / temsirolimus combination arms. [94] The analysis also showed that 75% of the
non clear-cell variant consisted of papillary subtype. This has led to subsequent FDA approval
of temsirolimus as treatment for non-clear-cell histology in advanced RCC.
Everolimus through RECORD-1 trial has reported efficacy in patient who progressed on one
or two line of TKI. This has led to the development of an open-label, single arm, multi-centre
phase II examining the efficacy of everolimus as first-line systemic therapy for patients with
advanced papillary RCC. [8] This trial will stratify the histology into type I and II, and
recruitment will hopefully show further insight into the treatment of papillary variant of RCC.
Epidermal growth factor receptor (EGFR) has been investigated as potential therapeutic target
in metastatic RCC. Erlotinib, an anti-EGFR was examined in a phase II study of treatment naïve
patients with locally advanced or metastatic papillary RCC. [95] Fifty two patients were
registered and 45 were evaluable. The ORR was reported as 11% and the disease control rate
was 64% with 5 partial responders and 24 patients with stable disease. The six month PFS was
30% and median survival of 27 months was documented. [95]
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Collecting duct tumour is a very aggressive but rare variant of aggressive but rare variant of
RCC. The largest data is derived from a phase II multi-centre trial of 23 treatment naïve patients
who received platinum based chemotherapy with gemcitabine. The choice of chemotherapy
is that of a platinum doublet based on some similarities to transitional cell carcinoma of the
bladder. The ORR was 26% with a median PFS and OS of 7.1 months and 10.5 months
respectively.[18] There is no data to support the use of TKI in this variant of tumour.
8. Side effects of targeted therapies used in renal cell carcinoma
The increasing use of novel anti-VEGF agents, and for longer periods of time for the treatment
of RCC has raised challenges in the management of the associated toxicities or adverse effects.
There are supportive interventions developed for their prevention and control. [96]
It has been identified in clinical trials and post marketing surveillance that the treatment
toxicities associated with the new targeted therapies against cancer differ significantly from
the toxicities seen with conventional chemotherapy. [96, 97]
Many of the anti-VEGF agents share similar toxicities, including hypertension, fatigue,
gastrointestinal, skin and bone marrow effects. The mTOR inhibitors have unique adverse
effects, which include metabolic alterations (hypercholesterolnaemia, hyperglycermia),
gastrointestinal alterations and interstitial pneumonitis. Hypothyroidism is seen uniquely in
patients on sunitinib, potentially sorafenib and pazopanib. [96]
8.1. Hyperension
Arterial hypertension is commonly observed as an adverse event in patients treated with
inhibitors of the VEGF pathway. [96, 98] The most common implicated anti-VEGF agents
include axitinib, bevacizumab, sorafenib, sunitinib and pazopanib. [33, 41, 51, 99, 100] Prompt
identification of arterial hypertension is essential to prevent serious consequences such as
strokes and heart failure. [101, 102] The regular use of ambulatory BP monitoring may be
valuable for early detection and accurate assessment of blood pressure (BP) changes. [103]
Hypertension has occurred whether or not the patient has a history of high blood pressure,
however incidence may be higher in patients with pre-existing cardiovascular disease. [33, 41,
50, 99] There are pre-existing algorithms to treat hypertension associated with targeted
therapies [96] but it falls on the clinician’s discretion to individualise treatment accordingly.
[98] For example, the use of angiotensin-converting enzyme (ACE) inhibitor is a logical choice
if bevacizumab is the underlying cause as they may improve the associated proteinuria. [104]
Angiotensin II inhibitors, diuretics, dihydropyridine calcium channel blockers (CCBs), and β-
blockers are also considered as appropriate anti-hypertensive agents.
8.1.1. Hypertension as a biomarker
Hypertension induced by sunitinib and bevacizumab is associated with improved clinical
outcomes, supporting its use as an efficacious biomarker. In a retrospective analysis which
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included pooled efficacy and safety data (n=544, n=4917) from four trials of patients with
metastatic RCC treated with sunitinib 50mg/d (4 week on / 2 week off), it was observed that
patients who had a systolic BP ≥to 140mmHg and a diastolic blood pressure of ≥ 90mmHg had
better outcomes compared to those without treatment induced hypertension The ORR were
54.8% in the treatment induced hypertension cohort vs. 8.7% in the normotensive patients. The
median PFS was 12.5 vs. 2.5 months in the hypertensive and normotensive respectively and
similarly the median OS was 30.9 months in the hypertensive group vs. 7.2 months in the
normotensive group. [105] The rates of AEs were similar between patients with and without
hypertension. However patients with high BP experienced more frequent renal adverse events
(5% vs. 3%). [105] More importantly, no difference in outcome (PFS and ORR) was noted
regardless of whether patients received treatment for their hypertension. [105]
Treatment induced arterial hypertension is also correlated with good clinical outcomes in
patients treated with bevacizumab for metastatic colorectal cancer [106] but this has not been
investigated widely in metastatic RCC.
8.2. Fatigue
Fatigue is a very frequent side-effect seen with the targeted agents used in metastatic RCC [74,
96, 107] The incidence of fatigue in phase III studies ranged from 14% to 51% for all grades and
up to 11% for grade 3–4.
There is no direct treatment available to alleviate treatment induced fatigue. Monitoring and
treating patients for any aggravating or reversible factors (i.e. anaemia, anxiety, hypothyroid‐
ism, depression may help. If grade 3–4 fatigue persists, dose reduction or cessation of the
treatment should be considered. [96, 108]
8.2.1. Fatigue as a biomarker
Fatigue is another potential biomarker in patients with metastatic RCC treated with sunitinib.
A retrospective analysis of pooled data from 770 patients who received sunitinib in 5 clinical
trials for metastatic RCC revealed that the development of grade 1-2 fatigue was linked with
significantly longer time to progression and improved overall survival. [109]
8.3. Hand and foot syndrome as biomarker
In a retrospective registry of metastatic RCC, 705 and 365 patients treated with sunitinib and
sorafenib respectively were assessed for outcomes of the disease in those who developed hand
and foot syndrome. In the sunitinib group, the median OS was 43 months for those with the
hand and foot syndrome vs. 31 months (p=0.027) in those without. The PFS in patients with
the dermatological toxicity was 20.8 months vs. 11.1 months (p=0.007) in those without. In the
sorafenib group, no differences was noted in median OS for those that did and did not
experience hand foot syndrome (27.9 vs. 24.6 months (p=0.244). The PFS was 12.2 vs. 8.8 months
(p=0.050) with a difference of 3.4 months in those that experienced hand foot syndrome. In
multivariable cox regression analysis, hand and foot syndrome was associated with longer OS
in the sunitinib group. In sorafenib, the survival benefits were less convincing. [110]
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significantly longer time to progression and improved overall survival. [109]
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sorafenib respectively were assessed for outcomes of the disease in those who developed hand
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hand and foot syndrome vs. 31 months (p=0.027) in those without. The PFS in patients with
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Emerging data has also shown that other adverse effects such as hypothyroidism, myelosup‐
pression in addition to the aforementioned hypertension and hand foot syndrome were
biomarkers for tumour control and OS when sunitinib is the agent in use. [111, 112] In mTOR
inhibitors, serum LDH, elevated cholesterol and pneumonitis have been studied as predictive
biomarkers. [113-115]
9. Quality of life in patients with renal cell carcinoma receiving targeted
9.1. Therapy
Quality of life (QoL) has been evaluated in a series of trials of patients taking novel targeted
agents for RCC. Questionnaires used have included the Functional Assessment of Cancer
Therapy-General (FACT-G), the FACT Kidney Symptom Index-15 item (FKSI-15), the FACT-
Kidney Symptom Index-Disease related Symptoms (FKSI-DRS), the European Organization
for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 and
the Euro QOL 5D (Index and Visual Analogue Scale) utility score (EQ-5D) Index.
One of the important outcomes was that newer treatment approaches may be better tolerated
with improved QOL compared to the older generation agents. Sunitinib has shown meaningful
differences, both in kidney cancer related symptoms and overall QOL over IFN-α. [33] This is
not unexpected given the more difficult toxicity profile of sunitinib.
Sorafenib, on the contrary revealed no worst QoL score based on the FACT-G or FKSI-15
undertaken in the TARGET trial. On the other hand, targeted therapies compared to placebo
were not revealing worse scores in the QOL questioners. Interestingly, qualitative assessment
of one’s ability to enjoy life, concerns for well-being, fevers, dyspnea and cough were reported
less in the patients on sorafenib. [116]
Pazopanib unexpectedly did not have a clinically different QoL compared with placebo,
despite the adverse events that a clinician may expect with pazopanib. [50, 100]
In the AXIS trial where axitinib was compared head-to-head with sorafenib, patient-reported
kidney-specific  symptom and function assessments  were secondary endpoints  that  were
examined. [57] Overall, patients on the axitinib treatment arm reported comparable outcomes
to that of sorafenib. The PFS benefit seen by axitinib is associated with a delay in worsening of
the composite endpoint of advanced RCC symptoms, progression, or death with sorafenib. [57]
PSICES is a small but important randomized trial comparing patient’s preference for pazopa‐
nib or sunitinib for first-line treatment of metastatic RCC. The rationale of this trial was to select
the more tolerable agent with the recent approval of numerous TKIs as front-line agents. [117]
One hundred and sixty nine patients with metastatic RCC were randomly assigned to blinded
treatment of pazopanib for 10 weeks with a wash out prior to 50mg of sunitinib for 10 weeks,
and vice versa (4 weeks of sunitinib followed by 2 weeks break before 10 weeks of pazopanib).
Fifty four and sixty patients first received pazopanib and sunitinib respectively. The patience
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preference when assessed at 22 weeks revealed 70% of patients preferred pazopanib, 22%
preferred sunitinib, and 8% expressed no preference. The magnitude of difference was 49.3%
between pazopanib and sunitinib. Fewer patients received pazopanib required a dose reduc‐
tion (13% vs. 20%), prematurely discontinued treatment during the first study period (14% vs.
8%), or prematurely discontinued treatment during the second period (15% vs. 31%). [117, 118]
10. Conclusion
The discovery of anti-angiogenic (small molecule tyrosine kinase inhibitors and anti-VEGF
agents) agents has altered the treatment landscape for patients with metastatic RCC. Their
effective anti-neoplastic activities have provided hope of survival beyond six month, in
contrast to that traditionally gained from IFN-α therapy. Different treatment strategies are
being investigated vigorously, either in combination or in sequence with the aim of improving
the pre-existing survival and response rates. Whilst the treatment algorithm for advanced
clear-cell variant of renal cell carcinoma is constantly evolving with increasing treatment
options, the non clear-cell counterpart remains an area in need of significant research. With
improved understanding of the various molecular pathways, options for non clear-cell
variants would hopefully become more established. The recognition of the potentially serious
side-effects of targeted agents begs for vigilance in the clinician’s part to improve treatment
adherence and compliance. Close monitoring of these toxicities will also allow for better
identification of their role as bio-markers of efficacy. The ultimate goal is to have an effective
agent that leads to durable response with a tolerable side-effect profile.
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1. Introduction
Renal cell carcinoma (RCC) affects more than 200.000 people annually worldwide resulting in
102.000 deaths each year. Men are twice as frequently affected as women; population aged
between 50 and 70 years is most frequently affected. Obesity, hypertension, tobacco smoking
and certain occupational exposures have been shown to increase one’s risk for developing
RCC. Rarely RCC develops as a part of the familiar syndrome (e.g. von Hippel-Lindau) [1,2].
Treatment of renal cell carcinoma has changed dramatically over the past few years. Until 2005
cytokine therapy (interferon (IFN-α) or interleukin (IL-2)) was the only (IFN-α) or interleukin
(IL-2) was the only available treatment for mRCC patients. Treatment with cytokines was
associated with little clinical benefit together with substantial side effects; even treatment
related deaths were not infrequent. Treatment options for second line therapy were very
limited; patients could be treated only with another cytokine or best supportive care. Re‐
sponses to second line cytokine therapy were modest. Fewer than 4% of patients had partial
response and < 12% had stable disease [2,3].
Lack of effective therapy together with better knowledge about the cancer biology led to the
development of new targeted agents. Since the start of the “targeted era” development of
new therapies evolved swiftly. Better treatment results in the first line therapy are allied to
the better outcome of the patients on subsequent lines of treatment. Prognosis of patients
improved and mRCC is becoming more a chronic type of disease, rather than a rapidly
progressing and fatal one [3].
Despite rapid progress in development of new treatments, many questions still remain
unanswered. Patients on targeted therapies progress some time during their treatment and
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mRCC is considered an incurable disease [4]. In trying to overcome this, the mechanism of
action and especially mechanisms of resistance to targeted therapies, need to be studied and
explained even more in detail [3-7].
In this chapter evidence on sequential therapy after progression to the first line will be
presented with the emphasis on changing mechanism of action. Additionally, mechanisms of
resistance to targeted therapies and therapeutic options to overcome resistance will be
discussed.
2. Molecular biology of renal cell carcinoma
Most of the knowledge about molecular biology comes from the studies of a hereditary form
of renal cell carcinoma. Studies of families with inherited RCC over the past twenty years lead
to the identification of five inherited renal cancer syndromes and their related genes. Descrip‐
tion of all five syndromes is beyond the scope of this chapter; only Von Hippel-Lindau
syndrome will be explored [2].
2.1. Von Hippel-Lindau tumor suppressor gene
The von Hippel-Lindau (VHL) disease is a rare, autosomal dominantly inherited disease.
Individuals with this syndrome are predisposed to development of multiple benign and
malignant tumors. Most common are clear cell renal tumors, retinal and central nervous system
hemangioblastomas, pheocromocytomas, pancreatic neuroendocrine tumors, endolymphatic
sac tumors and pancreatic and kidney cists. VHL occurs in 1 in 36.000 and symptomatic disease
develops in 70% of affected persons by the age of 60 years. Bilateral RCC develop in 25-45%
of VHL patients. VHL results from mutation in the von Hippel-Lindau gene on chromosome
3p25-26. The VHL gene discovered in 1993 is a tumor suppressor gene; both copies of gene
must be inactivated for tumor initiation. Different germline mutations predisposing to VHL
include; large deletions, protein-truncating mutations and missense mutations that exchange
the amino acids in the VHL protein. More than 1000 different mutations have been identified
until now. According to the type of mutation, patients are classified in different groups,
predisposed to different types of tumors. Group of patients bearing deletions or nonsense
mutations, most often develop RCC [2,8].
The research on VHL gave light to the inside of molecular biology of sporadic kidney cancer.
It is known, that loss of VHL function, including somatic mutations and epigenetic defects, is
found in 70–90% of the sporadic clear cell RCC [8]. The pathophysiologic mechanism of such
strong association is currently not very understood [8,9].
The VHL protein pVHL has several functions. The most studied is its role in the regulation of
hypoxia inducible factor (HIF1α), member of transcription factors family. At normal cellular
oxygen levels, pVHL binds to HIF1α and causes its degradation. In low oxygen or in the case
when VHL gene is mutated pVHL does not bind to HIF1α. Consequently HIF1α dimerise with
HIF1β and activate the transcription of genes involved in vessel development (vascular
endothelial growth factor, platelet-derived growth factor B, erythropoietin) and genes
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involved in glucose uptake and metabolism. Up-regulation of targeted genes involved in neo-
vascularization by HIF1α offers the explanation of high vascularity of RCC [2,8]. Beside this,
pVHL has numerous other functions in the processes of regulation of extracellular matrix,
senescence, phosphorylation enhancers and other. The importance of many physiologically
relevant functions of pVHL is at present difficult to interpret [8].
Besides VHL, six other genes have been found to predispose to RCC (MET, FLCN, FH, SDH,
TSC 1 and TSC 2). These genes interact trough common nutrient and energy sensing pathways.
Understanding of the molecular mechanisms by which these genes interact in these pathways
has enabled the development of targeted therapies [2].
2.2. VEGF-R pathway
Loss of both alleles of VHL gene leads to up-regulated transcription of growth factors such as
VEGF, PDGF and TGF-α. These factors bind to their tyrosine kinase receptors. This leads to
downstream signalling and ultimately to effects such as increased angiogenesis, increased cell
proliferation and decreased apoptosis. As described previously pVHL mutations are inevita‐
bly connected to flawed HIF inactivation which results in production of VEGF. VEGF is the
most prominent angiogenesis regulator. Its function is mediated through two tyrosine kinase
receptors VEGF-R1 and VEGF-R2 in vascular endothelial cells. VEGF in the beginning binds
to VEGF-R2, which promotes endothelial cell proliferation, migration and vascular permea‐
bility. In the next step VEGF binds to VEGF-R1 to assist the organization of new capillaries [9].
2.3. mTOR pathway
mTOR is another regulator of HIF 1α, its signalling activity increases the cellular levels of HIF
1α, which worsens the already high levels of it because of absence of pVHL function. mTOR
is a serine/threonine kinase that has a key function in apoptosis, cell growth and tumor
proliferation. mTOR forms complexes with regulatory associated proteins named mTORC1
and mTORC2. mTORC 1 can be activated by growth factors including VEGFR, PDGFR, EGFR
and IGFR and nutrients trough phosphatidylinositol-3 kinase/Akt (PI3K/Akt) pathway.
Activated mTORC1 stimulate protein synthesis, entrance into G 1 phase, and proteins that
regulate apoptosis [9].
3. Development of systemic therapy in mRCC
3.1. Chemotherapy
The successes on other solid tumors led researches to the assumption chemotherapy would be
effective also in mRCC. Chemotherapeutic trials were conducted between 1983 and 1993.
Different agents; bleomycin, cisplatin, 5-FU, gemcitabine and vinblastine have been tested.
Results were disappointing; less than 10% of patients had clinical benefit in all of these trials.
Response rates in the range of 10 to 15% have been achieved with combination of two agents.
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Today chemotherapy has no role in the treatment of mRCC patients and is not part of the
everyday clinical practice [2].
Several mechanisms have been discovered to be responsible to the resistance of RCC cells to
chemotherapy. Beside increased detoxification, altered targets and impaired apoptosis
pathways, increased expression of transporting proteins play an important role. P-glycopro‐
tein is a 170-kD membrane glycoprotein that acts as a pump that expels chemicals like
vinblastine out of the cell [2].
3.2. Cytokines
The interest in interferon in the treatment of RCC came when sporadic responses in patients
with RCC on leucocyte interferon, were observed. Natural interferon produced from donor’s
leucocytes, was later substituted with recombinant. Different forms and dosages were tested
and no major differences between them were observed. Uniformly response rates ranged from
0 to 29% with few complete and very few durable responses. Some trials suggested that certain
group of patients have larger benefit (good performance status, prior nephrectomy and
restricted metastases to the lungs), but this was not a uniform finding. Today interferon as
mono-therapy is not widely used, because of the low efficacy coupled with high toxicity [2].
IL-2 was discovered in 1979 and it soon became clear that it could be effective in the treatment
of RCC. Response rates of 33% have been reported in the initial trials. Later multicentric trials
reported response rates in 7-19% of patients. In small number of patients responses were
complete and durable; 7-9% of all patients did not relapse even after 10 years and these patients
are considered to be cured from cancer. Unfortunately until today the selection of patients
likely to have durable responses is not possible, because patient and tumor characteristics that
predict best responses to IL-2 have not been identified yet [2]. Beside uncertain responses,
unfavourable toxicity profile limits the use of IL-2. Patients treated with high doses of IL-2 may
experience vascular leak syndrome, hypotension, multiorgan dysfunction and a variety of
other toxicities. In the two decades, when IL-2 was the standard therapy of mRCC patients
were selected on safety bases (performance status, co-morbidities), tumor histology (clear cell),
risk scores (e.g. Memorial Sloan Kettering Cancer Center) and patient preferences [2,10].
3.3. VEGF targeted therapy
It  is  not  surprising that  several  agents  targeting VEGF demonstrate activity in RCC. As
described  in  previous  sub  chapter  there  is  direct  link  between  VHL  mutation  and  up
regulation of angiogenesis- promoting proteins including VEGF and PDGF. VEGF is the
main factor responsible for tumor angiogenesis and PDGF is signalling protein for perycites,




Sunitinib is a potent multi-kinase inhibitor including platelet-derived growth factor receptor
(PDGFR) α and β, stem cell factor receptor (c-KIT), FMS-like tyrosine kinase-3 (FLT-3), VEGF
receptors 1,2,3, colony stimulating factor (CSF-1R) and neurotropic factor receptor. Large
multicentric phase 3 trial in which 750 patients were randomized in a 1:1 fashion between
treatment with IFN-α and sunitinib, demonstrated its superiority over IFN-α. Overall response
rate was 31% in the sunitinib and 6% in the IFN group (p<0.0001).The median PFS in the
sunitinib group was 11 and in IFN-α 5 months. Difference was observed also in overall survival
(median 26.8 months in sunitinib and 21.8 months in the IFN group, p=0.051). The most
common adverse events were fatigue, diarrhea, mucositis, hand-foot syndrome and hyper‐
tension [12,13]. Sunitinib was approved by FDA in 2007 and is today standard of care in the
first-line treatment of mRCC [2,9].
3.3.2. Pazopanib
Pazopanib is an oral multitargeted tyrosine kinase inhibitor that targets VEGFR 1,2,3, PDGFR
α and β and c-KIT. Approval of pazopanib in 2009 was based on a phase III trial in which 435
patients were randomized (2:1) to receive either pazopanib 800 mg once daily or placebo. The
median PFS of 9.2 months in the pazopanib group was significantly longer than in placebo
group where PFS was 4.2 months (p<0.0001). Main side effects were diarrhoea in half, hyper‐
tension in 40% and nausea, anorexia, vomiting and fatigue in 20% of patients [14]. Grade 3
hepatotoxicity was also reported. Pazopanib is recommended in the first line treatment of
mRCC [2,14].
3.3.3. Bevacisumab
Bevacisumab is a recombinant monoclonal antibody that binds circulating VEGF protein and
neutralizes it [15]. In the AVOREN trial 649 previously untreated patients were randomized
to receive either bevacisumab every two weeks and IFN-α or placebo and IFN-α. Differences
in PFS (10.2 vs. 5.4 months) and ORR (31 vs. 13%) were significantly better in bevacisumab
group (p<0.0001 for both parameters) [16]. The second trial conducted by Cancer and Leukemia
Group B was similar. PFS of 8.5 months in the bevacisumab was statistically significant better
than in the IFN monotherapy group (PFS 5.2 months, p<0,0001). Differences were also
demonstrated comparing ORR favoring bevacisumab group (25.5 vs. 13.1% p<0,0001). Fatigue,
anorexia, hypertension and proteinuria were among the most common side effects and more
prominent in the combination group [2,11,16,17].
3.3.4. Sorafenib
Sorafenib is a small molecule, oral multikinase inhibitor that inhibits VEGFR 1,2,3, PDGFR-β,
RAF, serine/threonine intracellular kinase, FLT-3, cKIT and RET. Sorefenib was tested in a
phase III trial (TARGET), 903 patients with mRCC resistant to standard therapy were random‐
ized to receive sorafenib twice daily or placebo. PFS in the sorafenib group was 5.5 months
and in placebo group 2.8 months (p<0.000001). Difference in OS did not reach statistical
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significance. Major side effects of sorafenib were rash, hand-foot syndrome, fatigue, diarrhoea
and hypertension [18].
3.3.5. Axitinib
Axitinib is a second line inhibitor of VEGFR 1 and 2 and is approved in the second line
treatment of mRCC. Axitinib was compared to sorafenib in a phase III trial (AXIX). 723 patients
previously treated with suntinib, bevacisumab plus IFN, temsirolimus or cytokines that
progressed, were randomized to receive axitinib or sorafenib 400 mg. Median PFS in the
axitinib group was 6.7 months and was statistically significant better than in sorafenib group
(4.7 months, p<0.0001). Patients in axitinib group had more hypertension, diarrhoea, dyspho‐
nia, fatigue and nausea, while patients in sorafenib had more hand foot syndrome, rash and
alopecia [19].
3.4. mTOR targeted therapy
Abnormal functioning of signaling pathways contributes to many malignancies including
RCC [20-22]. The mammalian target of rapamycin (mTOR) is a protein kinase that regulates
cell growth, cell proliferation, cell motility, cell survival, protein synthesis, and transcription
[2]. The disruption of mTOR signaling leads to suppression of the production of proteins that
regulate progression of the cell trough the cell cycle and angiogenesis [22].
3.4.1. Temsirolimus
Temsirolimus, an mTOR inhibitor was approved for the treatment of mRCC in the 2007. Global
Advance Renal Cell Carcinoma (ARCC) was a phase III trial of temsirolimus in previously
untreated mRCC. Patients were randomized to receive either IFN-α, temsirolimus or both. PFS
in the groups receiving temsirolimus was significantly longer than in the IFN group (3.7
months in temsirolimus groups vs. 1.9 months in the IFN group; p=0.0019). Patients treated
with temsirolimus alone had better overall survival than patients treated with IFN alone (10.9
months vs. 7.3 months, p=0.096). Toxicity was greater in the combination group and included
rash, stomatitis, pain, infection, peripheral edema, thrombocytopenia, hyperlipidemia,
hypercholesterolemia and hyperglycemia [20].
3.4.2. Everolimus
Everolimus is an oral mTOR inhibitor approved for the treatment of mRCC in the second line
after progression on sunitinib or sorafenib. Everolimus treatment was tested in phase III trial
named RECORD-1. 410 patients which had progressed to previous treatment were randomly
assigned to receive either everolimus or placebo. Median PFS in the everolimus group was 4.9
months, in placebo group 1.9 months (p<0.001). The median OS was not significantly different
between the two groups (14.8 in everolimus and 14.4 in placebo group, p=0.126) The most
common side effects of everolimus were stomatitis, rash, fatigue, asthenia and diarrhea [21,22].
Summary of phase III trials is presented in Tables 1 and 2.
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4. Mechanism of resistance to targeted therapies
Large advances in treatment results achieved with targeted therapies in mRCC are remarkable,
but still between a third and two-thirds of patients with mRCC have tumors refractory to anti-
VEGF and mTOR inhibitors from the beginning of treatment and all patients develop drug
resistance and relapse some time during the course of their disease. Research of the mecha‐
nisms of resistance is very important in planning the development of new targeted agents [3,
23,24]. Most of information about drug resistance in mRCC known today is from the preclinical
studies or studies on patients with different types of cancer, where targeted therapies are being
in clinical practice for longer time (e.g. breast cancer). This is partially due to the rapid approval
of targeted agents in mRCC which surpassed understanding of the mechanisms of response
and resistance [3].
Until now two types of resistance to targeted therapy have been determined, so called intrinsic
and extrinsic resistance [3].
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significance. Major side effects of sorafenib were rash, hand-foot syndrome, fatigue, diarrhoea
and hypertension [18].
3.3.5. Axitinib
Axitinib is a second line inhibitor of VEGFR 1 and 2 and is approved in the second line
treatment of mRCC. Axitinib was compared to sorafenib in a phase III trial (AXIX). 723 patients
previously treated with suntinib, bevacisumab plus IFN, temsirolimus or cytokines that
progressed, were randomized to receive axitinib or sorafenib 400 mg. Median PFS in the
axitinib group was 6.7 months and was statistically significant better than in sorafenib group
(4.7 months, p<0.0001). Patients in axitinib group had more hypertension, diarrhoea, dyspho‐
nia, fatigue and nausea, while patients in sorafenib had more hand foot syndrome, rash and
alopecia [19].
3.4. mTOR targeted therapy
Abnormal functioning of signaling pathways contributes to many malignancies including
RCC [20-22]. The mammalian target of rapamycin (mTOR) is a protein kinase that regulates
cell growth, cell proliferation, cell motility, cell survival, protein synthesis, and transcription
[2]. The disruption of mTOR signaling leads to suppression of the production of proteins that
regulate progression of the cell trough the cell cycle and angiogenesis [22].
3.4.1. Temsirolimus
Temsirolimus, an mTOR inhibitor was approved for the treatment of mRCC in the 2007. Global
Advance Renal Cell Carcinoma (ARCC) was a phase III trial of temsirolimus in previously
untreated mRCC. Patients were randomized to receive either IFN-α, temsirolimus or both. PFS
in the groups receiving temsirolimus was significantly longer than in the IFN group (3.7
months in temsirolimus groups vs. 1.9 months in the IFN group; p=0.0019). Patients treated
with temsirolimus alone had better overall survival than patients treated with IFN alone (10.9
months vs. 7.3 months, p=0.096). Toxicity was greater in the combination group and included
rash, stomatitis, pain, infection, peripheral edema, thrombocytopenia, hyperlipidemia,
hypercholesterolemia and hyperglycemia [20].
3.4.2. Everolimus
Everolimus is an oral mTOR inhibitor approved for the treatment of mRCC in the second line
after progression on sunitinib or sorafenib. Everolimus treatment was tested in phase III trial
named RECORD-1. 410 patients which had progressed to previous treatment were randomly
assigned to receive either everolimus or placebo. Median PFS in the everolimus group was 4.9
months, in placebo group 1.9 months (p<0.001). The median OS was not significantly different
between the two groups (14.8 in everolimus and 14.4 in placebo group, p=0.126) The most
common side effects of everolimus were stomatitis, rash, fatigue, asthenia and diarrhea [21,22].
Summary of phase III trials is presented in Tables 1 and 2.
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and resistance [3].
Until now two types of resistance to targeted therapy have been determined, so called intrinsic
and extrinsic resistance [3].
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Intrinsic resistance (primary resistance) occurs when tumor does not respond to the targeted
therapy from the beginning of the treatment. Lack of the clinical benefit, even a short-lasting
one is observed in these patients. Roughly 25% of patients are resistant to therapy; no response
is detected on first evaluation after 2-3 months [23]. This type of resistance has not been
explained entirely jet.
In the case of the resistance to VEGF inhibitors and TKI-s pre-existing pro-angiogenic factors,
such as fibroblast growth factor-2 promote tumor angiogenesis. Pre-existence of pro-angio‐
genic factors compensate for the inhibition of VEGF signaling and thus allow angiogenesis to
continue [3,23]. Pre-existing inflammatory cells may also contribute to the angiogenesis by
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to anti-VEGF antibody were associated with increase in infiltrating CD11b + GR1 + myeloid
cells, which expressed several pro-angiogenic factors [23].
The proposed mechanisms of resistance to inhibitors of mammalian target of rapamycin
(mTOR) include the presence of redundant signaling pathways, presence of KRAS or BRAF
mutations, loss of phosphatase and tension homologue deleted on chromosome ten (PTEN),
low cellular levels of p27 or 4E-bp1 and overexpression of eIF4E [3].
Intrinsic resistance to anti-angiogenic factors and mTOR inhibitors is widespread and leads to
poor patient outcome. Alternative pathways should be considered in this patients such as
targeting RAF and MEK or PI3K/AKT. Including patients with resistant tumors in clinical trials
testing these new agents that target these pathways is strongly recommended [23].
4.2. Extrinsic resistance
All  patients  who  initially  have  clinical  benefit  of  targeted  therapy  eventually  develop
resistance to it and experience disease progression. This resistance, named extrinsic resist‐
ance  (also  known  as  secondary,  evasive,  acquired  or  adaptive  resistance)  has  been  ex‐
plained more  in  detail  [23].  TKI  and VEGF inhibitors  both  target  components  of  VEGF
signaling pathway. Thus the mechanisms involved will affect any of these targeted agents.
Extrinsic resistance results from the acquisition of adaptive mechanisms to the action of
angiogenesis inhibitors which ultimately results in evasion of the angiogenesis and reemer‐
gence of tumor-related vasculature [3,25].
Sprouting of new vessels has been detected in Xenograft RCC tumors resected shortly after
the start of sunitinib. The development of resistance is constantly preceded by restoration of
blood flow, which suggests that new vasculature is less dependent (but not necessary inde‐
pendent) of VEGF [25].
4.2.1. Up-regulation of pro-angiogenic factors
Different pro-angiogenic factors involved in the mechanism of resistance to targeted agents
have been recognized. In a mouse model of pancreatic neuroendocrine cancer, resistant tumors
expressed high levels of FGF 1, 2, ephrin A1, angiopoetin and interleukin-8 [23,25]. Inhibition
of these proteins was shown to inhibit tumor growth of resistant RCC-s [25].
Interleukin-8 (IL-8) is a potent pro-angiogenic factor. Up-regulation of IL-8 plays an important
role in RCC resistance. In a xenograft model of RCC mimicking clinical resistance to sunitinib,
increased IL-8 secretion from tumors was associated with reactivation of tumor angiogenesis
and administration of IL-8 neutralizing antibody lead to re-sensitization to sunitinib. Elevated
IL-8 expression was also found in patients with tumors who did not respond to sunitinib from
the beginning [5,22]. IL-angiogenic signaling may functionally compensate for the inhibition
of VEGF/VEGFR-mediated angiogenesis [5].
Angiopoetin 2 (Ang-2) is a plasma glycoprotein involved in angiogenesis and cancer neovas‐
cularization. It is thought to have a role in development of the resistance. Levels of Ang-2
decrease after the initiation of sunitinib treatment and increase after the resistance occurs [23].
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to anti-VEGF antibody were associated with increase in infiltrating CD11b + GR1 + myeloid
cells, which expressed several pro-angiogenic factors [23].
The proposed mechanisms of resistance to inhibitors of mammalian target of rapamycin
(mTOR) include the presence of redundant signaling pathways, presence of KRAS or BRAF
mutations, loss of phosphatase and tension homologue deleted on chromosome ten (PTEN),
low cellular levels of p27 or 4E-bp1 and overexpression of eIF4E [3].
Intrinsic resistance to anti-angiogenic factors and mTOR inhibitors is widespread and leads to
poor patient outcome. Alternative pathways should be considered in this patients such as
targeting RAF and MEK or PI3K/AKT. Including patients with resistant tumors in clinical trials
testing these new agents that target these pathways is strongly recommended [23].
4.2. Extrinsic resistance
All  patients  who  initially  have  clinical  benefit  of  targeted  therapy  eventually  develop
resistance to it and experience disease progression. This resistance, named extrinsic resist‐
ance  (also  known  as  secondary,  evasive,  acquired  or  adaptive  resistance)  has  been  ex‐
plained more  in  detail  [23].  TKI  and VEGF inhibitors  both  target  components  of  VEGF
signaling pathway. Thus the mechanisms involved will affect any of these targeted agents.
Extrinsic resistance results from the acquisition of adaptive mechanisms to the action of
angiogenesis inhibitors which ultimately results in evasion of the angiogenesis and reemer‐
gence of tumor-related vasculature [3,25].
Sprouting of new vessels has been detected in Xenograft RCC tumors resected shortly after
the start of sunitinib. The development of resistance is constantly preceded by restoration of
blood flow, which suggests that new vasculature is less dependent (but not necessary inde‐
pendent) of VEGF [25].
4.2.1. Up-regulation of pro-angiogenic factors
Different pro-angiogenic factors involved in the mechanism of resistance to targeted agents
have been recognized. In a mouse model of pancreatic neuroendocrine cancer, resistant tumors
expressed high levels of FGF 1, 2, ephrin A1, angiopoetin and interleukin-8 [23,25]. Inhibition
of these proteins was shown to inhibit tumor growth of resistant RCC-s [25].
Interleukin-8 (IL-8) is a potent pro-angiogenic factor. Up-regulation of IL-8 plays an important
role in RCC resistance. In a xenograft model of RCC mimicking clinical resistance to sunitinib,
increased IL-8 secretion from tumors was associated with reactivation of tumor angiogenesis
and administration of IL-8 neutralizing antibody lead to re-sensitization to sunitinib. Elevated
IL-8 expression was also found in patients with tumors who did not respond to sunitinib from
the beginning [5,22]. IL-angiogenic signaling may functionally compensate for the inhibition
of VEGF/VEGFR-mediated angiogenesis [5].
Angiopoetin 2 (Ang-2) is a plasma glycoprotein involved in angiogenesis and cancer neovas‐
cularization. It is thought to have a role in development of the resistance. Levels of Ang-2
decrease after the initiation of sunitinib treatment and increase after the resistance occurs [23].
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Sphingosine kinase (S1P) is also supposed to play a role in the resistance. S1P is an enzyme
that catalyzes the formation of sphingosine-1-phosphate which is associated with cell prolif‐
eration, survival and angiogenesis. Plasma levels of S1P decrease after the start of sunitinib
treatment and increase again upon the development of resistance. In pre-clinical models
administering neutralizing antibodies against S1P to mice, delayed the growth of sunitinib-
resistant tumors [23].
4.2.2. Down-regulation of angiostatic factors
Down-regulation of angiostatic factors is another mechanism of resistance to TKI-s. Treatment
with sunitinib and sorafenib results in the increased expression of several IFN-inducible genes
including the angiostatic chemokines CXCL 10 and CXCL 11 and tumor suppressor genes.
Following the development of resistance, the expression of IFN-γ and several of IFN-inducible
genes is reduced. Down regulation of these factors is associated with the development of
resistance to sunitinib and sorafenib [23].
4.2.3. Recruitment of bone marrow-derived cells
Recruitment of bone marrow-derived cells which can result in the development of new blood
vessels is another possible mechanism of resistance. In pre-clinical studies recruitment of
CD11b + GR1 + myeloid cells cells resulted in resistance development. There is also evidence
that tumor vasculature can be protected from anti-angiogenic therapy by increased pericyte
coverage [23].
4.2.4. Development of invasion without angiogenesis
Invasion of tumor in normal tissue and recruitment of normal tissue vasculature protect the
tumors from anti-angiogenic therapy. It has been reported that the tumor of a patient experi‐
encing disease progression during antiangiogenic therapy had invaded the surrounding tissue
and there had been increase of the vascularization from the normal tissue to the center of the
tumor [23].
4.2.5. Resistance to m-TOR inhibitors
Resistance to mTOR inhibitors is far less explained. It is supposed to be the result of activation
of feedback loops that promote the activation of molecular signaling pathways of survival,
increased activity of mTOR-complex 2, up-regulation of insulin-like growth factor and increase
in the ERK/MAPK pathway signaling [4,24,25].
4.2.6. Reversible resistance
Preclinical studies revealed that resistance to VEGF targeted therapies can be reversible.
Hammers and colleagues grafted skin metastases of mRCC patient who had become resistant
to sunitinib into mice and these xenogafts regained sensitivity and responded to sunitinib.
Histology of original skin metastasis and xenograft revealed that a reversible epithelial-to-
mesenchymal transition could be responsible for acquired resistance to sunitinib. Zhang
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concluded that reversible changes in gene expression within the tumor cells and/or their
microenvironment could be the possible mechanism of reversible resistance. He implanted
sorafenib-resistant RCC into mice and after implantation tumors regained the sensitivity to
sorafenib [4,25].
4.2.7. Mechanism of resistance to different targeted agents
In the case of sunitinib, the proposed mechanism of resistance is the activation or up-regulation
of alternative angiogenic signals (e.g. FGF-s, ephrins, andiopoetins) while in the case of
sorafenib this mechanism seem to be recruitment of pro-angiogenic bone marrow-derived cells
and monocytes. Recruitment of perycites that help to maintain vessels permeable and func‐
tional and prevent endothelial cells from being affected by antiangiogenic therapies, is the
proposed mechanisms of resistance to pasopanib. In the case of bevacisumab resistance the
increased potential of tumor cells to invade without the need of neovascularization is supposed
to be the mechanism [4,9,25].
5. Overcoming the resistance
Overcoming the resistance to first line therapy is one of the aims of administering the second
line and beyond. Several factors play important role in selection of second line strategy: clinical
evidence, toxicity issues and individual patient profile [4,25,26].
Sequential use of targeted agents is currently the standard of care for mRCC patients. This
approach enables patients to get most benefit from these agents avoiding the excessive toxicity
associated with combination therapy [26-28]. Targeted agent in the second line can have the
same or different mechanism of action as first-line one. Limited data suggest that the use of a
TKI after the failure of another TKI is reasonable and that there is not complete cross-resistance
of these agents. The hypothesis behind this is that although TKIs share the same mechanism
of action, their molecular targets are different. Despite this, the evidence of this approach is
not strong; prospective, phase III trials are missing. Changing mechanism of action can have
several advantages: greater chance of overcoming resistance while decreasing the probability
of cumulative toxicity [4,25]. Toxicities of TKI-s and mTOR inhibitors for example, differ
considerably. Frequent grade 3 toxicities encountered in patients on TKI-s are hand-foot
syndrome, diarrhoea, fatigue, hypertension, neutropenia and leukopenia, while grade 3
toxicities in patients treated with mTOR inhibitors are rash, stomatitis, pneumonitis, anemia
and infection [25-30].
5.1. TKI-s following cytokine therapy
The almost historical treatment strategy where changing of mechanism of action proved to be
effective was TKI-s following cytokines. Currently this approach is not of clinical use anymore,
because most of the patients get molecular targeted agent in the first line; however it is likely
that some patients will have been treated with a cytokine previously. Phase III trials demon‐
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strated that this approach is effective and safe and become a basis of approval of sunitinib and
pazopanib in the first line treatment [3].
5.2. Combinations of targeted agents
Combinations of targeted agents could be in theory effective mechanism to overcome the
resistance because we could combine agents with different mechanisms of action. However
combining these therapies may increase the incidence of side effects if the combination drugs
are not selected carefully [29]. Most of patients do not tolerate full doses of two VEGF inhibitors
at the same time. That is the reason why administering combination therapy long enough to
surpass the clinical benefit of subsequent mono-therapy is not possible [25].
Combinations of VEGF-TKI and mTOR inhibitors also lead to unacceptable toxicity. In a trial
of Patel et.al, combination of temsirolimus and sunitinib lead to dose limiting toxicity in 2 of
3 patients [31]. Data suggest that the side effects and tolerability of combinations correlate with
the total number of inhibited targets. This is the explanation why some combinations with
VEGF specific agent bevacisumab may be tolerated (e.g. bevacisumab plus everolimus). At
present combination of targeted agents in the treatment of mRCC is not recommended in
clinical practice mainly because of excessive toxicity [23,29].
5.3. Second VEGF-TKI after the first line VEGF-TKI
Retrospective and prospective phase II trials showed that treatment with second TKI could be
beneficial in patients that progressed on first TKI. At first sight this may seem not logical, but
variations in kinase targets and interaction may avoid resistance. However definitive data from
phase III trials on this topic are still missing. Benefit of the second TKI after the first TKI may
be dependent on its relative potency and selectivity profile [9]. Most of the results from
retrospective and small prospective trials suggest that patients with mRCC who progress on
sorafenib could benefit from sunitinib. Conversely the use of sorafenib after sunitinib or
bevacisumab showed limited efficacy [9,27].
Sabin et.al. evaluated 68 patients treated with sunitinib and sorafenib consequently. ORR was
better when the patients received sorafenib first; 15% in the group that received sunitinib
followed by sorafnib group and 9% in the group that received sorafenib after sunitinib. Median
PFS in the first group was 12.4 months (6 months on sorafenib and 6.4 months on sunitinib)
and 8.9 months in the second group (5 months on sunitinib and 3.9 months on sorafenib) [26].
Porta et.al evaluated retrospectively 99 patients treated with sunitinib followed by sorafenib
(SuSo) and 90 patients treated with sorafenib followed by sunitnib (SoSu). The median PFS of
second line treatment in the first group (SuSo) was 7.9 months and in the second group was
4.2 months (SoSu) [32]. Clinical trial in progress NCT00732914 with the aim to evaluate if total
PFS of sorafenib followed by sunitinib is superior compared to sunitinib followed by sorafenib
is expected to give some additional light to this issue [3].
AXIS trial directly compared the efficacy and safety of axitinib to sorafenib after progression
on sunitinib, bevacisumab, temsirolimus or cytokines. In the subpopulation of patients who
previously received sunitinib, median PFS was 4.8 months with axitinib and 3.4 months with
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sorafenib (p=0,001). Shorter median PFS in both arms receiving first line sunitinib compared
to those receiving cytokines (median PFS 12.1 in axitinib and 6.5 moths in sunitinib) suggest
that at least partial cross-resistance with sequential TKI-s [3,9,19].
Reduced clinical efficacy of second line therapy as a result of cross resistance is key concern
associated with the sequential administration of agents targeting the same molecular path‐
ways. Two prospective trials showed that because of the cross-resistance, sorafenib had limited
efficacy in patients who progressed on sunitinib or bevacisumab [27].
Another concern about using sequential VEGF-TKI therapies is toxicity. Although they may
differ in toxicity profiles, all TKI-s share similar targets and exhibit class effect toxicities like
hypertension, hand foot syndrome and rash [9]. Current data suggest that Switching to agents
with different mechanisms of action in the second line therapy may provide superior efficacy
and reduced cumulative toxicity [27].
5.4. VEGF-TKI after first line anti VEGF
Very limited data are available on the use of TKI-s after progression on bevacisumab and no
clinical trial is currently ongoing to address this issue. Only two minor prospective trials
conducted by Garcia and Rini evaluated the use of sunitinib or sorafenib in patients with
bevacisumab-refractory mRCC [3].
In a phase II trial of Garcia, 48 patients were enrolled. After progression on treatment with
sunitinib or bevacisumab, patients received twice daily 400 mg of sorafenib. One unconfirmed
objective partial response was observed and the tumor burden reduction rate was 30%. The
median PFS was 4.4 months. There was no association of PFS and tumor shrinkage with
response to prior therapy. Most treatment-related adverse events were of mild-to-moderate
intensity, and included fatigue, hypertension, diarrhoea, and hand-foot syndrome [33].
Rini et.al. conducted a phase II multicentric trial in which patients with mRCC and disease
progression after bevacizumab-based therapy received oral sunitinib 50 mg once daily in 6-
week cycles on a 4/2 schedule (4 weeks with treatment followed by 2 weeks without treatment).
Sixty-one patients were enrolled. The ORR was 23.0%, median PFS was 30.4 weeks and median
OS was 47.1 weeks. Most treatment-related adverse events were of mild-to-moderate intensity
and included fatigue, hypertension, and hand-foot syndrome. Results from measuring
different VEGF-s in the plasma suggest that sunitinib could inhibit some of the signaling factors
involved in bevacisumab resistance [34].
5.5. mTOR inhibitor after first line VEGF-TKI
Another approach in patients who progress on first line TKI-s is to switch to a second line
therapy with an agent with different mechanism of action like mTOR inhibitor [3,9]. On
theoretical basis mTOR inhibitors could overcome the resistance to VEGF-TKIs. VEGF-TKIs
increase tumor hypoxia which results in up-regulation of proangiogenic factors and increase
potential of metastases. mTor inhibition decreases translation of proangiogenic factors and
tumors that have become resistant to VEGF-TKI may respond to treatment with mTOR
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previously received sunitinib, median PFS was 4.8 months with axitinib and 3.4 months with
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sorafenib (p=0,001). Shorter median PFS in both arms receiving first line sunitinib compared
to those receiving cytokines (median PFS 12.1 in axitinib and 6.5 moths in sunitinib) suggest
that at least partial cross-resistance with sequential TKI-s [3,9,19].
Reduced clinical efficacy of second line therapy as a result of cross resistance is key concern
associated with the sequential administration of agents targeting the same molecular path‐
ways. Two prospective trials showed that because of the cross-resistance, sorafenib had limited
efficacy in patients who progressed on sunitinib or bevacisumab [27].
Another concern about using sequential VEGF-TKI therapies is toxicity. Although they may
differ in toxicity profiles, all TKI-s share similar targets and exhibit class effect toxicities like
hypertension, hand foot syndrome and rash [9]. Current data suggest that Switching to agents
with different mechanisms of action in the second line therapy may provide superior efficacy
and reduced cumulative toxicity [27].
5.4. VEGF-TKI after first line anti VEGF
Very limited data are available on the use of TKI-s after progression on bevacisumab and no
clinical trial is currently ongoing to address this issue. Only two minor prospective trials
conducted by Garcia and Rini evaluated the use of sunitinib or sorafenib in patients with
bevacisumab-refractory mRCC [3].
In a phase II trial of Garcia, 48 patients were enrolled. After progression on treatment with
sunitinib or bevacisumab, patients received twice daily 400 mg of sorafenib. One unconfirmed
objective partial response was observed and the tumor burden reduction rate was 30%. The
median PFS was 4.4 months. There was no association of PFS and tumor shrinkage with
response to prior therapy. Most treatment-related adverse events were of mild-to-moderate
intensity, and included fatigue, hypertension, diarrhoea, and hand-foot syndrome [33].
Rini et.al. conducted a phase II multicentric trial in which patients with mRCC and disease
progression after bevacizumab-based therapy received oral sunitinib 50 mg once daily in 6-
week cycles on a 4/2 schedule (4 weeks with treatment followed by 2 weeks without treatment).
Sixty-one patients were enrolled. The ORR was 23.0%, median PFS was 30.4 weeks and median
OS was 47.1 weeks. Most treatment-related adverse events were of mild-to-moderate intensity
and included fatigue, hypertension, and hand-foot syndrome. Results from measuring
different VEGF-s in the plasma suggest that sunitinib could inhibit some of the signaling factors
involved in bevacisumab resistance [34].
5.5. mTOR inhibitor after first line VEGF-TKI
Another approach in patients who progress on first line TKI-s is to switch to a second line
therapy with an agent with different mechanism of action like mTOR inhibitor [3,9]. On
theoretical basis mTOR inhibitors could overcome the resistance to VEGF-TKIs. VEGF-TKIs
increase tumor hypoxia which results in up-regulation of proangiogenic factors and increase
potential of metastases. mTor inhibition decreases translation of proangiogenic factors and
tumors that have become resistant to VEGF-TKI may respond to treatment with mTOR
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inhibitor [27]. The evidence of effectiveness of this approach comes from preclinical data. Trial
conducted by Larkin and colleagues compared treatment with sunitinib, sunitinib followed
by sorafenib or sunitinib followed by everolimus in mice implanted with murine RCC.
Sunitinib followed by everolimus was associated with reduced primary tumor weight and
volume in a greater extend compared to tumors treated with sunitinib and sunitinib followed
by sorafenib. The conclusion was that sequential therapy with sunitinib followed by everoli‐
mus is associated with significant anti-tumor and anti-metastatic effect [35].
Everolimus was approved in the second line therapy on results of RECORD-1 trial. In this
double blind, phase III trial, patients who had progressed on first line sunitinib, sorafenib or
both were randomized to everolimus or placebo. Patients receiving everolimus had longer PFS
compared to placebo (4.9 vs. 1.9 months, p<0.001). The clinical benefit of everolimus was
observed regardless if the patients received previously one or two consequent TKI-s. In the
subgroup of patients who received one TKI, median PFS in everolimus group was 5.4 months,
and in group who received two TKI-s 4 months. This was statistically significant longer than
in placebo groups, where PFS was 1.9 and 1.8 months respectively [8,20,36-38].
Prospective head to head trials to compare mTOR inhibitors and VEGF-TKI-s in the second
line of treatment in patients who progressed on the first line VEGF-TKI-s have not been done.
Di Lorenzo and colleagues indirectly compared survival benefit in patients on everolimus or
sorafenib in the second line. Median overall survival was 81.5 weeks for patients receiving
everolimus and 32.0 weeks for sorafenib [37].
The optimal sequencing of sunitinib and everolimus is currently being evaluated in the
RECORD-3 trial and furthermore the everolimus plus bevacisumab in the second line after
progression on TKI-s is currently being compared to everolimus plus placebo in the
NCT01198158 trial [3].
The efficacy and safety of temsirolimus after progression on TKI-s are expected to be revealed
in an ongoing trial NCT00474786, a phase III trial comparing temsirolimus vs. sorafenib in the
second line treatment in patients who have failed on first-line sunitinib. Results from small
population in retrospective and prospective phase II trial presented on ASCO 2010 suggest,
that temsirolimus is safe and effective in pretreated patients, especially those with good
performance status and good prognostic factors [3].
Regarding toxicity mTOR inhibitors and VEGF-TKIs block different molecular mechanisms,
the toxicity profiles are usually not overlapping. In the RECORD-1 trial patients could tolerate
treatment with everolimus after progression on VEGF-TKIs. Stomatitis, infection, asthenia and
fatigue were the most common side effects reported on everolimus therapy. Common toxicities
encountered in the treatment with VEGF-TKIs such as hypertension or hand-foot syndrome,
were not frequent [3,19].
5.6. Alternative scheduling and dosage
A different approach to overcome the resistance can potentially be the change in scheduling
and/or dosage of the targeted agent in usage. Sunitinib is approved in intermittent schedule
of 4 weeks on drug and 2 weeks off drug. Continuous low-dose therapy has been shown to be
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a feasible treatment option in first and second line of treatment [37,38]. Comparison between
the two scheduling is currently not very well determined, but clinical and toxicological
differences may in future be important issue in treatment individualization. Another option
is re-challenge with the same drug after discontinuation period on disease progression. The
basis for this approach comes from pre-clinical data that indicate that resistance to sorafenib
is reversed by re-implantation of resistant tumors in untreated mice [23].
The question of optimal treatment dosage becomes particularly relevant on disease progres‐
sion. Meta-analysis of patients with solid tumors receiving sunitinib revealed that patients
receiving higher dose, had longer time to progression compared to patients who received less
sunitinib. Additionally patient receiving higher dose had more complete or partial remissions
and greater decrease in tumor size. In the trial comparing sorafenib with IFN-α, patients in the
sorafenib group received higher dose of sorafenib (600 mg BID) after progression on 400 mg
BID. Reduction of tumor size was observed. Suggested clinical benefit of increased dose after
progression is outweighed by increased toxicity. Most of patients do not tolerate dosage
increase [22].
5.7. Intrinsic resistance
Prognosis of patients who progress early in the course of first line therapy VEGF targeted
therapy is poor. No available agents seem to alter the course of their disease and give them
clinical benefit. 86 patients with rapid progression after first line therapy were evaluated in a
retrospective trial. PFS after second line therapy with treatment with different VEGF-TKI was
2 months and after second line therapy with mTOR 0.9 months (p=0.536). Larger retrospective
trial in which 272 patients were included showed similar results. All patients had rapid disease
progression after first line VEGF-TKIs. The response rates, PFS and OS of those receiving
second-line VEGF-targeted therapy compared with mTOR inhibitors were 10 vs 6%, 2.8 vs.2
months and 7.9 vs. 4.7 months. Differences were not statistically significant [9].
6. Third line and beyond
Small prospective and retrospective trials suggest that changing the mechanism of action in
the third line may restore the sensitivity to the initial treatment [3,9,27,32,39,40]. In the ASCO
meeting in 2010 Ferrari presented the results of a prospective trial that compared the admin‐
istration of everolimus or temsirolimus as third line therapy to good performance status
patients resistant to TKI-s. Median PFS was 6 months and disease control was achieved in 39%
of patients. These results suggest that treatment with mTOR inhibitor in the third line and
further than, could be a potential promising treatment option [40].
Another trial conducted by Di Lorenzo et.al. evaluated sorafenib treatment in the third line
after treatment with sunitinib and mTor inhibitor. Of the 34 patients eligible, 23.5% responded
to third line sorafenib. Desease control was 44%, median PFS was 4 and median OS was 6
months. 47% of patients that responded to first line therapy, responded to third-line sorafenib
while of patients who did not respond to first-line, did not respond also to third-line sorafenib.
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second line treatment in patients who have failed on first-line sunitinib. Results from small
population in retrospective and prospective phase II trial presented on ASCO 2010 suggest,
that temsirolimus is safe and effective in pretreated patients, especially those with good
performance status and good prognostic factors [3].
Regarding toxicity mTOR inhibitors and VEGF-TKIs block different molecular mechanisms,
the toxicity profiles are usually not overlapping. In the RECORD-1 trial patients could tolerate
treatment with everolimus after progression on VEGF-TKIs. Stomatitis, infection, asthenia and
fatigue were the most common side effects reported on everolimus therapy. Common toxicities
encountered in the treatment with VEGF-TKIs such as hypertension or hand-foot syndrome,
were not frequent [3,19].
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A different approach to overcome the resistance can potentially be the change in scheduling
and/or dosage of the targeted agent in usage. Sunitinib is approved in intermittent schedule
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The question of optimal treatment dosage becomes particularly relevant on disease progres‐
sion. Meta-analysis of patients with solid tumors receiving sunitinib revealed that patients
receiving higher dose, had longer time to progression compared to patients who received less
sunitinib. Additionally patient receiving higher dose had more complete or partial remissions
and greater decrease in tumor size. In the trial comparing sorafenib with IFN-α, patients in the
sorafenib group received higher dose of sorafenib (600 mg BID) after progression on 400 mg
BID. Reduction of tumor size was observed. Suggested clinical benefit of increased dose after
progression is outweighed by increased toxicity. Most of patients do not tolerate dosage
increase [22].
5.7. Intrinsic resistance
Prognosis of patients who progress early in the course of first line therapy VEGF targeted
therapy is poor. No available agents seem to alter the course of their disease and give them
clinical benefit. 86 patients with rapid progression after first line therapy were evaluated in a
retrospective trial. PFS after second line therapy with treatment with different VEGF-TKI was
2 months and after second line therapy with mTOR 0.9 months (p=0.536). Larger retrospective
trial in which 272 patients were included showed similar results. All patients had rapid disease
progression after first line VEGF-TKIs. The response rates, PFS and OS of those receiving
second-line VEGF-targeted therapy compared with mTOR inhibitors were 10 vs 6%, 2.8 vs.2
months and 7.9 vs. 4.7 months. Differences were not statistically significant [9].
6. Third line and beyond
Small prospective and retrospective trials suggest that changing the mechanism of action in
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patients resistant to TKI-s. Median PFS was 6 months and disease control was achieved in 39%
of patients. These results suggest that treatment with mTOR inhibitor in the third line and
further than, could be a potential promising treatment option [40].
Another trial conducted by Di Lorenzo et.al. evaluated sorafenib treatment in the third line
after treatment with sunitinib and mTor inhibitor. Of the 34 patients eligible, 23.5% responded
to third line sorafenib. Desease control was 44%, median PFS was 4 and median OS was 6
months. 47% of patients that responded to first line therapy, responded to third-line sorafenib
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The most common 3/4 grade side effects of third line sorafenib were hand-foot syndrome,
anemia, fatigue, diarrhea and neutropenia. These results show that sorafenib could be
considered in the third line treatment in mRCC patients after the failure on sunitinib and mTOR
inhibitor [41]. Blesious retrospectively evaluated 105 patients in the RECORD-1 trial of whom
36 received a VEGF-TKI after receiving everolimus. Patients that received sunitinib, sorafenib
and dovitinib had median PFS of 8 months, 5.3 months and 12.0 months. A partial response
was reported in 8.6% of patients and 68.8% of patients had stable disease. Median OS was 29.1
months [42].
In a trial of Grunwald efficacy of VEGF-targeted therapies in patients after everolimus-
resistant patients who had progressed on a previous TKI was explored. Patients received
sunitinib, sorafenib, dovitinib or bevacisumab/ IFN therapy after failure of everolimus. Of the
40 patients included 10% had partial response and 55% had stable disease. Median PFS was
5.5 months. Authors conclude that VEGF targeted therapy show promising activity in
everolimus resistant metastatic RCC [43].
Porta et. al. evaluated retrospectively the overall PFS benefit of the sequence VEGF-TKI, mTor
inhibitor, VEGF-TKI sequence. The sequence of sorafenib-mTOR-sunitinib (14 patients) was
compared to the sequence sunitinib-mTOR-sorafenib (26 patients). No significant difference in
PFS was found between the two groups (21.9 months vs 22.8 months). The median PFS for the
three lines of treatment were 11.7 months-5.1 months-9.1 months for the group sorafenib-mTOR-
sunitinib and 14.4 months-4.3 months-3.9 months for sunitinib-mTOR-sorafenib group [44].
The results of these trials suggest that re-challenging strategy of VEGF-TKI in the third line of
treatment after progression on VEGF-TKI in the first and mTOR inhibitors in the second may
be a successful treatment approach. The other observation of these trials is that some patients
have minor benefit from the VEGF-TKI inhibitors in the third compared to the benefit in the
first line. The explanation for this is that probably partial cross-resistance to the VEGF-TKIs
accounts at least to some extent for this. One possible strategy to overcome this resistance is
to use the third-line agent with the ability to broadly inhibit multiple angiogenic pathways in
addition to VEGF signaling [9].
Even if no clinical guidelines exist for the fourth-line targeted therapy, some reports suggest
that patients may gain clinical benefit from the sequences of targeted agents with different
mechanisms of action. 48 months of PFS was achieved in an mRCC patient treated with four
lines of targeted therapies (sunitinib, everolimus, sorafenib, temsirolimus). Despite intensity,
treatment was well tolerated and no cumulative toxicity was present. This case study advocates
that sequential use of sunitinib, everolimus, sorafenib and temsirolimus and show that this
could be effective treatment approach with good toxicity profile [45].
Metastatic RCC patients can get benefit from multiple lines of targeted therapy. Resistance to
VEGF-TKIs and mTOR inhibitors seem to be at least partially reversible and re-challenging
with the inhibitors from the same group in subsequent lines of therapy may be a therapeutic




The current practice of delivery of sequential monotherapy targeted agents is empirical and
mainly based on non-comparative clinical trials. In treatment refractory patients often practical
issues like route of delivery or physician familiarity with the drug prevail over the scientific
evidence in selecting treatment. Deeper understanding of the biology of response and
resistance to targeted agents will elucidate future way in treatment of mRCC patients. New
multi-targeted inhibitors are being rapidly developed and their role in overcoming resistance
will become clear in the next few years. Together with the developments of these new drugs,
finding predictive biomarkers of these new and “old” therapies is one of the major research
goals [25].
7.1. New targeted agents
Dovitinib is an investigational multi-target inhibitor of FGF receptors 1-3, PDGF receptor,
VEGFrs 1-3 and c-KIT. One of the mechanisms of resistance to VEGF-TKI seems to be hypoxia-
mediated induction of FGF signaling. Dovitinib was tested in a phase II trial in which patients
with mRCC who failed prior treatment with VEGF-TKI or mTOR inhibitor or cytokines.
Median PFS and OS were 5.5 months and 11.8 months in all patients and 6.1 months and 10.2
months in patients treated with previous VEGF-TKI or mTOR inhibitor. The main grade 3
toxicities of dovitinib were nausea/vomiting in 15%, fatigue in 13.6%, asthenia in 13.5%,
diarrhoea in 10.2% and hypertension in 10.2% of patients. Grade 4 hypertriglicemia occurred
in 8.5% of patients [46].
Tivozanib is a potent selective long half-life tyrosine kinase inhibitor targeting VEGFR 1-3. 517
patients were included in a phase III trial published by Motzer et.al at ASCO 2012. Patients
were randomized to receive either tivozanib or sorafenib. Median PFS was 11.9 months for
tivozanib and 9.1 months for sorafenib (p=0.042). Overall response rate was 33% in tivozanib
and 23% in sorafwnib group (p=0.014). Adverse events grade 3 for tivozanib were hyperten‐
sion, diarrhea, fatigue, neutropenia and hand-foot syndrome [47].
7.2. Biomarkers
Predictive biomarkers could help clinicians to determine the best treatment approach [48,49].
Multiple candidate biomarkers of biological tumor activity as well as treatment response and
patient prognosis are being evaluated [49]. However up to date, none of them showed potential
in clinical use. VHL gene status did not correlate with PFS or OS. The reason for this may be
that almost all RCC cancers have VHL silencing and so this marker cannot be selective enough.
Biomarkers in the peripheral blood have also been tested. Results of some trials showed that
patients with mRCC and elevated expression of angiogenic factors have greater benefit from
VEGF-targeted therapies, although other trials yielded inconsistent results. Other types of
predictive markers, like changes in the tumor blood flow measured by MRI during treatment
with targeted agents are being explored [25,48,49].
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Despite great improvement in treatment outcomes with targeted agents in mRCC, the fact
remains that complete remissions are rarely achieved and most patients progress and develop
resistance to the treatment. Many questions are still open and at least some of them are expected
to be solved with the on-going and future clinical trials. Intrinsic and extrinsic tumor resis‐
tances are major obstacles in successful long term tumor control and one of the major questions
is the optimal sequencing of treatment. Use of sequential therapy with changing mechanisms
of action is a rational approach to overcome this resistance.
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Despite great improvement in treatment outcomes with targeted agents in mRCC, the fact
remains that complete remissions are rarely achieved and most patients progress and develop
resistance to the treatment. Many questions are still open and at least some of them are expected
to be solved with the on-going and future clinical trials. Intrinsic and extrinsic tumor resis‐
tances are major obstacles in successful long term tumor control and one of the major questions
is the optimal sequencing of treatment. Use of sequential therapy with changing mechanisms
of action is a rational approach to overcome this resistance.
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